{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: No staining is observed or membrane staining is observed in < 10% of the tumour cells.\nTarget: No se observa tinción o la tinción de membrana se observa en < 10% de las células tumorales.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: No staining is observed or membrane staining is observed in < 10% of the tumour cells.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "No staining is observed or membrane staining is observed in < 10% of the tumour cells.", "es": "No se observa tinción o la tinción de membrana se observa en < 10% de las células tumorales." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: How to take Rizmoic\nTarget: Cómo tomar Rizmoic", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: How to take Rizmoic\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "How to take Rizmoic", "es": "Cómo tomar Rizmoic" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Use should be with caution in patients with CNS disorders which may predispose to seizures or lower the seizure threshold.\nTarget: Por ello, deben utilizarse con precaución en pacientes con trastornos del SNC que puedan tener una predisposición a padecer convulsiones o una reducción en el umbral de las mismas.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Use should be with caution in patients with CNS disorders which may predispose to seizures or lower the seizure threshold.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Use should be with caution in patients with CNS disorders which may predispose to seizures or lower the seizure threshold.", "es": "Por ello, deben utilizarse con precaución en pacientes con trastornos del SNC que puedan tener una predisposición a padecer convulsiones o una reducción en el umbral de las mismas." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING LABEL with Blue Box - 1 BOTTLE OF 180 TABLETS 800 mg WITHOUT OUTER CARTON\nTarget: INFORMACIÓN QUE DEBE FIGURAR EN EL EMBALAJE EXTERIOR ETIQUETA con Blue Box - 1 FRASCO DE 180 COMPRIMIDOS SIN EMBALAJE EXTERIOR", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING LABEL with Blue Box - 1 BOTTLE OF 180 TABLETS 800 mg WITHOUT OUTER CARTON\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING LABEL with Blue Box - 1 BOTTLE OF 180 TABLETS 800 mg WITHOUT OUTER CARTON", "es": "INFORMACIÓN QUE DEBE FIGURAR EN EL EMBALAJE EXTERIOR ETIQUETA con Blue Box - 1 FRASCO DE 180 COMPRIMIDOS SIN EMBALAJE EXTERIOR" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Children:\nTarget: Niños:", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Children:\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Children:", "es": "Niños:" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Poly(vinyl alcohol) (E 1203) Titanium dioxide (E 171) Macrogol (3350) Talc (E 553b)\nTarget: Alcohol polivinílico (E 1203) Dióxido de titanio (E 171) Macrogol (3350) Talco (E 553b)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Poly(vinyl alcohol) (E 1203) Titanium dioxide (E 171) Macrogol (3350) Talc (E 553b)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Poly(vinyl alcohol) (E 1203) Titanium dioxide (E 171) Macrogol (3350) Talc (E 553b)", "es": "Alcohol polivinílico (E 1203) Dióxido de titanio (E 171) Macrogol (3350) Talco (E 553b)" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: The European Commission granted a conditional marketing authorisation valid throughout the European Union for Fampyra on 20 July 2011.\nTarget: La Comisión Europea emitió una autorización de comercialización condicional válida en toda la Unión Europea para el medicamento Fampyra el 20 de julio de 2011.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: The European Commission granted a conditional marketing authorisation valid throughout the European Union for Fampyra on 20 July 2011.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "The European Commission granted a conditional marketing authorisation valid throughout the European Union for Fampyra on 20 July 2011.", "es": "La Comisión Europea emitió una autorización de comercialización condicional válida en toda la Unión Europea para el medicamento Fampyra el 20 de julio de 2011." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Via Labriola (Zona industriale Lotto 40), SNC 70037, Ruvo di Puglia (BA) Italy\nTarget: Via Labriola (Zona industriale Lotto 40), SNC 70037, Ruvo di Puglia (BA) Italia", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Via Labriola (Zona industriale Lotto 40), SNC 70037, Ruvo di Puglia (BA) Italy\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Via Labriola (Zona industriale Lotto 40), SNC 70037, Ruvo di Puglia (BA) Italy", "es": "Via Labriola (Zona industriale Lotto 40), SNC 70037, Ruvo di Puglia (BA) Italia" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: France:\nTarget: Francia:", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: France:\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "France:", "es": "Francia:" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: • hair loss; itching,\nTarget: • pérdida de pelo; picor,", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: • hair loss; itching,\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• hair loss; itching,", "es": "• pérdida de pelo; picor," } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: 500 mg Powder for concentrate for solution for infusion\nTarget: Polvo para concentrado para solución para infusión", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: 500 mg Powder for concentrate for solution for infusion\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "500 mg Powder for concentrate for solution for infusion", "es": "Polvo para concentrado para solución para infusión" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Tredaptive was effective in reducing the blood levels of LDL cholesterol.\nTarget: Tredaptive redujo eficazmente las concentraciones de colesterol LDL en sangre.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Tredaptive was effective in reducing the blood levels of LDL cholesterol.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Tredaptive was effective in reducing the blood levels of LDL cholesterol.", "es": "Tredaptive redujo eficazmente las concentraciones de colesterol LDL en sangre." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: The financial impact of the scheme was in excess of € 140,000.\nTarget: La repercusión financiera del régimen excede los 140 000 euros.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: The financial impact of the scheme was in excess of € 140,000.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "The financial impact of the scheme was in excess of € 140,000.", "es": "La repercusión financiera del régimen excede los 140 000 euros." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: GAIA 0,15 MG/0,02 MG 0,15 mg 0,02 mg\nTarget: GAIA 0,15 MG/0,02 MG", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: GAIA 0,15 MG/0,02 MG 0,15 mg 0,02 mg\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "GAIA 0,15 MG/0,02 MG 0,15 mg 0,02 mg", "es": "GAIA 0,15 MG/0,02 MG" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Cardboard boxes with either 1 or 10 PET vials of 20, 50, 100, 200 or 500 ml.\nTarget: Cajas de cartón con 1 o 10 viales de PET de 20, 50, 100, 200 ó 500 ml.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Cardboard boxes with either 1 or 10 PET vials of 20, 50, 100, 200 or 500 ml.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Cardboard boxes with either 1 or 10 PET vials of 20, 50, 100, 200 or 500 ml.", "es": "Cajas de cartón con 1 o 10 viales de PET de 20, 50, 100, 200 ó 500 ml." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: It is advised not to drink alcohol while taking Pregabalin Zentiva k.s..\nTarget: Se aconseja no tomar alcohol durante el tratamiento con Pregabalina Zentiva k.s.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: It is advised not to drink alcohol while taking Pregabalin Zentiva k.s..\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "It is advised not to drink alcohol while taking Pregabalin Zentiva k.s..", "es": "Se aconseja no tomar alcohol durante el tratamiento con Pregabalina Zentiva k.s." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Absorption of ticagrelor is rapid with a median tmax of approximately 1.5 hours.\nTarget: El ticagrelor se absorbe rápidamente, con una mediana del tmáx de 1,5 horas aproximadamente.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Absorption of ticagrelor is rapid with a median tmax of approximately 1.5 hours.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Absorption of ticagrelor is rapid with a median tmax of approximately 1.5 hours.", "es": "El ticagrelor se absorbe rápidamente, con una mediana del tmáx de 1,5 horas aproximadamente." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Fifty five % of patients were receiving rhDNase in study DPM-CF-301 while in study DPM-CF-302 this number was 75% and for DPM-CF-303 this was 67.6%.\nTarget: El 55 % de los pacientes estaba recibiendo ADNasa hr en el ensayo DPM-CF-301, mientras que en el ensayo DPM-CF-302 la recibían el 75 % y en DPM-CF-303 era de 67,6 %.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Fifty five % of patients were receiving rhDNase in study DPM-CF-301 while in study DPM-CF-302 this number was 75% and for DPM-CF-303 this was 67.6%.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Fifty five % of patients were receiving rhDNase in study DPM-CF-301 while in study DPM-CF-302 this number was 75% and for DPM-CF-303 this was 67.6%.", "es": "El 55 % de los pacientes estaba recibiendo ADNasa hr en el ensayo DPM-CF-301, mientras que en el ensayo DPM-CF-302 la recibían el 75 % y en DPM-CF-303 era de 67,6 %." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: A reflection paper on the concept of risk-management plans for veterinary medicines was published for consultation.\nTarget: Se publicó para consulta un documento de reflexión sobre el concepto de los planes de gestión de riesgos para medicamentos de uso veterinario.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: A reflection paper on the concept of risk-management plans for veterinary medicines was published for consultation.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "A reflection paper on the concept of risk-management plans for veterinary medicines was published for consultation.", "es": "Se publicó para consulta un documento de reflexión sobre el concepto de los planes de gestión de riesgos para medicamentos de uso veterinario." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: In addition to the boxed text this may include a symbol/pictogram, with the details to be adapted at national level.\nTarget: Además de un recuadro de advertencia, se podría incluir un símbolo o pictograma cuyos detalles se adaptarían en cada país.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: In addition to the boxed text this may include a symbol/pictogram, with the details to be adapted at national level.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "In addition to the boxed text this may include a symbol/pictogram, with the details to be adapted at national level.", "es": "Además de un recuadro de advertencia, se podría incluir un símbolo o pictograma cuyos detalles se adaptarían en cada país." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Romiplostim should be used with caution in these populations.\nTarget: Romiplostim debe utilizarse con precaución en estas poblaciones.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Romiplostim should be used with caution in these populations.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Romiplostim should be used with caution in these populations.", "es": "Romiplostim debe utilizarse con precaución en estas poblaciones." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Reconstituted solution The reconstituted solution is physically-chemically stable for 24 hours at 25ºC.\nTarget: Solución reconstituida La solución reconstituida es fisicoquímicamente estable durante 24 horas a 25ºC.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Reconstituted solution The reconstituted solution is physically-chemically stable for 24 hours at 25ºC.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Reconstituted solution The reconstituted solution is physically-chemically stable for 24 hours at 25ºC.", "es": "Solución reconstituida La solución reconstituida es fisicoquímicamente estable durante 24 horas a 25ºC." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Teva Sante\nTarget: Francia Teva Sante", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Teva Sante\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Teva Sante", "es": "Francia Teva Sante" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: LUM 400 mg q12h/ IVA 250 mg q12h (n = 182)\nTarget: LUM 400 mg cada 12 horas/ IVA 250 mg cada 12 horas (n = 182)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: LUM 400 mg q12h/ IVA 250 mg q12h (n = 182)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "LUM 400 mg q12h/ IVA 250 mg q12h (n = 182)", "es": "LUM 400 mg cada 12 horas/ IVA 250 mg cada 12 horas (n = 182)" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: In addition to T cells, NK cells and residual levels of monocytes and of B cells may be present.\nTarget: Además de las células T, es posible que se encuentren presentes células NK, así como niveles residuales de monocitos y de células B.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: In addition to T cells, NK cells and residual levels of monocytes and of B cells may be present.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "In addition to T cells, NK cells and residual levels of monocytes and of B cells may be present.", "es": "Además de las células T, es posible que se encuentren presentes células NK, así como niveles residuales de monocitos y de células B." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: • Children given emtricitabine very commonly experienced changes in skin colour including darkening of the skin in patches\nTarget: • Los niños a los que se les administró emtricitabina presentaron muy frecuentemente cambios en el color de la piel que incluyen manchas oscuras en la piel", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: • Children given emtricitabine very commonly experienced changes in skin colour including darkening of the skin in patches\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Children given emtricitabine very commonly experienced changes in skin colour including darkening of the skin in patches", "es": "• Los niños a los que se les administró emtricitabina presentaron muy frecuentemente cambios en el color de la piel que incluyen manchas oscuras en la piel" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Solution for injection in pre-filled syringe 7 GRADUATED pre-filled syringes This box containing 7 pre-filled syringes is part of a 28-multipack.\nTarget: La caja que contiene 7 jeringas precargadas forma parte de un envase múltiple con 28 jeringas precargadas.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Solution for injection in pre-filled syringe 7 GRADUATED pre-filled syringes This box containing 7 pre-filled syringes is part of a 28-multipack.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Solution for injection in pre-filled syringe 7 GRADUATED pre-filled syringes This box containing 7 pre-filled syringes is part of a 28-multipack.", "es": "La caja que contiene 7 jeringas precargadas forma parte de un envase múltiple con 28 jeringas precargadas." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Kidney cancer\nTarget: Cáncer de cuello uterino", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Kidney cancer\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Kidney cancer", "es": "Cáncer de cuello uterino" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: • phosphate binders - used by people with chronic kidney failure to reduce how much phosphate gets absorbed into their blood\nTarget: • quelantes de fosfato - usados en pacientes con insuficiencia renal crónica para reducir la absorción de fosfato en sangre", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: • phosphate binders - used by people with chronic kidney failure to reduce how much phosphate gets absorbed into their blood\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• phosphate binders - used by people with chronic kidney failure to reduce how much phosphate gets absorbed into their blood", "es": "• quelantes de fosfato - usados en pacientes con insuficiencia renal crónica para reducir la absorción de fosfato en sangre" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Each Podhaler device and its case are used for seven days and then discarded and replaced.\nTarget: Cada dispositivo Podhaler y su estuche se utilizan durante siete días y luego se desechan y sustituyen.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Each Podhaler device and its case are used for seven days and then discarded and replaced.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Each Podhaler device and its case are used for seven days and then discarded and replaced.", "es": "Cada dispositivo Podhaler y su estuche se utilizan durante siete días y luego se desechan y sustituyen." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: What Telmisartan Actavis looks like and contents of the pack 20 mg tablets are white, round, flat with logo T on one side\nTarget: Aspecto de Telmisartán Actavis y contenido del envase Los comprimidos de 20 mg son blancos, redondos, planos con el logo T en una cara", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: What Telmisartan Actavis looks like and contents of the pack 20 mg tablets are white, round, flat with logo T on one side\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "What Telmisartan Actavis looks like and contents of the pack 20 mg tablets are white, round, flat with logo T on one side", "es": "Aspecto de Telmisartán Actavis y contenido del envase Los comprimidos de 20 mg son blancos, redondos, planos con el logo T en una cara" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: How are capsicum medicines approved in the EU?\nTarget: ¿Cómo se aprueban en la UE los medicamentos que contienen fruto de cápsico?", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: How are capsicum medicines approved in the EU?\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "How are capsicum medicines approved in the EU?", "es": "¿Cómo se aprueban en la UE los medicamentos que contienen fruto de cápsico?" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Desloratadine ratiopharm contains lactose\nTarget: Desloratadine ratiopharm contiene lactosa", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Desloratadine ratiopharm contains lactose\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Desloratadine ratiopharm contains lactose", "es": "Desloratadine ratiopharm contiene lactosa" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Sofosbuvir (400 mg once daily)/ velpatasvir (100 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily)3\nTarget: Sofosbuvir (400 mg una vez al día)/velpatasvir (100 mg una vez al día), emtricitabina (200 mg una vez al día)/tenofovir alafenamida (10 mg una vez al día)3", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Sofosbuvir (400 mg once daily)/ velpatasvir (100 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily)3\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Sofosbuvir (400 mg once daily)/ velpatasvir (100 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily)3", "es": "Sofosbuvir (400 mg una vez al día)/velpatasvir (100 mg una vez al día), emtricitabina (200 mg una vez al día)/tenofovir alafenamida (10 mg una vez al día)3" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Anaemia Neutropenia Leukopenia\nTarget: Anemia Neutropenia Leucopenia", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Anaemia Neutropenia Leukopenia\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Anaemia Neutropenia Leukopenia", "es": "Anemia Neutropenia Leucopenia" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Pylobactell tablet - 6 glass tubes with caps and bar code labels - 3 additional bar code labels - 30 ml mixing and administration vial.\nTarget: - Seis tubos de vidrio, con tapas y etiquetas con código de barras.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Pylobactell tablet - 6 glass tubes with caps and bar code labels - 3 additional bar code labels - 30 ml mixing and administration vial.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Pylobactell tablet - 6 glass tubes with caps and bar code labels - 3 additional bar code labels - 30 ml mixing and administration vial.", "es": "- Seis tubos de vidrio, con tapas y etiquetas con código de barras." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Link to the withdrawal letter.\nTarget: enlace con la carta de retirada de la solicitud.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Link to the withdrawal letter.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Link to the withdrawal letter.", "es": "enlace con la carta de retirada de la solicitud." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Profender for Medium Cats (> 2.5 - 5 kg)\nTarget: Profender para gatos medianos (> 2,5 - 5 kg)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Profender for Medium Cats (> 2.5 - 5 kg)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Profender for Medium Cats (> 2.5 - 5 kg)", "es": "Profender para gatos medianos (> 2,5 - 5 kg)" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Luxembourg: Meronem IV\nTarget: Lituania: Meronem IV Luxemburgo: Meronem IV Malta: Meronem IV", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Luxembourg: Meronem IV\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Luxembourg: Meronem IV", "es": "Lituania: Meronem IV Luxemburgo: Meronem IV Malta: Meronem IV" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Table 9 Outcomes at Months 6 and 24 (BRIGHTER and CRYSTAL)\nTarget: Tabla 9 Resultados a los Meses 6 y 24 (BRIGHTER y CRYSTAL)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Table 9 Outcomes at Months 6 and 24 (BRIGHTER and CRYSTAL)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Table 9 Outcomes at Months 6 and 24 (BRIGHTER and CRYSTAL)", "es": "Tabla 9 Resultados a los Meses 6 y 24 (BRIGHTER y CRYSTAL)" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: • low count of white blood cells that fight infection; pain or swollen glands (lymph nodes) in the neck, armpit and groin\nTarget: • recuento bajo de los leucocitos responsables de combatir las infecciones; dolor o hinchazón de ganglios linfáticos del cuello, las axilas y las ingles", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: • low count of white blood cells that fight infection; pain or swollen glands (lymph nodes) in the neck, armpit and groin\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• low count of white blood cells that fight infection; pain or swollen glands (lymph nodes) in the neck, armpit and groin", "es": "• recuento bajo de los leucocitos responsables de combatir las infecciones; dolor o hinchazón de ganglios linfáticos del cuello, las axilas y las ingles" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: A potential increased risk of liver enzymes increase cannot be excluded.\nTarget: No se puede excluir un aumento potencial del riesgo de aumento de las enzimas hepáticas.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: A potential increased risk of liver enzymes increase cannot be excluded.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "A potential increased risk of liver enzymes increase cannot be excluded.", "es": "No se puede excluir un aumento potencial del riesgo de aumento de las enzimas hepáticas." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Keep the vial in the outer carton in order to protect from light.\nTarget: Conservar el vial dentro del envase exterior para mantenerlo protegido de la luz.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Keep the vial in the outer carton in order to protect from light.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Keep the vial in the outer carton in order to protect from light.", "es": "Conservar el vial dentro del envase exterior para mantenerlo protegido de la luz." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: - Do not use in cats less than 6 weeks of age.\nTarget: - No administrar a gatos de menos de 6 semanas.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: - Do not use in cats less than 6 weeks of age.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "- Do not use in cats less than 6 weeks of age.", "es": "- No administrar a gatos de menos de 6 semanas." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Reckitt Benckiser Healthcare (UK) Ltd\nTarget: Reino Unido Reckitt Benckiser Healthcare (UK) Ltd.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Reckitt Benckiser Healthcare (UK) Ltd\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Reckitt Benckiser Healthcare (UK) Ltd", "es": "Reino Unido Reckitt Benckiser Healthcare (UK) Ltd." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: 10 pre-filled syringes with needles\nTarget: 10 jeringas precargadas con agujas", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: 10 pre-filled syringes with needles\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "10 pre-filled syringes with needles", "es": "10 jeringas precargadas con agujas" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: 2500 Valby DENMARK\nTarget: 2500 Valby Dinamarca", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: 2500 Valby DENMARK\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "2500 Valby DENMARK", "es": "2500 Valby Dinamarca" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: This corresponds to a 3.8 cm line of ointment (see below).\nTarget: Esto corresponde a una línea de pomada de 3,8 cm (véase más adelante).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: This corresponds to a 3.8 cm line of ointment (see below).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "This corresponds to a 3.8 cm line of ointment (see below).", "es": "Esto corresponde a una línea de pomada de 3,8 cm (véase más adelante)." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Other medicines and Epclusa\nTarget: Otros medicamentos y Epclusa", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Other medicines and Epclusa\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Other medicines and Epclusa", "es": "Otros medicamentos y Epclusa" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: - Pull the needle straight out of the skin.\nTarget: - Retirar la aguja para inyección de la piel.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: - Pull the needle straight out of the skin.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "- Pull the needle straight out of the skin.", "es": "- Retirar la aguja para inyección de la piel." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Clinical signs of porcine colonic spirochaetosis (colitis)\nTarget: Espiroquetosis cólica porcina (colitis)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Clinical signs of porcine colonic spirochaetosis (colitis)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Clinical signs of porcine colonic spirochaetosis (colitis)", "es": "Espiroquetosis cólica porcina (colitis)" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Toxicity a\nTarget: Toxicidad a", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Toxicity a\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Toxicity a", "es": "Toxicidad a" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Rare: non-protein-nitrogen (Npn) 2 increased\nTarget: Raras: aumento del nitrógeno no proteínico (Npn) (2) Poco frecuentes: dolor de cabeza", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Rare: non-protein-nitrogen (Npn) 2 increased\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Rare: non-protein-nitrogen (Npn) 2 increased", "es": "Raras: aumento del nitrógeno no proteínico (Npn) (2) Poco frecuentes: dolor de cabeza" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Polyvinylchloride bag containing 800 ml of solvent in individual over-pouch.\nTarget: Bolsa de cloruro de polivinilo con 800 ml en una funda individual.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Polyvinylchloride bag containing 800 ml of solvent in individual over-pouch.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Polyvinylchloride bag containing 800 ml of solvent in individual over-pouch.", "es": "Bolsa de cloruro de polivinilo con 800 ml en una funda individual." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Adolescent from 9 to 17 years old:\nTarget: Adolescentes entre 9 y 17 años de edad:", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Adolescent from 9 to 17 years old:\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Adolescent from 9 to 17 years old:", "es": "Adolescentes entre 9 y 17 años de edad:" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Lacrimation increased\nTarget: • Mayor producción de lágrimas", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Lacrimation increased\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Lacrimation increased", "es": "• Mayor producción de lágrimas" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: The average molecular mass of pegloticase is approximately 545 kDa of which the protein moiety constitutes approximately 137 kDa.\nTarget: La masa molecular media de la pegloticasa es aproximadamente de 545 kDa, de los cuales aproximadamente 137 kDa corresponden a la fracción proteica.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: The average molecular mass of pegloticase is approximately 545 kDa of which the protein moiety constitutes approximately 137 kDa.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "The average molecular mass of pegloticase is approximately 545 kDa of which the protein moiety constitutes approximately 137 kDa.", "es": "La masa molecular media de la pegloticasa es aproximadamente de 545 kDa, de los cuales aproximadamente 137 kDa corresponden a la fracción proteica." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: BOVECTIN Ivermectin 10 mg/ml\nTarget: BOVECTIN Ivermectina 10 mg/ml", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: BOVECTIN Ivermectin 10 mg/ml\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "BOVECTIN Ivermectin 10 mg/ml", "es": "BOVECTIN Ivermectina 10 mg/ml" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: • Autoimmune hepatitis\nTarget: • Hepatitis autoinmune", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: • Autoimmune hepatitis\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Autoimmune hepatitis", "es": "• Hepatitis autoinmune" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE\nTarget: A FABRICANTE(S) DEL (DE LOS) PRINCIPIO(S) ACTIVO(S) BIOLÓGICO(S) ACTIVO(S) Y TITULAR(ES) DE LA AUTORIZACIÓN DE FABRICACIÓN RESPONSABLE(S) DE LA LIBERACIÓN DE LOS LOTES", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE", "es": "A FABRICANTE(S) DEL (DE LOS) PRINCIPIO(S) ACTIVO(S) BIOLÓGICO(S) ACTIVO(S) Y TITULAR(ES) DE LA AUTORIZACIÓN DE FABRICACIÓN RESPONSABLE(S) DE LA LIBERACIÓN DE LOS LOTES" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: What were the major concerns that led the CHMP to recommend the refusal of the change to the marketing authorisation?\nTarget: ¿Cuáles fueron los principales problemas que llevaron al CHMP a recomendar que se denegara la modificación de la autorización de comercialización?", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: What were the major concerns that led the CHMP to recommend the refusal of the change to the marketing authorisation?\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "What were the major concerns that led the CHMP to recommend the refusal of the change to the marketing authorisation?", "es": "¿Cuáles fueron los principales problemas que llevaron al CHMP a recomendar que se denegara la modificación de la autorización de comercialización?" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: STEP 4\nTarget: PASO 4", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: STEP 4\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "STEP 4", "es": "PASO 4" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: If ALT and AST levels remain below 3-times the upper limit of normal (ULN), Jinarc therapy may be cautiously re-started, with frequent monitoring at the same or lower doses, as transaminase levels appear to stabilise during continued therapy in some patients.\nTarget: Si los valores de ALT y AST se mantienen por debajo de tres veces el límite superior normal (LSN), se puede continuar el tratamiento con Jinarc con precaución, manteniendo una supervisión frecuente con las mismas dosis o bien a dosis más bajas, ya que en algunos pacientes, las concentraciones de transaminasas parecen estabilizarse durante el tratamiento continuo.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: If ALT and AST levels remain below 3-times the upper limit of normal (ULN), Jinarc therapy may be cautiously re-started, with frequent monitoring at the same or lower doses, as transaminase levels appear to stabilise during continued therapy in some patients.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "If ALT and AST levels remain below 3-times the upper limit of normal (ULN), Jinarc therapy may be cautiously re-started, with frequent monitoring at the same or lower doses, as transaminase levels appear to stabilise during continued therapy in some patients.", "es": "Si los valores de ALT y AST se mantienen por debajo de tres veces el límite superior normal (LSN), se puede continuar el tratamiento con Jinarc con precaución, manteniendo una supervisión frecuente con las mismas dosis o bien a dosis más bajas, ya que en algunos pacientes, las concentraciones de transaminasas parecen estabilizarse durante el tratamiento continuo." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: For those < 90 kg, the 1-inch, 23 gauge needle (25.4 mm x 0.64 mm) is recommended.\nTarget: En los pacientes < 90 kg, se recomienda la aguja de calibre 23 de 1 pulgada (25,4 mm x 0,64 mm).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: For those < 90 kg, the 1-inch, 23 gauge needle (25.4 mm x 0.64 mm) is recommended.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "For those < 90 kg, the 1-inch, 23 gauge needle (25.4 mm x 0.64 mm) is recommended.", "es": "En los pacientes < 90 kg, se recomienda la aguja de calibre 23 de 1 pulgada (25,4 mm x 0,64 mm)." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: There is insufficient data on the diagnostic liability of the Helicobacter Test INFAI to recommend its use in patients with gastrectomy.\nTarget: Hay datos insuficientes sobre la capacidad diagnóstica del Helicobacter Test INFAI para recomendar su uso en pacientes con gastrectomía.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: There is insufficient data on the diagnostic liability of the Helicobacter Test INFAI to recommend its use in patients with gastrectomy.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "There is insufficient data on the diagnostic liability of the Helicobacter Test INFAI to recommend its use in patients with gastrectomy.", "es": "Hay datos insuficientes sobre la capacidad diagnóstica del Helicobacter Test INFAI para recomendar su uso en pacientes con gastrectomía." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Haemolytic units\nTarget: Unidades hemolíticas", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Haemolytic units\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Haemolytic units", "es": "Unidades hemolíticas" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Do not overtighten (2).\nTarget: No la apriete en exceso (2).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Do not overtighten (2).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Do not overtighten (2).", "es": "No la apriete en exceso (2)." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Diclofenac sodium Arthrotec 50 modified release tablets\nTarget: Diclofenaco sódico Arthrotec 50 modified release tablets", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Diclofenac sodium Arthrotec 50 modified release tablets\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Diclofenac sodium Arthrotec 50 modified release tablets", "es": "Diclofenaco sódico Arthrotec 50 modified release tablets" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Prontax subcutaneous Cattle\nTarget: Prontax subcutánea", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Prontax subcutaneous Cattle\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Prontax subcutaneous Cattle", "es": "Prontax subcutánea" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Parenteral Inhalation\nTarget: Parenteral Inhalatoria", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Parenteral Inhalation\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Parenteral Inhalation", "es": "Parenteral Inhalatoria" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Renal failure may not be reversible with discontinuation of therapy and dialysis may be required.\nTarget: Incluso después de suspender el tratamiento, el fallo renal puede ser irreversible y precisar diálisis.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Renal failure may not be reversible with discontinuation of therapy and dialysis may be required.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Renal failure may not be reversible with discontinuation of therapy and dialysis may be required.", "es": "Incluso después de suspender el tratamiento, el fallo renal puede ser irreversible y precisar diálisis." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: If you suffer from these side effects, do not drive any vehicles and/or use any machines.\nTarget: Si sufre estos efectos adversos, no conduzca ningún vehículo ni utilice máquinas.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: If you suffer from these side effects, do not drive any vehicles and/or use any machines.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "If you suffer from these side effects, do not drive any vehicles and/or use any machines.", "es": "Si sufre estos efectos adversos, no conduzca ningún vehículo ni utilice máquinas." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Eviplera has not been studied in patients with severe hepatic impairment (CPT Score C).\nTarget: No se ha estudiado Eviplera en pacientes con insuficiencia hepática grave (puntuación C de CPT).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Eviplera has not been studied in patients with severe hepatic impairment (CPT Score C).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Eviplera has not been studied in patients with severe hepatic impairment (CPT Score C).", "es": "No se ha estudiado Eviplera en pacientes con insuficiencia hepática grave (puntuación C de CPT)." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Each tablet contains 180 mg of deferasirox.\nTarget: Cada sobre contiene 180 mg de deferasirox.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Each tablet contains 180 mg of deferasirox.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Each tablet contains 180 mg of deferasirox.", "es": "Cada sobre contiene 180 mg de deferasirox." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Place your other hand on the longer portion of the container.\nTarget: Colocar la otra mano sobre la parte más larga del envase.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Place your other hand on the longer portion of the container.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Place your other hand on the longer portion of the container.", "es": "Colocar la otra mano sobre la parte más larga del envase." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Other information about Bonviva\nTarget: Otras informaciones sobre Bonviva", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Other information about Bonviva\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Other information about Bonviva", "es": "Otras informaciones sobre Bonviva" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).\nTarget: Las frecuencias se definen como: muy frecuentes (≥1/10); frecuentes (≥1/100 a <1/10); poco frecuentes (≥1/1.000 a <1/100); raras (≥1/10.000 a <1/1.000); muy raras (<1/10.000); frecuencia no conocida (no puede estimarse a partir de los datos disponibles).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).", "es": "Las frecuencias se definen como: muy frecuentes (≥1/10); frecuentes (≥1/100 a <1/10); poco frecuentes (≥1/1.000 a <1/100); raras (≥1/10.000 a <1/1.000); muy raras (<1/10.000); frecuencia no conocida (no puede estimarse a partir de los datos disponibles)." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: The cumulative incidence of relapse/progression is 15.7% (90% CI 8.6-22.9%) at month +12.\nTarget: La incidencia acumulada de la recidiva/progresión es del 15,7 % (IC del 90 % 8,6-22,9 %) al mes +12.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: The cumulative incidence of relapse/progression is 15.7% (90% CI 8.6-22.9%) at month +12.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "The cumulative incidence of relapse/progression is 15.7% (90% CI 8.6-22.9%) at month +12.", "es": "La incidencia acumulada de la recidiva/progresión es del 15,7 % (IC del 90 % 8,6-22,9 %) al mes +12." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Bortezomib Hospira therapy should be withheld\nTarget: Se debe interrumpir el tratamiento de Bortezomib Hospira", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Bortezomib Hospira therapy should be withheld\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Bortezomib Hospira therapy should be withheld", "es": "Se debe interrumpir el tratamiento de Bortezomib Hospira" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: • Gottfried KREUTZ (Germany) Alternate: Karl BROICH2\nTarget: • Gottfried KREUTZ (Alemania) Suplente: Karl BROICH2", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: • Gottfried KREUTZ (Germany) Alternate: Karl BROICH2\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Gottfried KREUTZ (Germany) Alternate: Karl BROICH2", "es": "• Gottfried KREUTZ (Alemania) Suplente: Karl BROICH2" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: STEP 6 Remove and Dispose of the Needle\nTarget: Retire y Deseche la Aguja", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: STEP 6 Remove and Dispose of the Needle\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "STEP 6 Remove and Dispose of the Needle", "es": "Retire y Deseche la Aguja" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Other side effects include: - Common (may affect up to 1 in 10 people): Benign polyps in the stomach\nTarget: Otros efectos adversos incluyen: - Efectos adversos frecuentes (pueden afectar hasta 1 de cada 10 personas): Pólipos benignos en el estómago.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Other side effects include: - Common (may affect up to 1 in 10 people): Benign polyps in the stomach\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Other side effects include: - Common (may affect up to 1 in 10 people): Benign polyps in the stomach", "es": "Otros efectos adversos incluyen: - Efectos adversos frecuentes (pueden afectar hasta 1 de cada 10 personas): Pólipos benignos en el estómago." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Symptomatic recurrent VTE* 50\nTarget: Hemorragia intracraneal* 55", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Symptomatic recurrent VTE* 50\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Symptomatic recurrent VTE* 50", "es": "Hemorragia intracraneal* 55" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: 1 Committee for Medicinal Products for Human Use (CHMP) or Committee for Medicinal Products for Veterinary Use (CVMP).\nTarget: 1 Comité de Medicamentos de Uso Humano (CHMP), o Comité de Medicamentos de Uso Veterinario (CVMP).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: 1 Committee for Medicinal Products for Human Use (CHMP) or Committee for Medicinal Products for Veterinary Use (CVMP).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "1 Committee for Medicinal Products for Human Use (CHMP) or Committee for Medicinal Products for Veterinary Use (CVMP).", "es": "1 Comité de Medicamentos de Uso Humano (CHMP), o Comité de Medicamentos de Uso Veterinario (CVMP)." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Possible side effects 5 How to store PhotoBarr 6.\nTarget: Posibles efectos adversos 5.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Possible side effects 5 How to store PhotoBarr 6.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Possible side effects 5 How to store PhotoBarr 6.", "es": "Posibles efectos adversos 5." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Bromocriptine is used to prevent or suppress lactation in women who have given birth.\nTarget: La bromocriptina se utiliza para prevenir o suprimir la lactancia en mujeres que han dado a luz.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Bromocriptine is used to prevent or suppress lactation in women who have given birth.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Bromocriptine is used to prevent or suppress lactation in women who have given birth.", "es": "La bromocriptina se utiliza para prevenir o suprimir la lactancia en mujeres que han dado a luz." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Superiority was not shown for the main outcome measures and concluding from statistically not different results on non-inferiority was not possible.\nTarget: No se demostró superioridad con respecto a los criterios de valoración principales, ni se pudo establecer la ausencia de inferioridad a partir de unos resultados que no fueron estadísticamente diferentes.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Superiority was not shown for the main outcome measures and concluding from statistically not different results on non-inferiority was not possible.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Superiority was not shown for the main outcome measures and concluding from statistically not different results on non-inferiority was not possible.", "es": "No se demostró superioridad con respecto a los criterios de valoración principales, ni se pudo establecer la ausencia de inferioridad a partir de unos resultados que no fueron estadísticamente diferentes." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Features of randomized patients\nTarget: Características de los pacientes aleatorizados", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Features of randomized patients\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Features of randomized patients", "es": "Características de los pacientes aleatorizados" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Tablet coat for 5 mg and 10 mg film-coated tablets\nTarget: Recubrimiento de los comprimidos recubiertos con película de 5 mg y 10 mg", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Tablet coat for 5 mg and 10 mg film-coated tablets\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Tablet coat for 5 mg and 10 mg film-coated tablets", "es": "Recubrimiento de los comprimidos recubiertos con película de 5 mg y 10 mg" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: • allergic reaction (rash, itching, red raised itchy rash (hives), difficulty breathing or swallowing, dizziness)\nTarget: • reacción alérgica (exantemas, picores, sarpullido rojizo con picor (urticaria), dificultad para respirar o para tragar, mareos)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: • allergic reaction (rash, itching, red raised itchy rash (hives), difficulty breathing or swallowing, dizziness)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• allergic reaction (rash, itching, red raised itchy rash (hives), difficulty breathing or swallowing, dizziness)", "es": "• reacción alérgica (exantemas, picores, sarpullido rojizo con picor (urticaria), dificultad para respirar o para tragar, mareos)" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Myfenax 250 mg hard capsules\nTarget: Myfenax 250 mg cápsulas duras EFG", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Myfenax 250 mg hard capsules\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Myfenax 250 mg hard capsules", "es": "Myfenax 250 mg cápsulas duras EFG" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Very common (may affect more than 1 in 10 people):\nTarget: Muy frecuentes (pueden afectar a más de 1 de cada 10 pacientes)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Very common (may affect more than 1 in 10 people):\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Very common (may affect more than 1 in 10 people):", "es": "Muy frecuentes (pueden afectar a más de 1 de cada 10 pacientes)" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: 24 months\nTarget: 24 meses", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: 24 months\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "24 months", "es": "24 meses" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Clinically relevant improvement in these studies was defined a priori as at least 4-point improvement on the ADAS-Cog, improvement on the CIBIC-Plus, or at least a 10 % improvement on the PDS.\nTarget: En estos ensayos se definió a priori como una mejoría clínicamente relevante: una mejoría en el ADAS-Cog de al menos 4 puntos, una mejoría en el CIBIC-Plus o al menos un 10% de mejoría en la PDS.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Clinically relevant improvement in these studies was defined a priori as at least 4-point improvement on the ADAS-Cog, improvement on the CIBIC-Plus, or at least a 10 % improvement on the PDS.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Clinically relevant improvement in these studies was defined a priori as at least 4-point improvement on the ADAS-Cog, improvement on the CIBIC-Plus, or at least a 10 % improvement on the PDS.", "es": "En estos ensayos se definió a priori como una mejoría clínicamente relevante: una mejoría en el ADAS-Cog de al menos 4 puntos, una mejoría en el CIBIC-Plus o al menos un 10% de mejoría en la PDS." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: For enquiries concerning PMF certificates\nTarget: certificados PMF", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: For enquiries concerning PMF certificates\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "For enquiries concerning PMF certificates", "es": "certificados PMF" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Cosmetics are evaluated by authorities in each Member State.\nTarget: Los cosméticos son evaluados por las autoridades de cada estado miembro.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Cosmetics are evaluated by authorities in each Member State.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Cosmetics are evaluated by authorities in each Member State.", "es": "Los cosméticos son evaluados por las autoridades de cada estado miembro." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Zyclara has been shown to be effective in clearing actinic keratosis from the skin in two main studies involving 479 patients with actinic keratosis on the face and scalp.\nTarget: Se ha demostrado que Zyclara es eficaz para eliminar la queratosis actínica de la piel en dos estudios principales realizados en 479 pacientes con queratosis actínica en la cara y el cuero cabelludo.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Zyclara has been shown to be effective in clearing actinic keratosis from the skin in two main studies involving 479 patients with actinic keratosis on the face and scalp.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Zyclara has been shown to be effective in clearing actinic keratosis from the skin in two main studies involving 479 patients with actinic keratosis on the face and scalp.", "es": "Se ha demostrado que Zyclara es eficaz para eliminar la queratosis actínica de la piel en dos estudios principales realizados en 479 pacientes con queratosis actínica en la cara y el cuero cabelludo." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Shake vigorously each time before use for approximately 15 seconds.\nTarget: Agite vigorosamente cada vez antes de su administración, aproximadamente 15 segundos.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Shake vigorously each time before use for approximately 15 seconds.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Shake vigorously each time before use for approximately 15 seconds.", "es": "Agite vigorosamente cada vez antes de su administración, aproximadamente 15 segundos." } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: Strength Volume of solution\nTarget: Concentración Volumen de solución", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: Strength Volume of solution\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Strength Volume of solution", "es": "Concentración Volumen de solución" } }
{ "translation": { "text": "Translate the source text from English to Spanish.\nSource: 30-day carton\nTarget: Caja de 30 días", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Spanish.\nEnglish: 30-day carton\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "30-day carton", "es": "Caja de 30 días" } }
{ "translation": { "text": "Glossary:\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Contents of the pack and other information What Effentora contains\nSpanish: Contenido del envase e información adicional Composición de Effentora", "en_prompt": "<|im_start|>user\nGlossary:\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Contents of the pack and other information What Effentora contains\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "information|||información", "en": "Contents of the pack and other information What Effentora contains", "es": "Contenido del envase e información adicional Composición de Effentora" } }
{ "translation": { "text": "Glossaries:\n\"active substance\" -> \"principio activo\"\n\"system\" -> \"sistema\"\n\"fentanyl\" -> \"fentanilo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Ionsys transdermal system delivers the active substance, fentanyl, through the skin.\nSpanish: El sistema de liberación transdérmica Ionsys administra el principio activo, el fentanilo, a través de la piel.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"active substance\" -> \"principio activo\"\n\"system\" -> \"sistema\"\n\"fentanyl\" -> \"fentanilo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Ionsys transdermal system delivers the active substance, fentanyl, through the skin.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "active substance|||principio activo\tsystem|||sistema\tfentanyl|||fentanilo", "en": "Ionsys transdermal system delivers the active substance, fentanyl, through the skin.", "es": "El sistema de liberación transdérmica Ionsys administra el principio activo, el fentanilo, a través de la piel." } }
{ "translation": { "text": "Glossary:\n\"inflammation\" -> \"inflamación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not inject into an area with signs of inflammation, skin damage, lumps and/or bruises.\nSpanish: No inyecte en zonas con signos de inflamación, piel dañada, hinchazón y/o hematomas.", "en_prompt": "<|im_start|>user\nGlossary:\n\"inflammation\" -> \"inflamación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not inject into an area with signs of inflammation, skin damage, lumps and/or bruises.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "inflammation|||inflamación", "en": "Do not inject into an area with signs of inflammation, skin damage, lumps and/or bruises.", "es": "No inyecte en zonas con signos de inflamación, piel dañada, hinchazón y/o hematomas." } }
{ "translation": { "text": "Glossary:\n\"suspension\" -> \"suspensión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: White or whitish lyophilisate for oral suspension.\nSpanish: Liofilizado para suspensión oral blanco o blanquecino.", "en_prompt": "<|im_start|>user\nGlossary:\n\"suspension\" -> \"suspensión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: White or whitish lyophilisate for oral suspension.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "suspension|||suspensión", "en": "White or whitish lyophilisate for oral suspension.", "es": "Liofilizado para suspensión oral blanco o blanquecino." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"therapy\" -> \"terapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: When the decision is made to discontinue inhaled nitric oxide therapy, the dose should be reduced to 1 ppm for 30 minutes to one hour.\nSpanish: Cuando se tome la decisión de interrumpir la terapia de óxido nítrico inhalado, la dosis deberá mantenerse a 1 ppm de 30 minutos a una hora.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"therapy\" -> \"terapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: When the decision is made to discontinue inhaled nitric oxide therapy, the dose should be reduced to 1 ppm for 30 minutes to one hour.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\ttherapy|||terapia", "en": "When the decision is made to discontinue inhaled nitric oxide therapy, the dose should be reduced to 1 ppm for 30 minutes to one hour.", "es": "Cuando se tome la decisión de interrumpir la terapia de óxido nítrico inhalado, la dosis deberá mantenerse a 1 ppm de 30 minutos a una hora." } }
{ "translation": { "text": "Glossary:\n\"powder\" -> \"polvo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Equisolon 33 mg/g oral powder for horses\nSpanish: Equisolon 33 mg/g polvo para administración oral para caballos", "en_prompt": "<|im_start|>user\nGlossary:\n\"powder\" -> \"polvo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Equisolon 33 mg/g oral powder for horses\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "powder|||polvo", "en": "Equisolon 33 mg/g oral powder for horses", "es": "Equisolon 33 mg/g polvo para administración oral para caballos" } }
{ "translation": { "text": "Glossary:\n\"amiodarone\" -> \"amiodarona\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: AVRO studied the effect of vernakalant versus intravenous amiodarone in patients with recent onset atrial fibrillation (3 hrs to 48 hrs).\nSpanish: En el AVRO se estudió el efecto de vernakalant frente a amiodarona intravenosa en pacientes con fibrilación auricular de inicio reciente (de 3 horas a 48 horas).", "en_prompt": "<|im_start|>user\nGlossary:\n\"amiodarone\" -> \"amiodarona\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: AVRO studied the effect of vernakalant versus intravenous amiodarone in patients with recent onset atrial fibrillation (3 hrs to 48 hrs).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "amiodarone|||amiodarona", "en": "AVRO studied the effect of vernakalant versus intravenous amiodarone in patients with recent onset atrial fibrillation (3 hrs to 48 hrs).", "es": "En el AVRO se estudió el efecto de vernakalant frente a amiodarona intravenosa en pacientes con fibrilación auricular de inicio reciente (de 3 horas a 48 horas)." } }
{ "translation": { "text": "Glossary:\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Since contrast medium elimination is delayed in patients with severely impaired renal function, the benefits must be weighed very carefully against the risks in such cases.\nSpanish: En los casos de alteraciones graves de la función renal, debe realizarse una cuidadosa valoración riesgobeneficio, ya que la eliminación del medio de contraste está retrasada.", "en_prompt": "<|im_start|>user\nGlossary:\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Since contrast medium elimination is delayed in patients with severely impaired renal function, the benefits must be weighed very carefully against the risks in such cases.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "renal|||renal", "en": "Since contrast medium elimination is delayed in patients with severely impaired renal function, the benefits must be weighed very carefully against the risks in such cases.", "es": "En los casos de alteraciones graves de la función renal, debe realizarse una cuidadosa valoración riesgobeneficio, ya que la eliminación del medio de contraste está retrasada." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • patients having “high-dose immunosuppressive therapy” after “hematopoietic stem cell transplant” (HSCT).\nSpanish: • pacientes que estén recibiendo \"altas dosis de un tratamiento inmunodepresivo\" tras un", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • patients having “high-dose immunosuppressive therapy” after “hematopoietic stem cell transplant” (HSCT).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "• patients having “high-dose immunosuppressive therapy” after “hematopoietic stem cell transplant” (HSCT).", "es": "• pacientes que estén recibiendo \"altas dosis de un tratamiento inmunodepresivo\" tras un" } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"placebo\" -> \"placebo\"\n\"lumbar\" -> \"lumbar\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the pivotal study, Preotact increased BMD in the lumbar spine after 18 months treatment by 6.5% compared with -0.3% for placebo (p<0.001).\nSpanish: En el estudiopivotal, Preotact aumentó en un 6,5% la densidad mineral ósea (DMO) en la columna lumbar después de 18 meses de tratamiento, comparado con -0,3% con placebo (p<0,001).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"placebo\" -> \"placebo\"\n\"lumbar\" -> \"lumbar\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the pivotal study, Preotact increased BMD in the lumbar spine after 18 months treatment by 6.5% compared with -0.3% for placebo (p<0.001).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tplacebo|||placebo\tlumbar|||lumbar", "en": "In the pivotal study, Preotact increased BMD in the lumbar spine after 18 months treatment by 6.5% compared with -0.3% for placebo (p<0.001).", "es": "En el estudiopivotal, Preotact aumentó en un 6,5% la densidad mineral ósea (DMO) en la columna lumbar después de 18 meses de tratamiento, comparado con -0,3% con placebo (p<0,001)." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A treatment session consists of nasal administration of Spravato and a post-administration observation period.\nSpanish: Una sesión de tratamiento consiste en la administración nasal de Spravato y un período de observación tras la administración.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A treatment session consists of nasal administration of Spravato and a post-administration observation period.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento", "en": "A treatment session consists of nasal administration of Spravato and a post-administration observation period.", "es": "Una sesión de tratamiento consiste en la administración nasal de Spravato y un período de observación tras la administración." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"dystrophy\" -> \"distrofia\"\n\"vision\" -> \"visión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.\nSpanish: Luxturna está indicado para el tratamiento de adultos y niños con pérdida de visión debido a una distrofia retiniana hereditaria asociada a la mutación RPE65 bialélica confirmada y que tienen suficientes células retinianas viables.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"dystrophy\" -> \"distrofia\"\n\"vision\" -> \"visión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tdystrophy|||distrofia\tvision|||visión", "en": "Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.", "es": "Luxturna está indicado para el tratamiento de adultos y niños con pérdida de visión debido a una distrofia retiniana hereditaria asociada a la mutación RPE65 bialélica confirmada y que tienen suficientes células retinianas viables." } }
{ "translation": { "text": "Glossary:\n\"vaccination\" -> \"vacunación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It is recommended that patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Inflectra therapy.\nSpanish: Se recomienda que los pacientes lleven al día, siempre que sea posible, todas las vacunas correspondientes al calendario de vacunación en vigor antes de iniciar el tratamiento con Inflectra.", "en_prompt": "<|im_start|>user\nGlossary:\n\"vaccination\" -> \"vacunación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It is recommended that patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Inflectra therapy.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "vaccination|||vacunación", "en": "It is recommended that patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Inflectra therapy.", "es": "Se recomienda que los pacientes lleven al día, siempre que sea posible, todas las vacunas correspondientes al calendario de vacunación en vigor antes de iniciar el tratamiento con Inflectra." } }
{ "translation": { "text": "Glossary:\n\"weight\" -> \"peso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Very common side effects (may affect more than 1 in 10 people) include weight gain; sleepiness; and increases in levels of prolactin in the blood.\nSpanish: Efectos adversos muy frecuentes (que pueden afectar a más de 1 entre 10 personas) incluyen aumento de peso; somnolencia; y aumento de los niveles de prolactina en sangre.", "en_prompt": "<|im_start|>user\nGlossary:\n\"weight\" -> \"peso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Very common side effects (may affect more than 1 in 10 people) include weight gain; sleepiness; and increases in levels of prolactin in the blood.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "weight|||peso", "en": "Very common side effects (may affect more than 1 in 10 people) include weight gain; sleepiness; and increases in levels of prolactin in the blood.", "es": "Efectos adversos muy frecuentes (que pueden afectar a más de 1 entre 10 personas) incluyen aumento de peso; somnolencia; y aumento de los niveles de prolactina en sangre." } }
{ "translation": { "text": "Glossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No specific clinical studies have been performed with this combination, therefore Sprimeo HCT should not be used during the first trimester of pregnancy or in women planning to become pregnant and is contraindicated during the second and third trimesters (see section 4.3).\nSpanish: No se han realizado ensayos clínicos específicos con esta asociación, por ello Sprimeo HCT no debe utilizarse durante el primer trimestre del embarazo o en mujeres que planeen quedarse embarazadas y está contraindicado durante el segundo y tercer trimestre del embarazo (ver sección 4.3).", "en_prompt": "<|im_start|>user\nGlossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No specific clinical studies have been performed with this combination, therefore Sprimeo HCT should not be used during the first trimester of pregnancy or in women planning to become pregnant and is contraindicated during the second and third trimesters (see section 4.3).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección", "en": "No specific clinical studies have been performed with this combination, therefore Sprimeo HCT should not be used during the first trimester of pregnancy or in women planning to become pregnant and is contraindicated during the second and third trimesters (see section 4.3).", "es": "No se han realizado ensayos clínicos específicos con esta asociación, por ello Sprimeo HCT no debe utilizarse durante el primer trimestre del embarazo o en mujeres que planeen quedarse embarazadas y está contraindicado durante el segundo y tercer trimestre del embarazo (ver sección 4.3)." } }
{ "translation": { "text": "Glossary:\n\"myeloma\" -> \"mieloma\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Posology for previously untreated multiple myeloma patients eligible for haematopoietic stem cell transplantation (induction therapy)\nSpanish: Posología en pacientes con mieloma múltiple que no han sido previamente tratados y que sean candidatos a recibir un trasplante de progenitores hematopoyéticos (tratamiento de inducción) Tratamiento de combinación con dexametasona", "en_prompt": "<|im_start|>user\nGlossary:\n\"myeloma\" -> \"mieloma\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Posology for previously untreated multiple myeloma patients eligible for haematopoietic stem cell transplantation (induction therapy)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "myeloma|||mieloma", "en": "Posology for previously untreated multiple myeloma patients eligible for haematopoietic stem cell transplantation (induction therapy)", "es": "Posología en pacientes con mieloma múltiple que no han sido previamente tratados y que sean candidatos a recibir un trasplante de progenitores hematopoyéticos (tratamiento de inducción) Tratamiento de combinación con dexametasona" } }
{ "translation": { "text": "Glossaries:\n\"prescription\" -> \"receta\"\n\"doctor\" -> \"médico\"\n\"pharmacist\" -> \"farmacéutico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Tell your doctor, pharmacist or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.\nSpanish: Informe a su médico, farmacéutico o enfermero si usted está tomando o ha tomado recientemente cualquier otro medicamento, incluso los adquiridos sin receta.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"prescription\" -> \"receta\"\n\"doctor\" -> \"médico\"\n\"pharmacist\" -> \"farmacéutico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Tell your doctor, pharmacist or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "prescription|||receta\tdoctor|||médico\tpharmacist|||farmacéutico", "en": "Tell your doctor, pharmacist or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.", "es": "Informe a su médico, farmacéutico o enfermero si usted está tomando o ha tomado recientemente cualquier otro medicamento, incluso los adquiridos sin receta." } }
{ "translation": { "text": "Glossaries:\n\"veterinary medicinal product\" -> \"medicamento veterinario\"\n\"medicinal product\" -> \"medicamento\"\n\"expiry date\" -> \"fecha de caducidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle.\nSpanish: No usar este medicamento veterinario después de la fecha de caducidad que figura en la caja y en el frasco.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"veterinary medicinal product\" -> \"medicamento veterinario\"\n\"medicinal product\" -> \"medicamento\"\n\"expiry date\" -> \"fecha de caducidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "veterinary medicinal product|||medicamento veterinario\tmedicinal product|||medicamento\texpiry date|||fecha de caducidad", "en": "Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle.", "es": "No usar este medicamento veterinario después de la fecha de caducidad que figura en la caja y en el frasco." } }
{ "translation": { "text": "Glossaries:\n\"hypomagnesaemia\" -> \"hipomagnesemia\"\n\"appetite\" -> \"apetito\"\n\"hypophosphataemia\" -> \"hipofosfatemia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: metabolic acidoses, other electrolyte abnormalities, hyponatraemia, fluid overload, hyperuricaemia, hypomagnesaemia, hypokalaemia, hypocalcaemia, appetite decreased, hypercholesterolaemia, hyperlipidaemia, hypertriglyceridaemia, hypophosphataemia uncommon:\nSpanish: acidosis metabólica, otras anomalías electrolíticas, hiponatremia, sobrecarga de líquidos, hiperuricemia, hipomagnesemia, hipopotasemia, hipocalcemia, disminución del apetito, hipercolesterolemia, hiperlipidemia, hipertrigliceridemia, hipofosfatemia poco frecuentes:", "en_prompt": "<|im_start|>user\nGlossaries:\n\"hypomagnesaemia\" -> \"hipomagnesemia\"\n\"appetite\" -> \"apetito\"\n\"hypophosphataemia\" -> \"hipofosfatemia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: metabolic acidoses, other electrolyte abnormalities, hyponatraemia, fluid overload, hyperuricaemia, hypomagnesaemia, hypokalaemia, hypocalcaemia, appetite decreased, hypercholesterolaemia, hyperlipidaemia, hypertriglyceridaemia, hypophosphataemia uncommon:\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypomagnesaemia|||hipomagnesemia\tappetite|||apetito\thypophosphataemia|||hipofosfatemia", "en": "metabolic acidoses, other electrolyte abnormalities, hyponatraemia, fluid overload, hyperuricaemia, hypomagnesaemia, hypokalaemia, hypocalcaemia, appetite decreased, hypercholesterolaemia, hyperlipidaemia, hypertriglyceridaemia, hypophosphataemia uncommon:", "es": "acidosis metabólica, otras anomalías electrolíticas, hiponatremia, sobrecarga de líquidos, hiperuricemia, hipomagnesemia, hipopotasemia, hipocalcemia, disminución del apetito, hipercolesterolemia, hiperlipidemia, hipertrigliceridemia, hipofosfatemia poco frecuentes:" } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"doctor\" -> \"médico\"\n\"package leaflet\" -> \"prospecto\"\n\"pharmacist\" -> \"farmacéutico\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For more information about treatment with Jorveza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.\nSpanish: Para mayor información sobre el tratamiento con Jorveza, lea el prospecto (también incluido en el EPAR) o consulte a su médico o farmacéutico.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"doctor\" -> \"médico\"\n\"package leaflet\" -> \"prospecto\"\n\"pharmacist\" -> \"farmacéutico\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For more information about treatment with Jorveza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tdoctor|||médico\tpackage leaflet|||prospecto\tpharmacist|||farmacéutico\tinformation|||información", "en": "For more information about treatment with Jorveza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.", "es": "Para mayor información sobre el tratamiento con Jorveza, lea el prospecto (también incluido en el EPAR) o consulte a su médico o farmacéutico." } }
{ "translation": { "text": "Glossaries:\n\"sodium chloride\" -> \"cloruro de sodio\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: After the infusion is complete, flush with 30 mL of sodium chloride 9 mg/mL (0.9%) solution for injection.\nSpanish: Una vez finalizada la perfusión, se limpiará la vía con 30 ml de solución inyectable de cloruro de sodio 9 mg/ml (0,9 %).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"sodium chloride\" -> \"cloruro de sodio\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: After the infusion is complete, flush with 30 mL of sodium chloride 9 mg/mL (0.9%) solution for injection.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "sodium chloride|||cloruro de sodio\tinfusion|||perfusión", "en": "After the infusion is complete, flush with 30 mL of sodium chloride 9 mg/mL (0.9%) solution for injection.", "es": "Una vez finalizada la perfusión, se limpiará la vía con 30 ml de solución inyectable de cloruro de sodio 9 mg/ml (0,9 %)." } }
{ "translation": { "text": "Glossaries:\n\"heart\" -> \"corazón\"\n\"liver\" -> \"hígado\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: depending on how your kidneys are working - if you have recently had a heart attack or have severe circulatory problems, such as ‘shock' or breathing difficulties - if you have liver problems - if you drink alcohol to excess (either every day or only from time to time) - if you are breast-feeding.\nSpanish: Necesitará dejar de tomar Ristfor en el momento de la radiografía y durante 2 o más días después, tal como le indique su médico, dependiendo del funcionamiento de sus riñones - si ha tenido recientemente un ataque al corazón o tiene problemas circulatorios graves, como “shock” o dificultades para respirar - si tiene problemas de hígado (hepáticos) - si bebe alcohol en exceso (ya sea cada día o sólo de vez en cuando) - si se encuentra en periodo de lactancia.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"heart\" -> \"corazón\"\n\"liver\" -> \"hígado\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: depending on how your kidneys are working - if you have recently had a heart attack or have severe circulatory problems, such as ‘shock' or breathing difficulties - if you have liver problems - if you drink alcohol to excess (either every day or only from time to time) - if you are breast-feeding.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "heart|||corazón\tliver|||hígado", "en": "depending on how your kidneys are working - if you have recently had a heart attack or have severe circulatory problems, such as ‘shock' or breathing difficulties - if you have liver problems - if you drink alcohol to excess (either every day or only from time to time) - if you are breast-feeding.", "es": "Necesitará dejar de tomar Ristfor en el momento de la radiografía y durante 2 o más días después, tal como le indique su médico, dependiendo del funcionamiento de sus riñones - si ha tenido recientemente un ataque al corazón o tiene problemas circulatorios graves, como “shock” o dificultades para respirar - si tiene problemas de hígado (hepáticos) - si bebe alcohol en exceso (ya sea cada día o sólo de vez en cuando) - si se encuentra en periodo de lactancia." } }
{ "translation": { "text": "Glossary:\n\"powder\" -> \"polvo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • one vial with powder (10 ml clear glass type 1 vial with latex-free grey halogenobutyl rubber blend stopper and aluminium seal)\nSpanish: • un vial con polvo (vial de vidrio tipo 1, transparente, de 10 ml con tapón de mezcla de caucho halogenobutílico gris exento de látex y cierre de aluminio)", "en_prompt": "<|im_start|>user\nGlossary:\n\"powder\" -> \"polvo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • one vial with powder (10 ml clear glass type 1 vial with latex-free grey halogenobutyl rubber blend stopper and aluminium seal)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "powder|||polvo", "en": "• one vial with powder (10 ml clear glass type 1 vial with latex-free grey halogenobutyl rubber blend stopper and aluminium seal)", "es": "• un vial con polvo (vial de vidrio tipo 1, transparente, de 10 ml con tapón de mezcla de caucho halogenobutílico gris exento de látex y cierre de aluminio)" } }
{ "translation": { "text": "Glossary:\n\"material\" -> \"materiales\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: [*For the printed material, please refer to the guidance of the annotated QRD template.]\nSpanish: *[Para los materiales impresos, consultar la plantilla de QRD comentada.]", "en_prompt": "<|im_start|>user\nGlossary:\n\"material\" -> \"materiales\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: [*For the printed material, please refer to the guidance of the annotated QRD template.]\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "material|||materiales", "en": "[*For the printed material, please refer to the guidance of the annotated QRD template.]", "es": "*[Para los materiales impresos, consultar la plantilla de QRD comentada.]" } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"quality of life\" -> \"calidad de vida\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Nevertheless, the overall treatment benefit of nintedanib was observed without adversely affecting self-reported quality of life.\nSpanish: Sin embargo, la mejoría global proporcionada por el tratamiento con nintedanib no afectó negativamente a la calidad de vida global descrita por los propios pacientes.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"quality of life\" -> \"calidad de vida\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Nevertheless, the overall treatment benefit of nintedanib was observed without adversely affecting self-reported quality of life.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tquality of life|||calidad de vida", "en": "Nevertheless, the overall treatment benefit of nintedanib was observed without adversely affecting self-reported quality of life.", "es": "Sin embargo, la mejoría global proporcionada por el tratamiento con nintedanib no afectó negativamente a la calidad de vida global descrita por los propios pacientes." } }
{ "translation": { "text": "Glossaries:\n\"ECG\" -> \"ECG\"\n\"electrocardiogram\" -> \"ECG\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In these patients, it is recommended that an electrocardiogram (ECG) is obtained prior to dosing and at the end of the observation period.\nSpanish: En estos pacientes se recomienda realizar un electrocardiograma (ECG) antes de la primera dosis y al final del período de observación.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"ECG\" -> \"ECG\"\n\"electrocardiogram\" -> \"ECG\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In these patients, it is recommended that an electrocardiogram (ECG) is obtained prior to dosing and at the end of the observation period.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "ECG|||ECG\telectrocardiogram|||ECG", "en": "In these patients, it is recommended that an electrocardiogram (ECG) is obtained prior to dosing and at the end of the observation period.", "es": "En estos pacientes se recomienda realizar un electrocardiograma (ECG) antes de la primera dosis y al final del período de observación." } }
{ "translation": { "text": "Glossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you have an allergic reaction to Zutectra, the injection will be stopped immediately.\nSpanish: Si presenta una reacción alérgica a Zutectra, la inyección se interrumpirá inmediatamente.", "en_prompt": "<|im_start|>user\nGlossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you have an allergic reaction to Zutectra, the injection will be stopped immediately.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injection|||inyección", "en": "If you have an allergic reaction to Zutectra, the injection will be stopped immediately.", "es": "Si presenta una reacción alérgica a Zutectra, la inyección se interrumpirá inmediatamente." } }
{ "translation": { "text": "Glossaries:\n\"doctor\" -> \"médico\"\n\"liver\" -> \"hígado\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If your child is having blood tests (such as red blood cell status tests or liver fu tests (for glucose), let the doctor or nurse know that they are taking Augmentin.\nSpanish: Si se le están realizando a su hijo análisis de sangre para comprobar el funcionamiento de su hígado (estudios de función hepática) o análisis de orina (para controlar los niveles de glucosa), informe a su médico o enfermera de que está tomando Augmentin.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"doctor\" -> \"médico\"\n\"liver\" -> \"hígado\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If your child is having blood tests (such as red blood cell status tests or liver fu tests (for glucose), let the doctor or nurse know that they are taking Augmentin.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico\tliver|||hígado", "en": "If your child is having blood tests (such as red blood cell status tests or liver fu tests (for glucose), let the doctor or nurse know that they are taking Augmentin.", "es": "Si se le están realizando a su hijo análisis de sangre para comprobar el funcionamiento de su hígado (estudios de función hepática) o análisis de orina (para controlar los niveles de glucosa), informe a su médico o enfermera de que está tomando Augmentin." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Treatment with macitentan 10 mg at Month 6 resulted in a placebo-corrected mean increase in 6MWD of 22 meters (97.5% CI: 3 to 41; p = 0.0078).\nSpanish: El tratamiento con macitentan 10 mg a los 6 meses dio lugar a un aumento medio corregido para placebo en el TM6M de 22 metros (IC del 97,5% 3 a 41; p = 0,0078).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Treatment with macitentan 10 mg at Month 6 resulted in a placebo-corrected mean increase in 6MWD of 22 meters (97.5% CI: 3 to 41; p = 0.0078).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Treatment with macitentan 10 mg at Month 6 resulted in a placebo-corrected mean increase in 6MWD of 22 meters (97.5% CI: 3 to 41; p = 0.0078).", "es": "El tratamiento con macitentan 10 mg a los 6 meses dio lugar a un aumento medio corregido para placebo en el TM6M de 22 metros (IC del 97,5% 3 a 41; p = 0,0078)." } }
{ "translation": { "text": "Glossary:\n\"propofol\" -> \"propofol\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: However, there is limited clinical experience of the use of sevoflurane, after propofol induction, in bitches and queens undergoing caesarean section, without any ill effects being detected in either the bitch or queen or the puppies or kittens.\nSpanish: Sin embargo, existe experiencia clínica limitada sobre el uso de sevoflurano, tras la inducción con propofol, en perras y gatas sometidas a cesárea, sin que se detectaran efectos perjudiciales ni en las perras o las gatas ni en sus cachorros o sus gatitos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"propofol\" -> \"propofol\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: However, there is limited clinical experience of the use of sevoflurane, after propofol induction, in bitches and queens undergoing caesarean section, without any ill effects being detected in either the bitch or queen or the puppies or kittens.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "propofol|||propofol", "en": "However, there is limited clinical experience of the use of sevoflurane, after propofol induction, in bitches and queens undergoing caesarean section, without any ill effects being detected in either the bitch or queen or the puppies or kittens.", "es": "Sin embargo, existe experiencia clínica limitada sobre el uso de sevoflurano, tras la inducción con propofol, en perras y gatas sometidas a cesárea, sin que se detectaran efectos perjudiciales ni en las perras o las gatas ni en sus cachorros o sus gatitos." } }
{ "translation": { "text": "Glossary:\n\"reconstitution\" -> \"reconstitución\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Write the date of reconstitution and expiry on the label (expiry is 1 month after reconstitution).\nSpanish: Escriba la fecha de reconstitución y la de caducidad en la etiqueta (la caducidad es 1 mes después de la reconstitución).", "en_prompt": "<|im_start|>user\nGlossary:\n\"reconstitution\" -> \"reconstitución\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Write the date of reconstitution and expiry on the label (expiry is 1 month after reconstitution).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "reconstitution|||reconstitución", "en": "Write the date of reconstitution and expiry on the label (expiry is 1 month after reconstitution).", "es": "Escriba la fecha de reconstitución y la de caducidad en la etiqueta (la caducidad es 1 mes después de la reconstitución)." } }
{ "translation": { "text": "Glossary:\n\"fever\" -> \"fiebre\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • fever or chills\nSpanish: • fiebre o escalofríos", "en_prompt": "<|im_start|>user\nGlossary:\n\"fever\" -> \"fiebre\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • fever or chills\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "fever|||fiebre", "en": "• fever or chills", "es": "• fiebre o escalofríos" } }
{ "translation": { "text": "Glossaries:\n\"agent\" -> \"agente\"\n\"didanosine\" -> \"didanosina\"\n\"acid\" -> \"ácido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets.\nSpanish: El mecanismo de interacción es la reducción de la solubilidad de atazanavir con un aumentode pH relacionado con la presencia de un agente anti-ácido en los comprimidos tamponados de didanosina.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"agent\" -> \"agente\"\n\"didanosine\" -> \"didanosina\"\n\"acid\" -> \"ácido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "agent|||agente\tdidanosine|||didanosina\tacid|||ácido", "en": "reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets.", "es": "El mecanismo de interacción es la reducción de la solubilidad de atazanavir con un aumentode pH relacionado con la presencia de un agente anti-ácido en los comprimidos tamponados de didanosina." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Posology for MDS/MPD The recommended dose of imatinib is 400 mg/day for adult patients with MDS/MPD.\nSpanish: Posología para SMD/SMP La dosis recomendada de imatinib para pacientes adultos con SMD/SMP es de 400 mg/día.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Posology for MDS/MPD The recommended dose of imatinib is 400 mg/day for adult patients with MDS/MPD.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "Posology for MDS/MPD The recommended dose of imatinib is 400 mg/day for adult patients with MDS/MPD.", "es": "Posología para SMD/SMP La dosis recomendada de imatinib para pacientes adultos con SMD/SMP es de 400 mg/día." } }
{ "translation": { "text": "Glossary:\n\"in vitro\" -> \"in vitro\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Pharmacologically, Rebetol increases phosphorylated metabolites of purine nucleosides in vitro.\nSpanish: Farmacológicamente, Rebetol aumenta los metabolitos fosforilados de los nucleósidos de purina in vitro.", "en_prompt": "<|im_start|>user\nGlossary:\n\"in vitro\" -> \"in vitro\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Pharmacologically, Rebetol increases phosphorylated metabolites of purine nucleosides in vitro.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "in vitro|||in vitro", "en": "Pharmacologically, Rebetol increases phosphorylated metabolites of purine nucleosides in vitro.", "es": "Farmacológicamente, Rebetol aumenta los metabolitos fosforilados de los nucleósidos de purina in vitro." } }
{ "translation": { "text": "Glossaries:\n\"associated names\" -> \"denominaciones asociadas\"\n\"evaluation\" -> \"evaluación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Overall summary of the scientific evaluation of Oxynal and Targin and associated names (see Annex I)\nSpanish: Resumen general de la evaluación científica de Oxynal y Targin y denominaciones asociadas (ver anexo I)", "en_prompt": "<|im_start|>user\nGlossaries:\n\"associated names\" -> \"denominaciones asociadas\"\n\"evaluation\" -> \"evaluación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Overall summary of the scientific evaluation of Oxynal and Targin and associated names (see Annex I)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "associated names|||denominaciones asociadas\tevaluation|||evaluación", "en": "Overall summary of the scientific evaluation of Oxynal and Targin and associated names (see Annex I)", "es": "Resumen general de la evaluación científica de Oxynal y Targin y denominaciones asociadas (ver anexo I)" } }
{ "translation": { "text": "Glossary:\n\"in vitro\" -> \"in vitro\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Telaprevir is a weak in vitro inhibitor of the transporters multidrug and toxin extrusion (MATE) MATE1 and MATE2-K with an IC50 of 28.3 μM and 32.5 μM, respectively.\nSpanish: Telaprevir es un inhibidor débil in vitro de los transportadores de múltiples fármacos y extrusión de toxinas (MATE) MATE1 y MATE2-K con un IC50 de 28,3 μM y 32,5 μM, respectivamente.", "en_prompt": "<|im_start|>user\nGlossary:\n\"in vitro\" -> \"in vitro\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Telaprevir is a weak in vitro inhibitor of the transporters multidrug and toxin extrusion (MATE) MATE1 and MATE2-K with an IC50 of 28.3 μM and 32.5 μM, respectively.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "in vitro|||in vitro", "en": "Telaprevir is a weak in vitro inhibitor of the transporters multidrug and toxin extrusion (MATE) MATE1 and MATE2-K with an IC50 of 28.3 μM and 32.5 μM, respectively.", "es": "Telaprevir es un inhibidor débil in vitro de los transportadores de múltiples fármacos y extrusión de toxinas (MATE) MATE1 y MATE2-K con un IC50 de 28,3 μM y 32,5 μM, respectivamente." } }
{ "translation": { "text": "Glossary:\n\"analysis\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Virologic outcome in adolescent subjects in the TMC278-C213 trial - week 48 and week 240 analysis; ITT-TLOVR* Week 48 N=36\nSpanish: Resultado virológico en pacientes adolescentes en el ensayo TMC278-C213 - análisis a las 48 semanas y 240 semanas; ITT-TLOVR* Semana 48 N=36", "en_prompt": "<|im_start|>user\nGlossary:\n\"analysis\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Virologic outcome in adolescent subjects in the TMC278-C213 trial - week 48 and week 240 analysis; ITT-TLOVR* Week 48 N=36\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "analysis|||análisis", "en": "Virologic outcome in adolescent subjects in the TMC278-C213 trial - week 48 and week 240 analysis; ITT-TLOVR* Week 48 N=36", "es": "Resultado virológico en pacientes adolescentes en el ensayo TMC278-C213 - análisis a las 48 semanas y 240 semanas; ITT-TLOVR* Semana 48 N=36" } }
{ "translation": { "text": "Glossary:\n\"haemoglobin\" -> \"hemoglobina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: b. Includes preferred terms of anaemia, haematocrit decreased and haemoglobin decreased.\nSpanish: Incluye los términos preferidos de anemia, hematocrito disminuido y hemoglobina disminuida.", "en_prompt": "<|im_start|>user\nGlossary:\n\"haemoglobin\" -> \"hemoglobina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: b. Includes preferred terms of anaemia, haematocrit decreased and haemoglobin decreased.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "haemoglobin|||hemoglobina", "en": "b. Includes preferred terms of anaemia, haematocrit decreased and haemoglobin decreased.", "es": "Incluye los términos preferidos de anemia, hematocrito disminuido y hemoglobina disminuida." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"dose\" -> \"dosis\"\n\"toxicity\" -> \"toxicidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The effect of prolonged daily treatment with high doses of dolutegravir has been evaluated in repeat oral dose toxicity studies in rats (up to 26 weeks) and in monkeys (up to 38 weeks).\nSpanish: Se ha evaluado el efecto del tratamiento diario prolongado con dosis altas de dolutegravir en estudios de toxicidad a dosis orales repetidas en ratas (hasta 26 semanas) y en monos (hasta 38 semanas).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"dose\" -> \"dosis\"\n\"toxicity\" -> \"toxicidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The effect of prolonged daily treatment with high doses of dolutegravir has been evaluated in repeat oral dose toxicity studies in rats (up to 26 weeks) and in monkeys (up to 38 weeks).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tdose|||dosis\ttoxicity|||toxicidad", "en": "The effect of prolonged daily treatment with high doses of dolutegravir has been evaluated in repeat oral dose toxicity studies in rats (up to 26 weeks) and in monkeys (up to 38 weeks).", "es": "Se ha evaluado el efecto del tratamiento diario prolongado con dosis altas de dolutegravir en estudios de toxicidad a dosis orales repetidas en ratas (hasta 26 semanas) y en monos (hasta 38 semanas)." } }
{ "translation": { "text": "Glossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 1 sterile 1 mL Luer lock syringe.\nSpanish: 1 jeringa estéril de 1 ml con cierre Luer.", "en_prompt": "<|im_start|>user\nGlossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 1 sterile 1 mL Luer lock syringe.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "syringe|||jeringa", "en": "1 sterile 1 mL Luer lock syringe.", "es": "1 jeringa estéril de 1 ml con cierre Luer." } }
{ "translation": { "text": "Glossaries:\n\"product\" -> \"producto\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: After the Commission decision the Member State competent authorities, in liaison with the reference Member State, will update the product information as required.\nSpanish: Tras la emisión de la Decisión de la Comisión las Autoridades Competentes de cada Estado Miembro, en coordinación con el Estado Miembro de Referencia, actualizarán la información del producto según sea necesario.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"product\" -> \"producto\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: After the Commission decision the Member State competent authorities, in liaison with the reference Member State, will update the product information as required.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "product|||producto\tinformation|||información", "en": "After the Commission decision the Member State competent authorities, in liaison with the reference Member State, will update the product information as required.", "es": "Tras la emisión de la Decisión de la Comisión las Autoridades Competentes de cada Estado Miembro, en coordinación con el Estado Miembro de Referencia, actualizarán la información del producto según sea necesario." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: This medicine is intended solely for you or for your child.\nSpanish: Este medicamento es sólo para usted o para su hijo.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: This medicine is intended solely for you or for your child.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicamento", "en": "This medicine is intended solely for you or for your child.", "es": "Este medicamento es sólo para usted o para su hijo." } }
{ "translation": { "text": "Glossaries:\n\"contact\" -> \"contacto\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If your child has visual disturbances, contact your child's doctor or hospital immediately.\nSpanish: Si su hijo presenta trastornos visuales, póngase en contacto de forma inmediata con el médico u hospital de su hijo.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"contact\" -> \"contacto\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If your child has visual disturbances, contact your child's doctor or hospital immediately.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "contact|||contacto\tdoctor|||médico", "en": "If your child has visual disturbances, contact your child's doctor or hospital immediately.", "es": "Si su hijo presenta trastornos visuales, póngase en contacto de forma inmediata con el médico u hospital de su hijo." } }
{ "translation": { "text": "Glossaries:\n\"control\" -> \"control\"\n\"placebo\" -> \"placebo\"\n\"metformin\" -> \"metformina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The durability of glycaemic control for Eperzan over time relative to other classes of type 2 antidiabetic agents and placebo is shown in Figure 1 as add-on to metformin.\nSpanish: La durabilidad del control glucémico para Eperzan como tratamiento adicional a metformina a lo largo del tiempo en relación a otras clases de medicamentos para el tratamiento de la diabetes tipo 2 y placebo se muestra en la Figura 1.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"control\" -> \"control\"\n\"placebo\" -> \"placebo\"\n\"metformin\" -> \"metformina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The durability of glycaemic control for Eperzan over time relative to other classes of type 2 antidiabetic agents and placebo is shown in Figure 1 as add-on to metformin.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "control|||control\tplacebo|||placebo\tmetformin|||metformina", "en": "The durability of glycaemic control for Eperzan over time relative to other classes of type 2 antidiabetic agents and placebo is shown in Figure 1 as add-on to metformin.", "es": "La durabilidad del control glucémico para Eperzan como tratamiento adicional a metformina a lo largo del tiempo en relación a otras clases de medicamentos para el tratamiento de la diabetes tipo 2 y placebo se muestra en la Figura 1." } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"enfermedad\"\n\"radiation therapy\" -> \"radioterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • in combination with radiation therapy for locally advanced disease,\nSpanish: • En combinación con radioterapia para la enfermedad localmente avanzada.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"enfermedad\"\n\"radiation therapy\" -> \"radioterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • in combination with radiation therapy for locally advanced disease,\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||enfermedad\tradiation therapy|||radioterapia", "en": "• in combination with radiation therapy for locally advanced disease,", "es": "• En combinación con radioterapia para la enfermedad localmente avanzada." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"medical treatment\" -> \"tratamiento médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If immune-mediated reactions occur, discontinuation of the administration of alglucosidase alfa should be considered and appropriate medical treatment initiated.\nSpanish: En caso que se produzcan reacciones inmunitarias, se debe considerar la interrupción de la administración de alglucosidasa alfa e iniciar un tratamiento médico adecuado.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"medical treatment\" -> \"tratamiento médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If immune-mediated reactions occur, discontinuation of the administration of alglucosidase alfa should be considered and appropriate medical treatment initiated.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tmedical treatment|||tratamiento médico", "en": "If immune-mediated reactions occur, discontinuation of the administration of alglucosidase alfa should be considered and appropriate medical treatment initiated.", "es": "En caso que se produzcan reacciones inmunitarias, se debe considerar la interrupción de la administración de alglucosidasa alfa e iniciar un tratamiento médico adecuado." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\n\"weight\" -> \"peso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: - Children (4 to 12 years) and patients less than 50 kg body weight: the dose will be calculated according to your weight by your doctor.\nSpanish: Niños (4 a 12 años) y pacientes de menos de 50 kg de peso: la dosis será calculada por su médico en función del peso.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\n\"weight\" -> \"peso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: - Children (4 to 12 years) and patients less than 50 kg body weight: the dose will be calculated according to your weight by your doctor.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tdoctor|||médico\tweight|||peso", "en": "- Children (4 to 12 years) and patients less than 50 kg body weight: the dose will be calculated according to your weight by your doctor.", "es": "Niños (4 a 12 años) y pacientes de menos de 50 kg de peso: la dosis será calculada por su médico en función del peso." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Total number of tablets for treatment\nSpanish: Número total de comprimidos durante el tratamiento", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Total number of tablets for treatment\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento", "en": "Total number of tablets for treatment", "es": "Número total de comprimidos durante el tratamiento" } }
{ "translation": { "text": "Glossary:\n\"analysis\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Population pharmacokinetic analysis indicated that age did not have a clinically significant influence on the clearance of tildrakizumab in adult subjects with plaque psoriasis.\nSpanish: De acuerdo con el análisis de farmacocinética poblacional, la edad no ejerce una influencia clínicamente significativa sobre el aclaramiento de tildrakizumab en pacientes adultos con psoriasis en placas.", "en_prompt": "<|im_start|>user\nGlossary:\n\"analysis\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Population pharmacokinetic analysis indicated that age did not have a clinically significant influence on the clearance of tildrakizumab in adult subjects with plaque psoriasis.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "analysis|||análisis", "en": "Population pharmacokinetic analysis indicated that age did not have a clinically significant influence on the clearance of tildrakizumab in adult subjects with plaque psoriasis.", "es": "De acuerdo con el análisis de farmacocinética poblacional, la edad no ejerce una influencia clínicamente significativa sobre el aclaramiento de tildrakizumab en pacientes adultos con psoriasis en placas." } }
{ "translation": { "text": "Glossary:\n\"contact\" -> \"contacto\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Avoid contact with eyes.\nSpanish: Evitar el contacto con los ojos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"contact\" -> \"contacto\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Avoid contact with eyes.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "contact|||contacto", "en": "Avoid contact with eyes.", "es": "Evitar el contacto con los ojos." } }
{ "translation": { "text": "Glossary:\n\"tissue\" -> \"tejido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Inject the liquid into the tissue slowly and evenly, always keeping your skin pinched.\nSpanish: Inyectar el líquido dentro del tejido de forma lenta y regular, manteniendo siempre la piel pellizcada.", "en_prompt": "<|im_start|>user\nGlossary:\n\"tissue\" -> \"tejido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Inject the liquid into the tissue slowly and evenly, always keeping your skin pinched.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "tissue|||tejido", "en": "Inject the liquid into the tissue slowly and evenly, always keeping your skin pinched.", "es": "Inyectar el líquido dentro del tejido de forma lenta y regular, manteniendo siempre la piel pellizcada." } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"body\" -> \"cuerpo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you stop taking it, the excess iron will no longer be removed from your body (see also above section “How long to take EXJADE”).\nSpanish: Si deja de tomarlo, el exceso de hierro no se eliminará de su cuerpo (ver también sección anterior «Cuánto tiempo debe tomar EXJADE»).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"body\" -> \"cuerpo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you stop taking it, the excess iron will no longer be removed from your body (see also above section “How long to take EXJADE”).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\tbody|||cuerpo", "en": "If you stop taking it, the excess iron will no longer be removed from your body (see also above section “How long to take EXJADE”).", "es": "Si deja de tomarlo, el exceso de hierro no se eliminará de su cuerpo (ver también sección anterior «Cuánto tiempo debe tomar EXJADE»)." } }
{ "translation": { "text": "Glossary:\n\"weight\" -> \"peso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The amount of Ferriprox that you take will depend on your weight.\nSpanish: La cantidad de Ferriprox que tome dependerá de su peso.", "en_prompt": "<|im_start|>user\nGlossary:\n\"weight\" -> \"peso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The amount of Ferriprox that you take will depend on your weight.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "weight|||peso", "en": "The amount of Ferriprox that you take will depend on your weight.", "es": "La cantidad de Ferriprox que tome dependerá de su peso." } }
{ "translation": { "text": "Glossary:\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Contents of the pack and other information What Picato contains\nSpanish: Contenido del envase e información adicional Composición de Picato", "en_prompt": "<|im_start|>user\nGlossary:\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Contents of the pack and other information What Picato contains\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "information|||información", "en": "Contents of the pack and other information What Picato contains", "es": "Contenido del envase e información adicional Composición de Picato" } }
{ "translation": { "text": "Glossary:\n\"diabetes\" -> \"diabetes\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Liprolog Mix50 is used to treat diabetes.\nSpanish: Liprolog Mix50 se emplea para tratar la diabetes.", "en_prompt": "<|im_start|>user\nGlossary:\n\"diabetes\" -> \"diabetes\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Liprolog Mix50 is used to treat diabetes.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "diabetes|||diabetes", "en": "Liprolog Mix50 is used to treat diabetes.", "es": "Liprolog Mix50 se emplea para tratar la diabetes." } }
{ "translation": { "text": "Glossaries:\n\"injections\" -> \"inyectables\"\n\"concentrated\" -> \"concentrado\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hydrochloric acid, concentrated (pH adjustment) Sodium hydroxide (pH adjustment) Water for injections\nSpanish: Ácido clorhídrico, concentrado (ajuste del pH) Hidróxido sódico (ajuste del pH) Agua para preparaciones inyectables", "en_prompt": "<|im_start|>user\nGlossaries:\n\"injections\" -> \"inyectables\"\n\"concentrated\" -> \"concentrado\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hydrochloric acid, concentrated (pH adjustment) Sodium hydroxide (pH adjustment) Water for injections\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injections|||inyectables\tconcentrated|||concentrado", "en": "Hydrochloric acid, concentrated (pH adjustment) Sodium hydroxide (pH adjustment) Water for injections", "es": "Ácido clorhídrico, concentrado (ajuste del pH) Hidróxido sódico (ajuste del pH) Agua para preparaciones inyectables" } }
{ "translation": { "text": "Glossaries:\n\"methylphenidate\" -> \"metilfenidato\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you or your child is taking any of the following medicines, check with the doctor before taking methylphenidate:\nSpanish: Si usted o su hijo están tomando alguno de los medicamentos siguientes, consulte al médico antes de tomar metilfenidato.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"methylphenidate\" -> \"metilfenidato\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you or your child is taking any of the following medicines, check with the doctor before taking methylphenidate:\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "methylphenidate|||metilfenidato\tdoctor|||médico", "en": "If you or your child is taking any of the following medicines, check with the doctor before taking methylphenidate:", "es": "Si usted o su hijo están tomando alguno de los medicamentos siguientes, consulte al médico antes de tomar metilfenidato." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate.\nSpanish: Atripla es una combinación a dosis fija de efavirenz, emtricitabina y tenofovir disoproxilo fumarato.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate.", "es": "Atripla es una combinación a dosis fija de efavirenz, emtricitabina y tenofovir disoproxilo fumarato." } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"safety\" -> \"seguridad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Therefore, safety margins for potential IP receptor-mediated effects on reproduction are accordingly lower than for non-IP-related effects (see section 5.3).\nSpanish: Por tanto, los márgenes de seguridad para los posibles efectos asociados al receptor IP sobre la reproducción son menores a los efectos no asociados al IP. (ver sección 5.3).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"safety\" -> \"seguridad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Therefore, safety margins for potential IP receptor-mediated effects on reproduction are accordingly lower than for non-IP-related effects (see section 5.3).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\tsafety|||seguridad", "en": "Therefore, safety margins for potential IP receptor-mediated effects on reproduction are accordingly lower than for non-IP-related effects (see section 5.3).", "es": "Por tanto, los márgenes de seguridad para los posibles efectos asociados al receptor IP sobre la reproducción son menores a los efectos no asociados al IP. (ver sección 5.3)." } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"enfermedad\"\n\"treatment\" -> \"tratamiento\"\n\"Lyme disease\" -> \"enfermedad de Lyme\"\n\"urethritis\" -> \"uretritis\"\n\"impetigo\" -> \"impétigo\"\n\"prevention\" -> \"prevención\"\n\"sinusitis\" -> \"sinusitis\"\n\"otitis media\" -> \"otitis media\"\n\"cystitis\" -> \"cistitis\"\n\"bronchitis\" -> \"bronquitis\"\n\"acute otitis media\" -> \"otitis media aguda\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: - upper respiratory tract infections: acute otitis media, sinusitis, tonsillitis and pharyngitis - acute bronchitis, acute exacerbations of chronic bronchitis - lower uncomplicated urinary tract infections: cystitis - skin and soft tissue infections: furunculosis, pyoderma and impetigo - uncomplicated gonorrhoea: urethritis and cervicitis - treatment of early stage Lyme disease (stadium I) and subsequent prevention of late complications in adults and children above 12 years of age.\nSpanish: - infecciones de las vías respiratorias superiores: otitis media aguda, sinusitis, amigdalitis y faringitis - bronquitis aguda, exacerbaciones agudas de la bronquitis crónica - infecciones no complicadas de las vías urinarias inferiores: cistitis - infecciones de la piel y los tejidos blandos: furunculosis, piodermia e impétigo - gonorrea no complicada: uretritis y cervicitis - tratamiento de la enfermedad de Lyme en las primeras etapas (estadio I) y posterior prevención de las complicaciones tardías en adultos y niños mayores de 12 años.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"enfermedad\"\n\"treatment\" -> \"tratamiento\"\n\"Lyme disease\" -> \"enfermedad de Lyme\"\n\"urethritis\" -> \"uretritis\"\n\"impetigo\" -> \"impétigo\"\n\"prevention\" -> \"prevención\"\n\"sinusitis\" -> \"sinusitis\"\n\"otitis media\" -> \"otitis media\"\n\"cystitis\" -> \"cistitis\"\n\"bronchitis\" -> \"bronquitis\"\n\"acute otitis media\" -> \"otitis media aguda\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: - upper respiratory tract infections: acute otitis media, sinusitis, tonsillitis and pharyngitis - acute bronchitis, acute exacerbations of chronic bronchitis - lower uncomplicated urinary tract infections: cystitis - skin and soft tissue infections: furunculosis, pyoderma and impetigo - uncomplicated gonorrhoea: urethritis and cervicitis - treatment of early stage Lyme disease (stadium I) and subsequent prevention of late complications in adults and children above 12 years of age.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||enfermedad\ttreatment|||tratamiento\tLyme disease|||enfermedad de Lyme\turethritis|||uretritis\timpetigo|||impétigo\tprevention|||prevención\tsinusitis|||sinusitis\totitis media|||otitis media\tcystitis|||cistitis\tbronchitis|||bronquitis\tacute otitis media|||otitis media aguda", "en": "- upper respiratory tract infections: acute otitis media, sinusitis, tonsillitis and pharyngitis - acute bronchitis, acute exacerbations of chronic bronchitis - lower uncomplicated urinary tract infections: cystitis - skin and soft tissue infections: furunculosis, pyoderma and impetigo - uncomplicated gonorrhoea: urethritis and cervicitis - treatment of early stage Lyme disease (stadium I) and subsequent prevention of late complications in adults and children above 12 years of age.", "es": "- infecciones de las vías respiratorias superiores: otitis media aguda, sinusitis, amigdalitis y faringitis - bronquitis aguda, exacerbaciones agudas de la bronquitis crónica - infecciones no complicadas de las vías urinarias inferiores: cistitis - infecciones de la piel y los tejidos blandos: furunculosis, piodermia e impétigo - gonorrea no complicada: uretritis y cervicitis - tratamiento de la enfermedad de Lyme en las primeras etapas (estadio I) y posterior prevención de las complicaciones tardías en adultos y niños mayores de 12 años." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"chemotherapy\" -> \"quimioterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: b The table reflects the frequency of ADRs during the chemotherapy phase of study treatment in which Portrazza+GC was directly compared with GC.\nSpanish: b La tabla refleja la frecuencia de RAMs durante la fase de quimioterapia en el estudio del tratamiento en el que se comparó Portrazza+GC directamente con GC.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"chemotherapy\" -> \"quimioterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: b The table reflects the frequency of ADRs during the chemotherapy phase of study treatment in which Portrazza+GC was directly compared with GC.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tchemotherapy|||quimioterapia", "en": "b The table reflects the frequency of ADRs during the chemotherapy phase of study treatment in which Portrazza+GC was directly compared with GC.", "es": "b La tabla refleja la frecuencia de RAMs durante la fase de quimioterapia en el estudio del tratamiento en el que se comparó Portrazza+GC directamente con GC." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you are planning to have an operation on your eye, make sure you tell your eye doctor that you are taking this medicine.\nSpanish: Si usted está pensando en ser operado de los ojos, asegúrese de informar a su oftalmólogo que está usando este medicamento.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you are planning to have an operation on your eye, make sure you tell your eye doctor that you are taking this medicine.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicamento", "en": "If you are planning to have an operation on your eye, make sure you tell your eye doctor that you are taking this medicine.", "es": "Si usted está pensando en ser operado de los ojos, asegúrese de informar a su oftalmólogo que está usando este medicamento." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Following administration of 800 mg per day of posaconazole as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12 patients 8 - 17 years of age (776 ng/ml) were similar to concentrations from 194 patients 18 - 64 years of age (817 ng/ml).\nSpanish: Tras la administración de 800 mg al día de posaconazol en dosis fraccionadas para el tratamiento de infecciones fúngicas invasivas, las concentraciones mínimas plasmáticas medias de 12 pacientes de 817 años de edad (776 ng/ml) fueron similares a las concentraciones de 194 pacientes de 18 - 64 años de edad (817 ng/ml).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Following administration of 800 mg per day of posaconazole as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12 patients 8 - 17 years of age (776 ng/ml) were similar to concentrations from 194 patients 18 - 64 years of age (817 ng/ml).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tdose|||dosis", "en": "Following administration of 800 mg per day of posaconazole as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12 patients 8 - 17 years of age (776 ng/ml) were similar to concentrations from 194 patients 18 - 64 years of age (817 ng/ml).", "es": "Tras la administración de 800 mg al día de posaconazol en dosis fraccionadas para el tratamiento de infecciones fúngicas invasivas, las concentraciones mínimas plasmáticas medias de 12 pacientes de 817 años de edad (776 ng/ml) fueron similares a las concentraciones de 194 pacientes de 18 - 64 años de edad (817 ng/ml)." } }
{ "translation": { "text": "Glossary:\n\"test\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hepatic enzyme increased, blood electrolyes abnormal, laboratory test abnormal\nSpanish: Aumento de las enzimas hepáticas, anomalías de los electrolitos de la sangre, anomalías en los análisis clínicos", "en_prompt": "<|im_start|>user\nGlossary:\n\"test\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hepatic enzyme increased, blood electrolyes abnormal, laboratory test abnormal\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "test|||análisis", "en": "Hepatic enzyme increased, blood electrolyes abnormal, laboratory test abnormal", "es": "Aumento de las enzimas hepáticas, anomalías de los electrolitos de la sangre, anomalías en los análisis clínicos" } }
{ "translation": { "text": "Glossary:\n\"interval\" -> \"intervalo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: bd Twice daily; NR not reached; CI confidence interval; PFS2 time from randomisation to second progression or death;\nSpanish: bd Dos veces al día; NA no alcanzado; IC intervalo de confianza; PFS2 Tiempo desde la aleatorización hasta la segunda progresión o fallecimiento; TFST Tiempo desde la aleatorización hasta el inicio de la primera terapia siguiente o fallecimiento.", "en_prompt": "<|im_start|>user\nGlossary:\n\"interval\" -> \"intervalo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: bd Twice daily; NR not reached; CI confidence interval; PFS2 time from randomisation to second progression or death;\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "interval|||intervalo", "en": "bd Twice daily; NR not reached; CI confidence interval; PFS2 time from randomisation to second progression or death;", "es": "bd Dos veces al día; NA no alcanzado; IC intervalo de confianza; PFS2 Tiempo desde la aleatorización hasta la segunda progresión o fallecimiento; TFST Tiempo desde la aleatorización hasta el inicio de la primera terapia siguiente o fallecimiento." } }
{ "translation": { "text": "Glossaries:\n\"doctor\" -> \"médico\"\n\"package leaflet\" -> \"prospecto\"\n\"pharmacist\" -> \"farmacéutico\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For practical information about using Onbrez Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.\nSpanish: Para más información sobre el tratamiento con Onbrez Breezhaler, el paciente debe leer el prospecto (también incluido en el EPAR) o consultar a su médico o farmacéutico.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"doctor\" -> \"médico\"\n\"package leaflet\" -> \"prospecto\"\n\"pharmacist\" -> \"farmacéutico\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For practical information about using Onbrez Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico\tpackage leaflet|||prospecto\tpharmacist|||farmacéutico\tinformation|||información", "en": "For practical information about using Onbrez Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.", "es": "Para más información sobre el tratamiento con Onbrez Breezhaler, el paciente debe leer el prospecto (también incluido en el EPAR) o consultar a su médico o farmacéutico." } }
{ "translation": { "text": "Glossary:\n\"active substance\" -> \"principio activo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Zubrin contains the active substance tepoxalin.\nSpanish: Zubrin contiene el principio activo tepoxalin.", "en_prompt": "<|im_start|>user\nGlossary:\n\"active substance\" -> \"principio activo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Zubrin contains the active substance tepoxalin.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "active substance|||principio activo", "en": "Zubrin contains the active substance tepoxalin.", "es": "Zubrin contiene el principio activo tepoxalin." } }
{ "translation": { "text": "Glossary:\n\"cyanide\" -> \"cianuro\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Use with other cyanide antidotes\nSpanish: Uso con otros antídotos contra el cianuro", "en_prompt": "<|im_start|>user\nGlossary:\n\"cyanide\" -> \"cianuro\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Use with other cyanide antidotes\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "cyanide|||cianuro", "en": "Use with other cyanide antidotes", "es": "Uso con otros antídotos contra el cianuro" } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No increase in the incidence or severity of these events was seen with the second dose.\nSpanish: No se observó un aumento en la incidencia o la gravedad de estos acontecimientos tras la administración de la segunda dosis.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No increase in the incidence or severity of these events was seen with the second dose.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "No increase in the incidence or severity of these events was seen with the second dose.", "es": "No se observó un aumento en la incidencia o la gravedad de estos acontecimientos tras la administración de la segunda dosis." } }
{ "translation": { "text": "Glossaries:\n\"exposure\" -> \"exposición\"\n\"efficacy\" -> \"eficacia\"\n\"clinical study\" -> \"estudio clínico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Co-administration of encorafenib with a CYP3A4 inducer was not assessed in a clinical study; however, a reduction in encorafenib exposure is likely and may result in compromised efficacy.\nSpanish: La administración concomitante de encorafenib con un inductor de la CYP3A4 no se ha evaluado en ningún estudio clínico; sin embargo, es probable que la exposición a encorafenib se vea reducida y, por consiguiente, su eficacia puede resultar comprometida.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"exposure\" -> \"exposición\"\n\"efficacy\" -> \"eficacia\"\n\"clinical study\" -> \"estudio clínico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Co-administration of encorafenib with a CYP3A4 inducer was not assessed in a clinical study; however, a reduction in encorafenib exposure is likely and may result in compromised efficacy.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||exposición\tefficacy|||eficacia\tclinical study|||estudio clínico", "en": "Co-administration of encorafenib with a CYP3A4 inducer was not assessed in a clinical study; however, a reduction in encorafenib exposure is likely and may result in compromised efficacy.", "es": "La administración concomitante de encorafenib con un inductor de la CYP3A4 no se ha evaluado en ningún estudio clínico; sin embargo, es probable que la exposición a encorafenib se vea reducida y, por consiguiente, su eficacia puede resultar comprometida." } }
{ "translation": { "text": "Glossaries:\n\"tofacitinib\" -> \"tofacitinib\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Time of mandatory placebo rescue to tofacitinib 5 mg or 10 mg twice daily\nSpanish: Momento del cambio obligatorio de placebo a tofacitinib 5 mg o 10 mg dos veces al día", "en_prompt": "<|im_start|>user\nGlossaries:\n\"tofacitinib\" -> \"tofacitinib\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Time of mandatory placebo rescue to tofacitinib 5 mg or 10 mg twice daily\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "tofacitinib|||tofacitinib\tplacebo|||placebo", "en": "Time of mandatory placebo rescue to tofacitinib 5 mg or 10 mg twice daily", "es": "Momento del cambio obligatorio de placebo a tofacitinib 5 mg o 10 mg dos veces al día" } }
{ "translation": { "text": "Glossaries:\n\"ibandronic acid\" -> \"ácido ibandrónico\"\n\"acid\" -> \"ácido\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: QUALITATIVE AND QUANTITATIVE COMPOSITION One vial with 6 ml concentrate for solution for infusion contains 6 mg ibandronic acid (as sodium monohydrate).\nSpanish: COMPOSICIÓN CUALITATIVA Y CUANTITATIVA Un vial con 6 ml de concentrado para solución para perfusión contiene 6 mg de ácido ibandrónico (como monohidrato sódico).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"ibandronic acid\" -> \"ácido ibandrónico\"\n\"acid\" -> \"ácido\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: QUALITATIVE AND QUANTITATIVE COMPOSITION One vial with 6 ml concentrate for solution for infusion contains 6 mg ibandronic acid (as sodium monohydrate).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "ibandronic acid|||ácido ibandrónico\tacid|||ácido\tinfusion|||perfusión", "en": "QUALITATIVE AND QUANTITATIVE COMPOSITION One vial with 6 ml concentrate for solution for infusion contains 6 mg ibandronic acid (as sodium monohydrate).", "es": "COMPOSICIÓN CUALITATIVA Y CUANTITATIVA Un vial con 6 ml de concentrado para solución para perfusión contiene 6 mg de ácido ibandrónico (como monohidrato sódico)." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Following careful benefit/risk assessment, a decision should be made to discontinue either breast-feeding or treatment with Cinacalcet Mylan.\nSpanish: Después de una valoración detenida de la relación beneficio/riesgo, habrá que decidir si suspender la lactancia o interrumpir el tratamiento con Cinacalcet Mylan.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Following careful benefit/risk assessment, a decision should be made to discontinue either breast-feeding or treatment with Cinacalcet Mylan.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento", "en": "Following careful benefit/risk assessment, a decision should be made to discontinue either breast-feeding or treatment with Cinacalcet Mylan.", "es": "Después de una valoración detenida de la relación beneficio/riesgo, habrá que decidir si suspender la lactancia o interrumpir el tratamiento con Cinacalcet Mylan." } }
{ "translation": { "text": "Glossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Appropriate medical support and monitoring measures should be readily available when Bonviva intravenous injection is administered.\nSpanish: Cuando se administre la inyección intravenosa de Bonviva se debe disponer fácilmente de apoyo médico apropiado y medidas de monitorización.", "en_prompt": "<|im_start|>user\nGlossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Appropriate medical support and monitoring measures should be readily available when Bonviva intravenous injection is administered.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injection|||inyección", "en": "Appropriate medical support and monitoring measures should be readily available when Bonviva intravenous injection is administered.", "es": "Cuando se administre la inyección intravenosa de Bonviva se debe disponer fácilmente de apoyo médico apropiado y medidas de monitorización." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (See Table 24).\nSpanish: Los resultados de ambos estudios demostraron una reducción estadísticamente significativa del riesgo de fallo a tratamiento en pacientes tratados con adalimumab versus aquellos pacientes que recibieron placebo (ver Tabla 24).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (See Table 24).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tplacebo|||placebo", "en": "Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (See Table 24).", "es": "Los resultados de ambos estudios demostraron una reducción estadísticamente significativa del riesgo de fallo a tratamiento en pacientes tratados con adalimumab versus aquellos pacientes que recibieron placebo (ver Tabla 24)." } }
{ "translation": { "text": "Glossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Tell your doctor if you are breast-feeding or about to start breast-feeding.\nSpanish: Informe a su médico si va a iniciar o está en periodo de lactancia puesto que no se recomienda administrar Rasitrio a mujeres durante este periodo.", "en_prompt": "<|im_start|>user\nGlossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Tell your doctor if you are breast-feeding or about to start breast-feeding.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico", "en": "Tell your doctor if you are breast-feeding or about to start breast-feeding.", "es": "Informe a su médico si va a iniciar o está en periodo de lactancia puesto que no se recomienda administrar Rasitrio a mujeres durante este periodo." } }
{ "translation": { "text": "Glossaries:\n\"S\" -> \"S\"\n\"mesilate\" -> \"mesilato\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: NAME OF THE MEDICINAL PRODUCT LENVIMA 4 mg hard capsules lenvatinib STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 4 mg lenvatinib (as mesilate).\nSpanish: NOMBRE DEL MEDICAMENTO LENVIMA 4 mg cápsulas duras lenvatinib PRINCIPIO(S) ACTIVO(S) Cada cápsula dura contiene 4 mg de lenvatinib (como mesilato).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"S\" -> \"S\"\n\"mesilate\" -> \"mesilato\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: NAME OF THE MEDICINAL PRODUCT LENVIMA 4 mg hard capsules lenvatinib STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 4 mg lenvatinib (as mesilate).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "S|||S\tmesilate|||mesilato", "en": "NAME OF THE MEDICINAL PRODUCT LENVIMA 4 mg hard capsules lenvatinib STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 4 mg lenvatinib (as mesilate).", "es": "NOMBRE DEL MEDICAMENTO LENVIMA 4 mg cápsulas duras lenvatinib PRINCIPIO(S) ACTIVO(S) Cada cápsula dura contiene 4 mg de lenvatinib (como mesilato)." } }
{ "translation": { "text": "Glossary:\n\"appetite\" -> \"apetito\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Reduced appetite\nSpanish: • Disminución del apetito", "en_prompt": "<|im_start|>user\nGlossary:\n\"appetite\" -> \"apetito\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Reduced appetite\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "appetite|||apetito", "en": "• Reduced appetite", "es": "• Disminución del apetito" } }
{ "translation": { "text": "Glossaries:\n\"agent\" -> \"agente\"\n\"medicine\" -> \"medicamento\"\n\"active substance\" -> \"principio activo\"\n\"acid\" -> \"ácido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: When Ameluz is applied to the abnormal skin growths or lesions, the active substance in the medicine, 5-aminolaevulinic acid, is absorbed by cells where it acts as a photosensitising agent (a substance that changes when exposed to light of a certain wavelength).\nSpanish: Cuando Ameluz se aplica a las excrecencias o lesiones cutáneas anómalas, el principio activo del medicamento, el ácido 5-aminolevulínico, es absorbido por las células de esta zona en las que actúa como agente fotosensibilizante (sustancia que cambia cuando se expone a la luz de una longitud de onda determinada).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"agent\" -> \"agente\"\n\"medicine\" -> \"medicamento\"\n\"active substance\" -> \"principio activo\"\n\"acid\" -> \"ácido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: When Ameluz is applied to the abnormal skin growths or lesions, the active substance in the medicine, 5-aminolaevulinic acid, is absorbed by cells where it acts as a photosensitising agent (a substance that changes when exposed to light of a certain wavelength).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "agent|||agente\tmedicine|||medicamento\tactive substance|||principio activo\tacid|||ácido", "en": "When Ameluz is applied to the abnormal skin growths or lesions, the active substance in the medicine, 5-aminolaevulinic acid, is absorbed by cells where it acts as a photosensitising agent (a substance that changes when exposed to light of a certain wavelength).", "es": "Cuando Ameluz se aplica a las excrecencias o lesiones cutáneas anómalas, el principio activo del medicamento, el ácido 5-aminolevulínico, es absorbido por las células de esta zona en las que actúa como agente fotosensibilizante (sustancia que cambia cuando se expone a la luz de una longitud de onda determinada)." } }
{ "translation": { "text": "Glossary:\n\"breath\" -> \"aliento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 2 breath bags for breath samples 1 bendable straw\nSpanish: 2 recipientes para las muestras del aliento 1 tubo flexible", "en_prompt": "<|im_start|>user\nGlossary:\n\"breath\" -> \"aliento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 2 breath bags for breath samples 1 bendable straw\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "breath|||aliento", "en": "2 breath bags for breath samples 1 bendable straw", "es": "2 recipientes para las muestras del aliento 1 tubo flexible" } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • If you forget to take Erleada for the whole day - take your usual dose the following day.\nSpanish: • Si olvidó tomar Erleada durante todo el día, tome la dosis habitual al día siguiente.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • If you forget to take Erleada for the whole day - take your usual dose the following day.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "• If you forget to take Erleada for the whole day - take your usual dose the following day.", "es": "• Si olvidó tomar Erleada durante todo el día, tome la dosis habitual al día siguiente." } }
{ "translation": { "text": "Glossary:\n\"infarction\" -> \"infarto\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Adults patients suffering from myocardial infarction (from a few days until less than 35 days),\nSpanish: • Pacientes adultos que han sufrido recientemente un infarto agudo de miocardio (desde pocos días antes hasta un máximo de 35 días), un infarto cerebral (desde 7 días antes hasta un máximo de 6 meses después) o que padecen enfermedad arterial periférica establecida.", "en_prompt": "<|im_start|>user\nGlossary:\n\"infarction\" -> \"infarto\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Adults patients suffering from myocardial infarction (from a few days until less than 35 days),\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "infarction|||infarto", "en": "• Adults patients suffering from myocardial infarction (from a few days until less than 35 days),", "es": "• Pacientes adultos que han sufrido recientemente un infarto agudo de miocardio (desde pocos días antes hasta un máximo de 35 días), un infarto cerebral (desde 7 días antes hasta un máximo de 6 meses después) o que padecen enfermedad arterial periférica establecida." } }
{ "translation": { "text": "Glossary:\n\"Prevention\" -> \"Prevención\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Prevention of VTE and Treatment of UA/NSTEMI and STEMI - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment.\nSpanish: • Prevención de ETV y Tratamiento de AI/IMSEST e IMCEST - No es necesario un ajuste de la dosis en pacientes con insuficiencia hepática leve o moderada.", "en_prompt": "<|im_start|>user\nGlossary:\n\"Prevention\" -> \"Prevención\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Prevention of VTE and Treatment of UA/NSTEMI and STEMI - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "Prevention|||Prevención", "en": "Prevention of VTE and Treatment of UA/NSTEMI and STEMI - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment.", "es": "• Prevención de ETV y Tratamiento de AI/IMSEST e IMCEST - No es necesario un ajuste de la dosis en pacientes con insuficiencia hepática leve o moderada." } }
{ "translation": { "text": "Glossaries:\n\"connective tissue\" -> \"tejido conjuntivo\"\n\"tissue\" -> \"tejido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Musculoskeletal and connective tissue disorders Rare\nSpanish: Trastornos musculoesqueléticos y del tejido conjuntivo Raras", "en_prompt": "<|im_start|>user\nGlossaries:\n\"connective tissue\" -> \"tejido conjuntivo\"\n\"tissue\" -> \"tejido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Musculoskeletal and connective tissue disorders Rare\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "connective tissue|||tejido conjuntivo\ttissue|||tejido", "en": "Musculoskeletal and connective tissue disorders Rare", "es": "Trastornos musculoesqueléticos y del tejido conjuntivo Raras" } }
{ "translation": { "text": "Glossaries:\n\"cough\" -> \"tos\"\n\"irritation\" -> \"irritación\"\n\"dyspnoea\" -> \"disnea\"\n\"shortness of breath\" -> \"disnea\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: (Seen in less than 1 in 10 but more than 1 in 100 patients) Commonly reported side effects are mild to moderate shortness of breath (dyspnoea), productive cough, throat irritation and dry throat.\nSpanish: Los efectos adversos comunicados frecuentemente de intensidad leve a moderada son dificultad al respirar (disnea), tos productiva, irritación y sequedad de garganta.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"cough\" -> \"tos\"\n\"irritation\" -> \"irritación\"\n\"dyspnoea\" -> \"disnea\"\n\"shortness of breath\" -> \"disnea\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: (Seen in less than 1 in 10 but more than 1 in 100 patients) Commonly reported side effects are mild to moderate shortness of breath (dyspnoea), productive cough, throat irritation and dry throat.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "cough|||tos\tirritation|||irritación\tdyspnoea|||disnea\tshortness of breath|||disnea", "en": "(Seen in less than 1 in 10 but more than 1 in 100 patients) Commonly reported side effects are mild to moderate shortness of breath (dyspnoea), productive cough, throat irritation and dry throat.", "es": "Los efectos adversos comunicados frecuentemente de intensidad leve a moderada son dificultad al respirar (disnea), tos productiva, irritación y sequedad de garganta." } }
{ "translation": { "text": "Glossaries:\n\"powder\" -> \"polvo\"\n\"suspension\" -> \"suspensión\"\n\"aspartame\" -> \"aspartamo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Augmentin 125 mg/31.25 mg powder for oral suspension in sachets contains 3.75 mg of aspartame (E951) per sachet, a source of phenylalanine.\nSpanish: Augmentin 125 mg/31,25 mg polvo para suspensión oral en sobres contiene 3,75 mg de aspartamo (E951) por sobre, una fuente de fenilalanina.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"powder\" -> \"polvo\"\n\"suspension\" -> \"suspensión\"\n\"aspartame\" -> \"aspartamo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Augmentin 125 mg/31.25 mg powder for oral suspension in sachets contains 3.75 mg of aspartame (E951) per sachet, a source of phenylalanine.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "powder|||polvo\tsuspension|||suspensión\taspartame|||aspartamo", "en": "Augmentin 125 mg/31.25 mg powder for oral suspension in sachets contains 3.75 mg of aspartame (E951) per sachet, a source of phenylalanine.", "es": "Augmentin 125 mg/31,25 mg polvo para suspensión oral en sobres contiene 3,75 mg de aspartamo (E951) por sobre, una fuente de fenilalanina." } }
{ "translation": { "text": "Glossary:\n\"tissue\" -> \"tejido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Skin and subcutaneous tissue disorders Very common: rash1, 2, 3\nSpanish: Trastornos de la piel y del tejido subcutáneo Muy frecuentes: exantema1, 2, 3", "en_prompt": "<|im_start|>user\nGlossary:\n\"tissue\" -> \"tejido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Skin and subcutaneous tissue disorders Very common: rash1, 2, 3\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "tissue|||tejido", "en": "Skin and subcutaneous tissue disorders Very common: rash1, 2, 3", "es": "Trastornos de la piel y del tejido subcutáneo Muy frecuentes: exantema1, 2, 3" } }
{ "translation": { "text": "Glossaries:\n\"injections\" -> \"inyectables\"\n\"acid\" -> \"ácido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Benzalkonium chloride, boric acid, mannitol, sodium hydroxide, water for injections.\nSpanish: Cloruro de benzalconio, ácido bórico, manitol, hidróxido de sodio, agua para preparaciones inyectables.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"injections\" -> \"inyectables\"\n\"acid\" -> \"ácido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Benzalkonium chloride, boric acid, mannitol, sodium hydroxide, water for injections.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injections|||inyectables\tacid|||ácido", "en": "Benzalkonium chloride, boric acid, mannitol, sodium hydroxide, water for injections.", "es": "Cloruro de benzalconio, ácido bórico, manitol, hidróxido de sodio, agua para preparaciones inyectables." } }
{ "translation": { "text": "Glossary:\n\"suspension\" -> \"suspensión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Parvoduk is available as a suspension and diluent for injection.\nSpanish: Parvoduk se presenta en forma de una suspensión y disolvente para suspensión inyectable.", "en_prompt": "<|im_start|>user\nGlossary:\n\"suspension\" -> \"suspensión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Parvoduk is available as a suspension and diluent for injection.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "suspension|||suspensión", "en": "Parvoduk is available as a suspension and diluent for injection.", "es": "Parvoduk se presenta en forma de una suspensión y disolvente para suspensión inyectable." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"hepatitis\" -> \"hepatitis\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination, and glecaprevir/pibrentasvir fixed dose combination (used to treat chronic hepatitis C infection)\nSpanish: medicamentos que contienen grazoprevir, incluida la combinación a dosis fija de elbasvir/grazoprevir y la combinación a dosis fija de glecaprevir/pibrentasvir (utilizadas para tratar la infección crónica por hepatitis C)", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"hepatitis\" -> \"hepatitis\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination, and glecaprevir/pibrentasvir fixed dose combination (used to treat chronic hepatitis C infection)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\thepatitis|||hepatitis\tinfection|||infección", "en": "grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination, and glecaprevir/pibrentasvir fixed dose combination (used to treat chronic hepatitis C infection)", "es": "medicamentos que contienen grazoprevir, incluida la combinación a dosis fija de elbasvir/grazoprevir y la combinación a dosis fija de glecaprevir/pibrentasvir (utilizadas para tratar la infección crónica por hepatitis C)" } }
{ "translation": { "text": "Glossaries:\n\"efficacy\" -> \"eficacia\"\n\"ferritin\" -> \"ferritina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: One of the secondary efficacy parameters was the change in serum ferritin between baseline and fourth quarter.\nSpanish: Uno de los parámetros de eficacia secundarios fue el cambio en el valor de ferritina sérica basal y el cuarto trimestre.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"efficacy\" -> \"eficacia\"\n\"ferritin\" -> \"ferritina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: One of the secondary efficacy parameters was the change in serum ferritin between baseline and fourth quarter.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "efficacy|||eficacia\tferritin|||ferritina", "en": "One of the secondary efficacy parameters was the change in serum ferritin between baseline and fourth quarter.", "es": "Uno de los parámetros de eficacia secundarios fue el cambio en el valor de ferritina sérica basal y el cuarto trimestre." } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"enfermedad\"\n\"activity\" -> \"actividad\"\n\"histology\" -> \"histología\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In two single arm phase II studies of ADCETRIS, disease activity has been shown in the subtypes Sézary syndrome (SS), lymphomatoid papulosis (LyP) and mixed CTCL histology.\nSpanish: En dos estudios en fase II de un solo brazo de ADCETRIS, se ha detectado actividad de la enfermedad en los subtipos: síndrome de Sézary (SS), papulosis linfomatoide (PL) e histología mixta de LCCT.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"enfermedad\"\n\"activity\" -> \"actividad\"\n\"histology\" -> \"histología\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In two single arm phase II studies of ADCETRIS, disease activity has been shown in the subtypes Sézary syndrome (SS), lymphomatoid papulosis (LyP) and mixed CTCL histology.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||enfermedad\tactivity|||actividad\thistology|||histología", "en": "In two single arm phase II studies of ADCETRIS, disease activity has been shown in the subtypes Sézary syndrome (SS), lymphomatoid papulosis (LyP) and mixed CTCL histology.", "es": "En dos estudios en fase II de un solo brazo de ADCETRIS, se ha detectado actividad de la enfermedad en los subtipos: síndrome de Sézary (SS), papulosis linfomatoide (PL) e histología mixta de LCCT." } }
{ "translation": { "text": "Glossaries:\n\"MAH\" -> \"TAC\"\n\"to prescribe\" -> \"prescribir\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all healthcare professionals who are expected to prescribe FABLYN or order gynaecological ultrasound of patients treated with FABLYN, are provided with access to risk minimisation educational programme.\nSpanish: El Titular de la Autorización de Comercialización (TAC) deberá garantizar que, antes de la comercialización, todos los profesionales sanitarios que se prevé puedan prescribir FABLYN o pedir ecografías ginecológicas a pacientes en tratamiento con FABLYN, tengan acceso al programa educacional de minimización del riesgo.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"MAH\" -> \"TAC\"\n\"to prescribe\" -> \"prescribir\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all healthcare professionals who are expected to prescribe FABLYN or order gynaecological ultrasound of patients treated with FABLYN, are provided with access to risk minimisation educational programme.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "MAH|||TAC\tto prescribe|||prescribir", "en": "The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all healthcare professionals who are expected to prescribe FABLYN or order gynaecological ultrasound of patients treated with FABLYN, are provided with access to risk minimisation educational programme.", "es": "El Titular de la Autorización de Comercialización (TAC) deberá garantizar que, antes de la comercialización, todos los profesionales sanitarios que se prevé puedan prescribir FABLYN o pedir ecografías ginecológicas a pacientes en tratamiento con FABLYN, tengan acceso al programa educacional de minimización del riesgo." } }
{ "translation": { "text": "Glossary:\n\"congestion\" -> \"congestión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The most common adverse reactions reported in clinical studies were headache, flushing, nasal and sinus congestion and back pain.\nSpanish: Las reacciones adversas más frecuentes notificadas en los estudios clínicos fueron cefaleas, sofocos, congestión nasal y sinusal y lumbalgia.", "en_prompt": "<|im_start|>user\nGlossary:\n\"congestion\" -> \"congestión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The most common adverse reactions reported in clinical studies were headache, flushing, nasal and sinus congestion and back pain.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "congestion|||congestión", "en": "The most common adverse reactions reported in clinical studies were headache, flushing, nasal and sinus congestion and back pain.", "es": "Las reacciones adversas más frecuentes notificadas en los estudios clínicos fueron cefaleas, sofocos, congestión nasal y sinusal y lumbalgia." } }
{ "translation": { "text": "Glossary:\n\"ritonavir\" -> \"ritonavir\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Outcomes darunavir/ ritonavir 800/100 mg once daily N=343\nSpanish: Resultados darunavir / ritonavir 800/100 mg una vez al día N=343", "en_prompt": "<|im_start|>user\nGlossary:\n\"ritonavir\" -> \"ritonavir\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Outcomes darunavir/ ritonavir 800/100 mg once daily N=343\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "ritonavir|||ritonavir", "en": "Outcomes darunavir/ ritonavir 800/100 mg once daily N=343", "es": "Resultados darunavir / ritonavir 800/100 mg una vez al día N=343" } }
{ "translation": { "text": "Glossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you have questions, please ask your doctor.\nSpanish: Si tiene alguna duda, por favor consulte a su médico.", "en_prompt": "<|im_start|>user\nGlossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you have questions, please ask your doctor.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico", "en": "If you have questions, please ask your doctor.", "es": "Si tiene alguna duda, por favor consulte a su médico." } }
{ "translation": { "text": "Glossary:\n\"impurity\" -> \"impureza\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • For NDMA, the key step involves dimethylamine (DMA) which forms the impurity in the presence of nitrites, usually under acidic conditions.\nSpanish: • En el caso de la NDMA, la etapa clave radica en la dimetilamina (DMA), que forma la impureza en presencia de nitritos, habitualmente en condiciones ácidas.", "en_prompt": "<|im_start|>user\nGlossary:\n\"impurity\" -> \"impureza\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • For NDMA, the key step involves dimethylamine (DMA) which forms the impurity in the presence of nitrites, usually under acidic conditions.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "impurity|||impureza", "en": "• For NDMA, the key step involves dimethylamine (DMA) which forms the impurity in the presence of nitrites, usually under acidic conditions.", "es": "• En el caso de la NDMA, la etapa clave radica en la dimetilamina (DMA), que forma la impureza en presencia de nitritos, habitualmente en condiciones ácidas." } }
{ "translation": { "text": "Glossary:\n\"bones\" -> \"huesos\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Very common (may affect more than 1 in 10 people): - nausea - pain in your muscles, joints or bones (musculoskeletal pain) - low white blood cell counts (including neutrophils and lymphocytes which may increase the\nSpanish: Muy frecuentes (pueden afectar a más de 1 de cada 10 personas): - náuseas - dolor en sus músculos, articulaciones o huesos (dolor musculoesquelético) - bajo número de células blancas de la sangre (incluyendo neutrófilos y linfocitos lo cual puede aumentar el riesgo de infección)", "en_prompt": "<|im_start|>user\nGlossary:\n\"bones\" -> \"huesos\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Very common (may affect more than 1 in 10 people): - nausea - pain in your muscles, joints or bones (musculoskeletal pain) - low white blood cell counts (including neutrophils and lymphocytes which may increase the\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "bones|||huesos", "en": "Very common (may affect more than 1 in 10 people): - nausea - pain in your muscles, joints or bones (musculoskeletal pain) - low white blood cell counts (including neutrophils and lymphocytes which may increase the", "es": "Muy frecuentes (pueden afectar a más de 1 de cada 10 personas): - náuseas - dolor en sus músculos, articulaciones o huesos (dolor musculoesquelético) - bajo número de células blancas de la sangre (incluyendo neutrófilos y linfocitos lo cual puede aumentar el riesgo de infección)" } }
{ "translation": { "text": "Glossary:\n\"asthma\" -> \"asma\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Fasenra may reduce the number of asthma attacks you are experiencing, help you breathe better and decrease your asthma symptoms.\nSpanish: Fasenra puede disminuir la frecuencia de las crisis asmáticas que está experimentando, ayudándole a respirar mejor y disminuyendo sus síntomas del asma.", "en_prompt": "<|im_start|>user\nGlossary:\n\"asthma\" -> \"asma\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Fasenra may reduce the number of asthma attacks you are experiencing, help you breathe better and decrease your asthma symptoms.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "asthma|||asma", "en": "Fasenra may reduce the number of asthma attacks you are experiencing, help you breathe better and decrease your asthma symptoms.", "es": "Fasenra puede disminuir la frecuencia de las crisis asmáticas que está experimentando, ayudándole a respirar mejor y disminuyendo sus síntomas del asma." } }
{ "translation": { "text": "Glossaries:\n\"product\" -> \"producto\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The PRAC therefore concluded that the product information of all RAS-acting agents should be revised to reflect the identified risks and provide guidance to prescribers and patients.\nSpanish: Por lo tanto, el PRAC concluyó que la información sobre el producto de todos los agentes que actúan sobre el SRA se debería revisar con el fin de reflejar los riesgos identificados y proporcionar directrices tanto a médicos como a pacientes.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"product\" -> \"producto\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The PRAC therefore concluded that the product information of all RAS-acting agents should be revised to reflect the identified risks and provide guidance to prescribers and patients.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "product|||producto\tinformation|||información", "en": "The PRAC therefore concluded that the product information of all RAS-acting agents should be revised to reflect the identified risks and provide guidance to prescribers and patients.", "es": "Por lo tanto, el PRAC concluyó que la información sobre el producto de todos los agentes que actúan sobre el SRA se debería revisar con el fin de reflejar los riesgos identificados y proporcionar directrices tanto a médicos como a pacientes." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The results showed that all of the above doses are effective and comparable in the treatment of GORD.\nSpanish: Los resultados demostraron que todas esas dosis son eficaces y equiparables en el tratamiento de la ERGE.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The results showed that all of the above doses are effective and comparable in the treatment of GORD.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento", "en": "The results showed that all of the above doses are effective and comparable in the treatment of GORD.", "es": "Los resultados demostraron que todas esas dosis son eficaces y equiparables en el tratamiento de la ERGE." } }
{ "translation": { "text": "Glossaries:\n\"gonadal\" -> \"gonadal\"\n\"therapy\" -> \"terapia\"\n\"suppression\" -> \"supresión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Clinically meaningful suppression of gonadal function should be managed with supportive endocrine replacement therapy until normal function returns.\nSpanish: Clínicamente, la supresión de la función gonadal deberá tratarse con terapia endocrina de apoyo hasta que retorne a la función normal.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"gonadal\" -> \"gonadal\"\n\"therapy\" -> \"terapia\"\n\"suppression\" -> \"supresión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Clinically meaningful suppression of gonadal function should be managed with supportive endocrine replacement therapy until normal function returns.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "gonadal|||gonadal\ttherapy|||terapia\tsuppression|||supresión", "en": "Clinically meaningful suppression of gonadal function should be managed with supportive endocrine replacement therapy until normal function returns.", "es": "Clínicamente, la supresión de la función gonadal deberá tratarse con terapia endocrina de apoyo hasta que retorne a la función normal." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Of those treated with Vabomere, overall 60% (21 out of 35) of patients were cured, compared with 32% (6 out of 19) of patients receiving best available antibiotic treatment.\nSpanish: De los tratados con Vabomere, el 60 % en total (21 de 35) de los pacientes se curaron, en comparación con el 32 % (6 de 19) de los pacientes que recibieron el mejor tratamiento con antibióticos disponible.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Of those treated with Vabomere, overall 60% (21 out of 35) of patients were cured, compared with 32% (6 out of 19) of patients receiving best available antibiotic treatment.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento", "en": "Of those treated with Vabomere, overall 60% (21 out of 35) of patients were cured, compared with 32% (6 out of 19) of patients receiving best available antibiotic treatment.", "es": "De los tratados con Vabomere, el 60 % en total (21 de 35) de los pacientes se curaron, en comparación con el 32 % (6 de 19) de los pacientes que recibieron el mejor tratamiento con antibióticos disponible." } }
{ "translation": { "text": "Glossary:\n\"horehound\" -> \"marrubio\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The HMPC concluded that, on the basis of its long-standing use, white horehound can be used in the following ways:\nSpanish: El HMPC llegó a la conclusión de que, teniendo en cuenta que lleva mucho tiempo utilizándose en la práctica, la sumidad florida de marrubio puede emplearse de las siguientes maneras:", "en_prompt": "<|im_start|>user\nGlossary:\n\"horehound\" -> \"marrubio\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The HMPC concluded that, on the basis of its long-standing use, white horehound can be used in the following ways:\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "horehound|||marrubio", "en": "The HMPC concluded that, on the basis of its long-standing use, white horehound can be used in the following ways:", "es": "El HMPC llegó a la conclusión de que, teniendo en cuenta que lleva mucho tiempo utilizándose en la práctica, la sumidad florida de marrubio puede emplearse de las siguientes maneras:" } }
{ "translation": { "text": "Glossaries:\n\"overdose\" -> \"sobredosis\"\n\"treatment\" -> \"tratamiento\"\n\"patient\" -> \"paciente\"\n\"symptomatic\" -> \"sintomático\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the event of overdose the patient should be observed and appropriate symptomatic treatment given.\nSpanish: En caso de sobredosis el paciente debe estar en observación y se le debe administrar el tratamiento sintomático adecuado.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"overdose\" -> \"sobredosis\"\n\"treatment\" -> \"tratamiento\"\n\"patient\" -> \"paciente\"\n\"symptomatic\" -> \"sintomático\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the event of overdose the patient should be observed and appropriate symptomatic treatment given.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "overdose|||sobredosis\ttreatment|||tratamiento\tpatient|||paciente\tsymptomatic|||sintomático", "en": "In the event of overdose the patient should be observed and appropriate symptomatic treatment given.", "es": "En caso de sobredosis el paciente debe estar en observación y se le debe administrar el tratamiento sintomático adecuado." } }
{ "translation": { "text": "Glossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Step 8 - Check the injection site\nSpanish: Paso 8 - Compruebe el lugar de la inyección", "en_prompt": "<|im_start|>user\nGlossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Step 8 - Check the injection site\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injection|||inyección", "en": "Step 8 - Check the injection site", "es": "Paso 8 - Compruebe el lugar de la inyección" } }
{ "translation": { "text": "Glossaries:\n\"medicine\" -> \"medicamento\"\n\"expiry date\" -> \"fecha de caducidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not use this medicine after the expiry date which is stated on the label/blister/carton after EXP.\nSpanish: No utilice este medicamento después de la fecha de caducidad que aparece en la etiqueta, el blíster o el envase después de CAD.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"medicine\" -> \"medicamento\"\n\"expiry date\" -> \"fecha de caducidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not use this medicine after the expiry date which is stated on the label/blister/carton after EXP.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicamento\texpiry date|||fecha de caducidad", "en": "Do not use this medicine after the expiry date which is stated on the label/blister/carton after EXP.", "es": "No utilice este medicamento después de la fecha de caducidad que aparece en la etiqueta, el blíster o el envase después de CAD." } }
{ "translation": { "text": "Glossaries:\n\"creatinine\" -> \"creatinina\"\n\"treatment\" -> \"tratamiento\"\n\"placebo\" -> \"placebo\"\n\"monotherapy\" -> \"monoterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The incidence of elevations in serum creatinine following treatment with Ipreziv was similar to placebo in the randomised placebo-controlled monotherapy studies.\nSpanish: La incidencia de la elevación de la creatinina sérica después del tratamiento con Ipreziv fue similar a la del placebo en los ensayos con monoterapia aleatorizados controlados con placebo.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"creatinine\" -> \"creatinina\"\n\"treatment\" -> \"tratamiento\"\n\"placebo\" -> \"placebo\"\n\"monotherapy\" -> \"monoterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The incidence of elevations in serum creatinine following treatment with Ipreziv was similar to placebo in the randomised placebo-controlled monotherapy studies.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "creatinine|||creatinina\ttreatment|||tratamiento\tplacebo|||placebo\tmonotherapy|||monoterapia", "en": "The incidence of elevations in serum creatinine following treatment with Ipreziv was similar to placebo in the randomised placebo-controlled monotherapy studies.", "es": "La incidencia de la elevación de la creatinina sérica después del tratamiento con Ipreziv fue similar a la del placebo en los ensayos con monoterapia aleatorizados controlados con placebo." } }
{ "translation": { "text": "Glossary:\n\"patient\" -> \"paciente\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Each pack contains 1, 2 or 6 pre-filled syringes for patient use with 1, 2 or 6 alcohol pads, respectively.\nSpanish: Cada envase contiene 1, 2 ó 6 jeringas precargadas para el uso del paciente y 1, 2 ó 6 toallitas empapadas en alcohol, respectivamente.", "en_prompt": "<|im_start|>user\nGlossary:\n\"patient\" -> \"paciente\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Each pack contains 1, 2 or 6 pre-filled syringes for patient use with 1, 2 or 6 alcohol pads, respectively.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "patient|||paciente", "en": "Each pack contains 1, 2 or 6 pre-filled syringes for patient use with 1, 2 or 6 alcohol pads, respectively.", "es": "Cada envase contiene 1, 2 ó 6 jeringas precargadas para el uso del paciente y 1, 2 ó 6 toallitas empapadas en alcohol, respectivamente." } }
{ "translation": { "text": "Glossaries:\n\"ribavirin\" -> \"ribavirina\"\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Duration of treatment - Treatment-naïve adults and prior treatment relapsers Treatment with INCIVO must be initiated in combination with peginterferon alfa and ribavirin and administered for 12 weeks (see figure 1).\nSpanish: Duración del tratamiento - Adultos previamente no tratados y pacientes recaedores tras tratamiento previo El tratamiento con INCIVO se debe iniciar en combinación con peginterferón alfa y ribavirina y administrarse durante 12 semanas (ver figura 1).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"ribavirin\" -> \"ribavirina\"\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Duration of treatment - Treatment-naïve adults and prior treatment relapsers Treatment with INCIVO must be initiated in combination with peginterferon alfa and ribavirin and administered for 12 weeks (see figure 1).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "ribavirin|||ribavirina\ttreatment|||tratamiento", "en": "Duration of treatment - Treatment-naïve adults and prior treatment relapsers Treatment with INCIVO must be initiated in combination with peginterferon alfa and ribavirin and administered for 12 weeks (see figure 1).", "es": "Duración del tratamiento - Adultos previamente no tratados y pacientes recaedores tras tratamiento previo El tratamiento con INCIVO se debe iniciar en combinación con peginterferón alfa y ribavirina y administrarse durante 12 semanas (ver figura 1)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Serious depression was reported in 0.3% (7/2002) of patients receiving Benlysta and <0.1% (1/2001) of patients receiving placebo.\nSpanish: Se notificó depresión grave en el 0,3% (7/2002) de los pacientes que recibían Benlysta y en <0,1% (1/2001) de los pacientes que recibían placebo.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Serious depression was reported in 0.3% (7/2002) of patients receiving Benlysta and <0.1% (1/2001) of patients receiving placebo.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Serious depression was reported in 0.3% (7/2002) of patients receiving Benlysta and <0.1% (1/2001) of patients receiving placebo.", "es": "Se notificó depresión grave en el 0,3% (7/2002) de los pacientes que recibían Benlysta y en <0,1% (1/2001) de los pacientes que recibían placebo." } }
{ "translation": { "text": "Glossary:\n\"oedema\" -> \"edema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • facial oedema associated with allergic reactions;\nSpanish: • edema facial asociado con reacciones alérgicas;", "en_prompt": "<|im_start|>user\nGlossary:\n\"oedema\" -> \"edema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • facial oedema associated with allergic reactions;\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "oedema|||edema", "en": "• facial oedema associated with allergic reactions;", "es": "• edema facial asociado con reacciones alérgicas;" } }
{ "translation": { "text": "Glossaries:\n\"daily dose\" -> \"dosis diaria\"\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For example, if you weigh 60 kg your daily dose will be 30 million international units (MIU).\nSpanish: Por ejemplo si pesa 60 kg, su dosis diaria será de 30 millones de unidades (MU).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"daily dose\" -> \"dosis diaria\"\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For example, if you weigh 60 kg your daily dose will be 30 million international units (MIU).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "daily dose|||dosis diaria\tdose|||dosis", "en": "For example, if you weigh 60 kg your daily dose will be 30 million international units (MIU).", "es": "Por ejemplo si pesa 60 kg, su dosis diaria será de 30 millones de unidades (MU)." } }
{ "translation": { "text": "Glossary:\n\"body\" -> \"cuerpo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Diarrhoea is a condition where your body produces more watery stools than normal.\nSpanish: La diarrea es un trastorno en el cual el cuerpo produce más heces líquidas de lo normal.", "en_prompt": "<|im_start|>user\nGlossary:\n\"body\" -> \"cuerpo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Diarrhoea is a condition where your body produces more watery stools than normal.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "body|||cuerpo", "en": "Diarrhoea is a condition where your body produces more watery stools than normal.", "es": "La diarrea es un trastorno en el cual el cuerpo produce más heces líquidas de lo normal." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If the repeat test confirms a baseline CK >5xULN, treatment should not be started.\nSpanish: Si el nuevo ensayo confirma los valores iniciales de CK >5xLSN, no se deberá iniciar el tratamiento.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If the repeat test confirms a baseline CK >5xULN, treatment should not be started.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento", "en": "If the repeat test confirms a baseline CK >5xULN, treatment should not be started.", "es": "Si el nuevo ensayo confirma los valores iniciales de CK >5xLSN, no se deberá iniciar el tratamiento." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A fever, flu-like symptoms, sore throat, or any other infection, as this could be a result of a very low white blood cell count, which may require Seroquel XR to be stopped and/or treatment to be given.\nSpanish: • Fiebre, síntomas similares a la gripe, dolor de garganta, o cualquier otra infección, ya que podría ser consecuencia de un recuento muy bajo de células blancas sanguíneas y requerir una interrupción del tratamiento con Seroquel XR y/o un tratamiento adicional.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A fever, flu-like symptoms, sore throat, or any other infection, as this could be a result of a very low white blood cell count, which may require Seroquel XR to be stopped and/or treatment to be given.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tinfection|||infección", "en": "A fever, flu-like symptoms, sore throat, or any other infection, as this could be a result of a very low white blood cell count, which may require Seroquel XR to be stopped and/or treatment to be given.", "es": "• Fiebre, síntomas similares a la gripe, dolor de garganta, o cualquier otra infección, ya que podría ser consecuencia de un recuento muy bajo de células blancas sanguíneas y requerir una interrupción del tratamiento con Seroquel XR y/o un tratamiento adicional." } }
{ "translation": { "text": "Glossary:\n\"anorexia\" -> \"anorexia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Oral Candida infection, stomatitis anorexia, constipation, ,\nSpanish: oral, estomatitis, anorexia, estreñimiento.", "en_prompt": "<|im_start|>user\nGlossary:\n\"anorexia\" -> \"anorexia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Oral Candida infection, stomatitis anorexia, constipation, ,\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "anorexia|||anorexia", "en": "Oral Candida infection, stomatitis anorexia, constipation, ,", "es": "oral, estomatitis, anorexia, estreñimiento." } }
{ "translation": { "text": "Glossaries:\n\"pharmacokinetics\" -> \"farmacocinética\"\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No clinical studies have been conducted to specifically evaluate the effect of renal impairment on the pharmacokinetics of osimertinib.\nSpanish: No se han realizado estudios clínicos que evalúen de forma específica el efecto de la insuficiencia renal en la farmacocinética de osimertinib.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"pharmacokinetics\" -> \"farmacocinética\"\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No clinical studies have been conducted to specifically evaluate the effect of renal impairment on the pharmacokinetics of osimertinib.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "pharmacokinetics|||farmacocinética\trenal|||renal", "en": "No clinical studies have been conducted to specifically evaluate the effect of renal impairment on the pharmacokinetics of osimertinib.", "es": "No se han realizado estudios clínicos que evalúen de forma específica el efecto de la insuficiencia renal en la farmacocinética de osimertinib." } }
{ "translation": { "text": "Glossary:\n\"fever\" -> \"fiebre\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness.\nSpanish: En muy raras ocasiones, medicamentos de este tipo producen una combinación de fiebre, respiración acelerada, sudoración, rigidez muscular y un estado de obnubilación o somnolencia.", "en_prompt": "<|im_start|>user\nGlossary:\n\"fever\" -> \"fiebre\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "fever|||fiebre", "en": "• Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness.", "es": "En muy raras ocasiones, medicamentos de este tipo producen una combinación de fiebre, respiración acelerada, sudoración, rigidez muscular y un estado de obnubilación o somnolencia." } }
{ "translation": { "text": "Glossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Always use Retacrit exactly as instructed by your doctor or nurse.\nSpanish: • Siga exactamente las instrucciones de administración de Retacrit indicadas por su médico o enfermero.", "en_prompt": "<|im_start|>user\nGlossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Always use Retacrit exactly as instructed by your doctor or nurse.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico", "en": "• Always use Retacrit exactly as instructed by your doctor or nurse.", "es": "• Siga exactamente las instrucciones de administración de Retacrit indicadas por su médico o enfermero." } }
{ "translation": { "text": "Glossary:\n\"patient\" -> \"paciente\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • dosing instructions and examples: how to calculate the body surface area of a patient and the volume of reconstituted Bortezomib Accord (both intravenous and subcutaneous use) required for different body surface areas.\nSpanish: • instrucciones de dosificación y ejemplos: cómo calcular el área de superficie corporal de un paciente y el volumen de Bortezomib Accord reconstituido (para ambas vías, IV y SC) que se necesita para las diferentes áreas de superficie corporal.", "en_prompt": "<|im_start|>user\nGlossary:\n\"patient\" -> \"paciente\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • dosing instructions and examples: how to calculate the body surface area of a patient and the volume of reconstituted Bortezomib Accord (both intravenous and subcutaneous use) required for different body surface areas.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "patient|||paciente", "en": "• dosing instructions and examples: how to calculate the body surface area of a patient and the volume of reconstituted Bortezomib Accord (both intravenous and subcutaneous use) required for different body surface areas.", "es": "• instrucciones de dosificación y ejemplos: cómo calcular el área de superficie corporal de un paciente y el volumen de Bortezomib Accord reconstituido (para ambas vías, IV y SC) que se necesita para las diferentes áreas de superficie corporal." } }
{ "translation": { "text": "Glossaries:\n\"clarithromycin\" -> \"claritromicina\"\n\"lansoprazole\" -> \"lansoprazol\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The effect of simultaneous administration of lansoprazole and various antibiotics (particularly clarithromycin) has not been systematically investigated.\nSpanish: El efecto de la administración simultánea de lansoprazol con varios antibióticos (en particular claritromicina) no ha sido investigado exhaustivamente.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"clarithromycin\" -> \"claritromicina\"\n\"lansoprazole\" -> \"lansoprazol\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The effect of simultaneous administration of lansoprazole and various antibiotics (particularly clarithromycin) has not been systematically investigated.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "clarithromycin|||claritromicina\tlansoprazole|||lansoprazol", "en": "The effect of simultaneous administration of lansoprazole and various antibiotics (particularly clarithromycin) has not been systematically investigated.", "es": "El efecto de la administración simultánea de lansoprazol con varios antibióticos (en particular claritromicina) no ha sido investigado exhaustivamente." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If DUTREBIS is missed within 6 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of DUTREBIS as soon as possible.\nSpanish: Si los pacientes olvidan tomar DUTREBIS, se les debe aconsejar que tomen la dosis prescrita de DUTREBIS tan pronto como sea posible dentro de las 6 horas posteriores a la hora habitual de la toma.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If DUTREBIS is missed within 6 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of DUTREBIS as soon as possible.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "If DUTREBIS is missed within 6 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of DUTREBIS as soon as possible.", "es": "Si los pacientes olvidan tomar DUTREBIS, se les debe aconsejar que tomen la dosis prescrita de DUTREBIS tan pronto como sea posible dentro de las 6 horas posteriores a la hora habitual de la toma." } }
{ "translation": { "text": "Glossaries:\n\"efficacy\" -> \"eficacia\"\n\"safety\" -> \"seguridad\"\n\"release\" -> \"liberación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The safety and efficacy of prolonged-release exenatide in children and adolescents aged under 18 years have not yet been established.\nSpanish: No se ha establecido todavía la seguridad y eficacia de exenatida de liberación prolongada en niños y adolescentes menores de 18 años.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"efficacy\" -> \"eficacia\"\n\"safety\" -> \"seguridad\"\n\"release\" -> \"liberación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The safety and efficacy of prolonged-release exenatide in children and adolescents aged under 18 years have not yet been established.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "efficacy|||eficacia\tsafety|||seguridad\trelease|||liberación", "en": "The safety and efficacy of prolonged-release exenatide in children and adolescents aged under 18 years have not yet been established.", "es": "No se ha establecido todavía la seguridad y eficacia de exenatida de liberación prolongada en niños y adolescentes menores de 18 años." } }
{ "translation": { "text": "Glossary:\n\"range\" -> \"rango\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients in Cohort 1 had a mean age of 15 years (range 12 to 17), were 44% male, 12% Asian, and 88% Black.\nSpanish: Los pacientes de la cohorte 1 tenían una media de edad de 15 años (rango: 12 a 17), el 44 % eran hombres, el 12 % asiáticos y el 88 % negros.", "en_prompt": "<|im_start|>user\nGlossary:\n\"range\" -> \"rango\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients in Cohort 1 had a mean age of 15 years (range 12 to 17), were 44% male, 12% Asian, and 88% Black.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "range|||rango", "en": "Patients in Cohort 1 had a mean age of 15 years (range 12 to 17), were 44% male, 12% Asian, and 88% Black.", "es": "Los pacientes de la cohorte 1 tenían una media de edad de 15 años (rango: 12 a 17), el 44 % eran hombres, el 12 % asiáticos y el 88 % negros." } }
{ "translation": { "text": "Glossaries:\n\"granisetron\" -> \"granisetrón\"\n\"dose\" -> \"dosis\"\n\"tolerance\" -> \"tolerabilidad\"\n\"functional\" -> \"funcional\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Given the wide variability in pharmacokinetic parameters of granisetron and the good tolerance well above the recommended dose, dose adjustment in patients with functional hepatic impairment is not necessary.\nSpanish: Dada la gran variabilidad en los parámetros farmacocinéticos del granisetrón y la buena tolerabilidad muy por encima de la dosis recomendada, no es necesario ajustar la dosis en pacientes con insuficiencia hepática funcional.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"granisetron\" -> \"granisetrón\"\n\"dose\" -> \"dosis\"\n\"tolerance\" -> \"tolerabilidad\"\n\"functional\" -> \"funcional\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Given the wide variability in pharmacokinetic parameters of granisetron and the good tolerance well above the recommended dose, dose adjustment in patients with functional hepatic impairment is not necessary.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "granisetron|||granisetrón\tdose|||dosis\ttolerance|||tolerabilidad\tfunctional|||funcional", "en": "Given the wide variability in pharmacokinetic parameters of granisetron and the good tolerance well above the recommended dose, dose adjustment in patients with functional hepatic impairment is not necessary.", "es": "Dada la gran variabilidad en los parámetros farmacocinéticos del granisetrón y la buena tolerabilidad muy por encima de la dosis recomendada, no es necesario ajustar la dosis en pacientes con insuficiencia hepática funcional." } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"overdose\" -> \"sobredosis\"\n\"SmPC\" -> \"RCP\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In section 4.9 of the SmPC regarding overdose, two different types are described; absolute and relative overdose.\nSpanish: En la sección 4.9 del RCP sobre sobredosis se describen dos tipos diferentes: sobredosis absoluta y relativa.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"overdose\" -> \"sobredosis\"\n\"SmPC\" -> \"RCP\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In section 4.9 of the SmPC regarding overdose, two different types are described; absolute and relative overdose.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\toverdose|||sobredosis\tSmPC|||RCP", "en": "In section 4.9 of the SmPC regarding overdose, two different types are described; absolute and relative overdose.", "es": "En la sección 4.9 del RCP sobre sobredosis se describen dos tipos diferentes: sobredosis absoluta y relativa." } }
{ "translation": { "text": "Glossary:\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The Empliciti infusion solution should be used immediately.\nSpanish: La solución para perfusión de Empliciti debe ser utilizada inmediatamente.", "en_prompt": "<|im_start|>user\nGlossary:\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The Empliciti infusion solution should be used immediately.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfusión", "en": "The Empliciti infusion solution should be used immediately.", "es": "La solución para perfusión de Empliciti debe ser utilizada inmediatamente." } }
{ "translation": { "text": "Glossary:\n\"active substance\" -> \"principio activo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: RXULTI contains the active substance brexpiprazole, which belongs to a group of medicines called antipsychotics.\nSpanish: RXULTI contiene el principio activo brexpiprazol, que pertenece a un grupo de medicamentos llamados antipsicóticos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"active substance\" -> \"principio activo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: RXULTI contains the active substance brexpiprazole, which belongs to a group of medicines called antipsychotics.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "active substance|||principio activo", "en": "RXULTI contains the active substance brexpiprazole, which belongs to a group of medicines called antipsychotics.", "es": "RXULTI contiene el principio activo brexpiprazol, que pertenece a un grupo de medicamentos llamados antipsicóticos." } }
{ "translation": { "text": "Glossary:\n\"sodium chloride\" -> \"cloruro de sodio\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Add approximately 0.8 ml sodium chloride 9 mg/ml (0.9%) solution to developing chamber assuring the liquid will not touch the 1.4 cm origin mark on the ITCL strip.\nSpanish: Añadir aproximadamente 0,8 ml de solución de cloruro de sodio de 9 mg/ml (0,9 %) a la cubeta, de modo que el líquido no toque la marca de origen de 1,4 cm de la tira de ITLC.", "en_prompt": "<|im_start|>user\nGlossary:\n\"sodium chloride\" -> \"cloruro de sodio\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Add approximately 0.8 ml sodium chloride 9 mg/ml (0.9%) solution to developing chamber assuring the liquid will not touch the 1.4 cm origin mark on the ITCL strip.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "sodium chloride|||cloruro de sodio", "en": "Add approximately 0.8 ml sodium chloride 9 mg/ml (0.9%) solution to developing chamber assuring the liquid will not touch the 1.4 cm origin mark on the ITCL strip.", "es": "Añadir aproximadamente 0,8 ml de solución de cloruro de sodio de 9 mg/ml (0,9 %) a la cubeta, de modo que el líquido no toque la marca de origen de 1,4 cm de la tira de ITLC." } }
{ "translation": { "text": "Glossaries:\n\"capecitabine\" -> \"capecitabina\"\n\"pharmacokinetics\" -> \"farmacocinética\"\n\"acid\" -> \"ácido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A combination study with capecitabine and folinic acid indicated that folinic acid has no major effect on the pharmacokinetics of capecitabine and its metabolites.\nSpanish: Un estudio de combinación de capecitabina y ácido folínico mostró que el ácido folínico no tiene un efecto importante sobre la farmacocinética de capecitabina y sus metabolitos.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"capecitabine\" -> \"capecitabina\"\n\"pharmacokinetics\" -> \"farmacocinética\"\n\"acid\" -> \"ácido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A combination study with capecitabine and folinic acid indicated that folinic acid has no major effect on the pharmacokinetics of capecitabine and its metabolites.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "capecitabine|||capecitabina\tpharmacokinetics|||farmacocinética\tacid|||ácido", "en": "A combination study with capecitabine and folinic acid indicated that folinic acid has no major effect on the pharmacokinetics of capecitabine and its metabolites.", "es": "Un estudio de combinación de capecitabina y ácido folínico mostró que el ácido folínico no tiene un efecto importante sobre la farmacocinética de capecitabina y sus metabolitos." } }
{ "translation": { "text": "Glossary:\n\"levetiracetam\" -> \"levetiracetam\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (< 10 %).\nSpanish: Ni levetiracetam ni su metabolito primario se unen de forma significativa a las proteínas plasmáticas (< 10 %).", "en_prompt": "<|im_start|>user\nGlossary:\n\"levetiracetam\" -> \"levetiracetam\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (< 10 %).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "levetiracetam|||levetiracetam", "en": "Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (< 10 %).", "es": "Ni levetiracetam ni su metabolito primario se unen de forma significativa a las proteínas plasmáticas (< 10 %)." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Any attempts to remove the depot should be monitored throughout treatment.\nSpanish: Se debe controlar cualquier intento de retirar el medicamento del depósito durante el tratamiento.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Any attempts to remove the depot should be monitored throughout treatment.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento", "en": "Any attempts to remove the depot should be monitored throughout treatment.", "es": "Se debe controlar cualquier intento de retirar el medicamento del depósito durante el tratamiento." } }
{ "translation": { "text": "Glossaries:\n\"medicine\" -> \"medicamento\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you have any further questions on the use of this medicine, ask your baby's doctor.\nSpanish: Si tiene cualquier otra duda sobre el uso de este medicamento, pregunte al médico de su bebé.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"medicine\" -> \"medicamento\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you have any further questions on the use of this medicine, ask your baby's doctor.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicamento\tdoctor|||médico", "en": "If you have any further questions on the use of this medicine, ask your baby's doctor.", "es": "Si tiene cualquier otra duda sobre el uso de este medicamento, pregunte al médico de su bebé." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"injection\" -> \"inyección\"\n\"initial dose\" -> \"dosis inicial\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Alternatively, in patients not on dialysis, an initial dose of 0.75 μg/kg may be administered subcutaneously as a single injection once every two weeks.\nSpanish: Por otra parte, en pacientes no sometidos a diálisis, se puede administrar una dosis inicial de 0,75 μg/kg como inyección única una vez cada dos semanas por vía subcutánea.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"injection\" -> \"inyección\"\n\"initial dose\" -> \"dosis inicial\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Alternatively, in patients not on dialysis, an initial dose of 0.75 μg/kg may be administered subcutaneously as a single injection once every two weeks.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tinjection|||inyección\tinitial dose|||dosis inicial", "en": "Alternatively, in patients not on dialysis, an initial dose of 0.75 μg/kg may be administered subcutaneously as a single injection once every two weeks.", "es": "Por otra parte, en pacientes no sometidos a diálisis, se puede administrar una dosis inicial de 0,75 μg/kg como inyección única una vez cada dos semanas por vía subcutánea." } }
{ "translation": { "text": "Glossaries:\n\"rifampicin\" -> \"rifampicina\"\n\"amlodipine\" -> \"amlodipino\"\n\"concomitant\" -> \"concomitante\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The concomitant use of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give a lower plasma concentration of amlodipine.\nSpanish: El uso concomitante de inductores del citocromo CYP3A4 (por ejemplo rifampicina, Hypericum perforatum [Hierba de San Juan]) puede producir una reducción en la concentración plasmática de amlodipino.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"rifampicin\" -> \"rifampicina\"\n\"amlodipine\" -> \"amlodipino\"\n\"concomitant\" -> \"concomitante\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The concomitant use of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give a lower plasma concentration of amlodipine.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "rifampicin|||rifampicina\tamlodipine|||amlodipino\tconcomitant|||concomitante", "en": "The concomitant use of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give a lower plasma concentration of amlodipine.", "es": "El uso concomitante de inductores del citocromo CYP3A4 (por ejemplo rifampicina, Hypericum perforatum [Hierba de San Juan]) puede producir una reducción en la concentración plasmática de amlodipino." } }
{ "translation": { "text": "Glossary:\n\"aprotinin\" -> \"aprotinina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Separate opinions and conclusions were issued by the CHMP for the three antifibrinolytics (aprotinin, EACA and TXA).\nSpanish: El CHMP emitió dictámenes y conclusiones separados sobre los tres antifibrinolíticos (aprotinina, AEAC y ATX).", "en_prompt": "<|im_start|>user\nGlossary:\n\"aprotinin\" -> \"aprotinina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Separate opinions and conclusions were issued by the CHMP for the three antifibrinolytics (aprotinin, EACA and TXA).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "aprotinin|||aprotinina", "en": "Separate opinions and conclusions were issued by the CHMP for the three antifibrinolytics (aprotinin, EACA and TXA).", "es": "El CHMP emitió dictámenes y conclusiones separados sobre los tres antifibrinolíticos (aprotinina, AEAC y ATX)." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The medicine was effective in patients with all three types of homocystinuria.\nSpanish: El medicamento fue eficaz en pacientes con los tres tipos de homocistinuria.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The medicine was effective in patients with all three types of homocystinuria.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicamento", "en": "The medicine was effective in patients with all three types of homocystinuria.", "es": "El medicamento fue eficaz en pacientes con los tres tipos de homocistinuria." } }
{ "translation": { "text": "Glossaries:\n\"daily dose\" -> \"dosis diaria\"\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The recommended daily dose is 4°tablets (2°g of the active ingredient) taken as 2°separate doses.\nSpanish: La dosis diaria recomendada es de 4 comprimidos (2 g de sustancia activa), administrada en 2 tomas separadas.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"daily dose\" -> \"dosis diaria\"\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The recommended daily dose is 4°tablets (2°g of the active ingredient) taken as 2°separate doses.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "daily dose|||dosis diaria\tdose|||dosis", "en": "The recommended daily dose is 4°tablets (2°g of the active ingredient) taken as 2°separate doses.", "es": "La dosis diaria recomendada es de 4 comprimidos (2 g de sustancia activa), administrada en 2 tomas separadas." } }
{ "translation": { "text": "Glossaries:\n\"efficacy\" -> \"eficacia\"\n\"safety\" -> \"seguridad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The safety and efficacy of OSSEOR in children aged below 18 years have not been established.\nSpanish: No se ha establecido todavía la seguridad y eficacia de OSSEOR en niños menores de 18 años.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"efficacy\" -> \"eficacia\"\n\"safety\" -> \"seguridad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The safety and efficacy of OSSEOR in children aged below 18 years have not been established.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "efficacy|||eficacia\tsafety|||seguridad", "en": "The safety and efficacy of OSSEOR in children aged below 18 years have not been established.", "es": "No se ha establecido todavía la seguridad y eficacia de OSSEOR en niños menores de 18 años." } }
{ "translation": { "text": "Glossaries:\n\"ribavirin\" -> \"ribavirina\"\n\"erythropoietin\" -> \"eritropoyetina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In clinical trials, the proportion of subjects who received erythropoietin for the management of anaemia was 43% (667/1,548) of subjects in the Victrelis-containing arms compared to 24% (131/547) of subjects receiving peginterferon alfa-2b and ribavirin alone.\nSpanish: En ensayos clínicos, el porcentaje de pacientes que recibieron eritropoyetina para el control de la anemia fue del 43% (667/1.548) de los pacientes en los grupos que contenían Victrelis comparado con el 24% (131/547) de los pacientes que sólo recibieron peginterferón alfa-2b y ribavirina.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"ribavirin\" -> \"ribavirina\"\n\"erythropoietin\" -> \"eritropoyetina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In clinical trials, the proportion of subjects who received erythropoietin for the management of anaemia was 43% (667/1,548) of subjects in the Victrelis-containing arms compared to 24% (131/547) of subjects receiving peginterferon alfa-2b and ribavirin alone.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "ribavirin|||ribavirina\terythropoietin|||eritropoyetina", "en": "In clinical trials, the proportion of subjects who received erythropoietin for the management of anaemia was 43% (667/1,548) of subjects in the Victrelis-containing arms compared to 24% (131/547) of subjects receiving peginterferon alfa-2b and ribavirin alone.", "es": "En ensayos clínicos, el porcentaje de pacientes que recibieron eritropoyetina para el control de la anemia fue del 43% (667/1.548) de los pacientes en los grupos que contenían Victrelis comparado con el 24% (131/547) de los pacientes que sólo recibieron peginterferón alfa-2b y ribavirina." } }
{ "translation": { "text": "Glossaries:\n\"prescription\" -> \"receta\"\n\"treatment\" -> \"tratamiento\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Blincyto can only be obtained with a prescription, and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood.\nSpanish: Blincyto solo se podrá dispensar con receta médica y el tratamiento deberá iniciarlo un médico experimentado en el tratamiento de pacientes con cánceres de la sangre.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"prescription\" -> \"receta\"\n\"treatment\" -> \"tratamiento\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Blincyto can only be obtained with a prescription, and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "prescription|||receta\ttreatment|||tratamiento\tdoctor|||médico", "en": "Blincyto can only be obtained with a prescription, and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood.", "es": "Blincyto solo se podrá dispensar con receta médica y el tratamiento deberá iniciarlo un médico experimentado en el tratamiento de pacientes con cánceres de la sangre." } }
{ "translation": { "text": "Glossaries:\n\"follow-up\" -> \"seguimiento\"\n\"lost to follow-up\" -> \"abandono\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: d. Includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.\nSpanish: d. Incluidos pacientes que interrumpieron debido a acontecimientos adversos, pérdida de seguimiento o abandono del estudio.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"follow-up\" -> \"seguimiento\"\n\"lost to follow-up\" -> \"abandono\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: d. Includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "follow-up|||seguimiento\tlost to follow-up|||abandono", "en": "d. Includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.", "es": "d. Incluidos pacientes que interrumpieron debido a acontecimientos adversos, pérdida de seguimiento o abandono del estudio." } }
{ "translation": { "text": "Glossaries:\n\"initiation\" -> \"iniciación\"\n\"interval\" -> \"intervalo\"\n\"vaccination\" -> \"vacunación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The interval between live vaccinations and initiation of RoActemra therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.\nSpanish: El intervalo entre la iniciación del tratamiento con RoActemra y la administración de vacunas vivas debe estar de acuerdo con las guías actuales de vacunación de agentes inmunosupresores.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"initiation\" -> \"iniciación\"\n\"interval\" -> \"intervalo\"\n\"vaccination\" -> \"vacunación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The interval between live vaccinations and initiation of RoActemra therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "initiation|||iniciación\tinterval|||intervalo\tvaccination|||vacunación", "en": "The interval between live vaccinations and initiation of RoActemra therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.", "es": "El intervalo entre la iniciación del tratamiento con RoActemra y la administración de vacunas vivas debe estar de acuerdo con las guías actuales de vacunación de agentes inmunosupresores." } }
{ "translation": { "text": "Glossaries:\n\"inhibition\" -> \"inhibición\"\n\"growth\" -> \"crecimiento\"\n\"dose\" -> \"dosis\"\n\"metastasis\" -> \"metástasis\"\n\"tumor regression\" -> \"regresión tumoral\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Cabozantinib exhibited dose-related tumour growth inhibition, tumor regression, and/or inhibited metastasis in a broad range of preclinical tumour models.\nSpanish: Cabozantinib presentó inhibición del crecimiento tumoral relacionada con la dosis, regresión tumoral y/o inhibición de metástasis en una gran variedad de modelos de tumores preclínicos.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"inhibition\" -> \"inhibición\"\n\"growth\" -> \"crecimiento\"\n\"dose\" -> \"dosis\"\n\"metastasis\" -> \"metástasis\"\n\"tumor regression\" -> \"regresión tumoral\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Cabozantinib exhibited dose-related tumour growth inhibition, tumor regression, and/or inhibited metastasis in a broad range of preclinical tumour models.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "inhibition|||inhibición\tgrowth|||crecimiento\tdose|||dosis\tmetastasis|||metástasis\ttumor regression|||regresión tumoral", "en": "Cabozantinib exhibited dose-related tumour growth inhibition, tumor regression, and/or inhibited metastasis in a broad range of preclinical tumour models.", "es": "Cabozantinib presentó inhibición del crecimiento tumoral relacionada con la dosis, regresión tumoral y/o inhibición de metástasis en una gran variedad de modelos de tumores preclínicos." } }
{ "translation": { "text": "Glossary:\n\"patient\" -> \"paciente\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: k One patient in this group became HBsAg negative for the first time at the 240 week visit and was ongoing in the study at the time of the data cut-off.\nSpanish: k Un paciente de este grupo se volvió HBsAg negativo por primera vez en la visita de la semana 240 y continuaba en el estudio en el momento del corte de los datos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"patient\" -> \"paciente\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: k One patient in this group became HBsAg negative for the first time at the 240 week visit and was ongoing in the study at the time of the data cut-off.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "patient|||paciente", "en": "k One patient in this group became HBsAg negative for the first time at the 240 week visit and was ongoing in the study at the time of the data cut-off.", "es": "k Un paciente de este grupo se volvió HBsAg negativo por primera vez en la visita de la semana 240 y continuaba en el estudio en el momento del corte de los datos." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"patient\" -> \"paciente\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The doctor should carry out blood tests to check the patient's liver, white blood cell counts and platelet counts before prescribing Repso, and regularly during treatment.\nSpanish: El médico debe realizar análisis de sangre para comprobar el higado del paciente, el recuento de glóbulos blancos y el recuento de plaquetas antes de recetar Repso y regularmente durante el tratamiento.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"patient\" -> \"paciente\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The doctor should carry out blood tests to check the patient's liver, white blood cell counts and platelet counts before prescribing Repso, and regularly during treatment.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tpatient|||paciente\tdoctor|||médico", "en": "The doctor should carry out blood tests to check the patient's liver, white blood cell counts and platelet counts before prescribing Repso, and regularly during treatment.", "es": "El médico debe realizar análisis de sangre para comprobar el higado del paciente, el recuento de glóbulos blancos y el recuento de plaquetas antes de recetar Repso y regularmente durante el tratamiento." } }
{ "translation": { "text": "Glossaries:\n\"eye\" -> \"ojo\"\n\"vision\" -> \"visión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: These new blood vessels can cause the leak of blood components into the eye and eventual damage to tissues in the eye responsible for vision.\nSpanish: Estos nuevos vasos sanguíneos pueden causar una fuga de los componentes de la sangre hacia el interior del ojo, con el consiguiente daño en los tejidos oculares responsables de la visión.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"eye\" -> \"ojo\"\n\"vision\" -> \"visión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: These new blood vessels can cause the leak of blood components into the eye and eventual damage to tissues in the eye responsible for vision.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "eye|||ojo\tvision|||visión", "en": "These new blood vessels can cause the leak of blood components into the eye and eventual damage to tissues in the eye responsible for vision.", "es": "Estos nuevos vasos sanguíneos pueden causar una fuga de los componentes de la sangre hacia el interior del ojo, con el consiguiente daño en los tejidos oculares responsables de la visión." } }
{ "translation": { "text": "Glossary:\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: However, no adjustment in dosage is necessary for patients with hepatic or renal impairment.\nSpanish: No obstante, no es necesario el ajuste de la dosis en pacientes con insuficiencia hepática o renal.", "en_prompt": "<|im_start|>user\nGlossary:\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: However, no adjustment in dosage is necessary for patients with hepatic or renal impairment.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "renal|||renal", "en": "However, no adjustment in dosage is necessary for patients with hepatic or renal impairment.", "es": "No obstante, no es necesario el ajuste de la dosis en pacientes con insuficiencia hepática o renal." } }
{ "translation": { "text": "Glossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Simultaneous use of medicines enhancing the pH of the stomach is not recommended (see section 4.5).\nSpanish: No se recomienda el uso simultáneo de medicamentos que aumentan el pH del estómago (ver sección", "en_prompt": "<|im_start|>user\nGlossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Simultaneous use of medicines enhancing the pH of the stomach is not recommended (see section 4.5).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección", "en": "Simultaneous use of medicines enhancing the pH of the stomach is not recommended (see section 4.5).", "es": "No se recomienda el uso simultáneo de medicamentos que aumentan el pH del estómago (ver sección" } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"dose\" -> \"dosis\"\n\"amlodipine\" -> \"amlodipino\"\n\"monotherapy\" -> \"monoterapia\"\n\"component\" -> \"componente\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to amlodipine or Exforge, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.\nSpanish: Cuando a los pacientes hipertensos candidatos (ver sección 4.1) con insuficiencia hepática se les cambie a amlodipino o Exforge, se debe utilizar la dosis más baja disponible de amlodipino en monoterapia o del componente de amlodipino respectivamente.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"dose\" -> \"dosis\"\n\"amlodipine\" -> \"amlodipino\"\n\"monotherapy\" -> \"monoterapia\"\n\"component\" -> \"componente\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to amlodipine or Exforge, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\tdose|||dosis\tamlodipine|||amlodipino\tmonotherapy|||monoterapia\tcomponent|||componente", "en": "When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to amlodipine or Exforge, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.", "es": "Cuando a los pacientes hipertensos candidatos (ver sección 4.1) con insuficiencia hepática se les cambie a amlodipino o Exforge, se debe utilizar la dosis más baja disponible de amlodipino en monoterapia o del componente de amlodipino respectivamente." } }
{ "translation": { "text": "Glossary:\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Ebymect must be discontinued prior to, or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see sections 4.2 and 4.4).\nSpanish: La administración de Ebymect se debe interrumpir antes o en el momento de la prueba y no se debe reanudar hasta pasadas al menos 48 horas, siempre que se haya reevaluado la función renal y comprobado que es estable (ver las secciones 4.2 y 4.4).", "en_prompt": "<|im_start|>user\nGlossary:\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Ebymect must be discontinued prior to, or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see sections 4.2 and 4.4).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "renal|||renal", "en": "Ebymect must be discontinued prior to, or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see sections 4.2 and 4.4).", "es": "La administración de Ebymect se debe interrumpir antes o en el momento de la prueba y no se debe reanudar hasta pasadas al menos 48 horas, siempre que se haya reevaluado la función renal y comprobado que es estable (ver las secciones 4.2 y 4.4)." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"bilirubin\" -> \"bilirrubina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the Phase III dose-optimisation study in chronic phase CML, grade 3 or 4 elevations of transaminases or bilirubin were reported in ≤ 1% of patients with similar low incidence in the four treatment groups.\nSpanish: En el ensayo Fase III de optimización de la dosis, estudio en fase crónica de LMC, elevaciones de transaminasas o bilirrubina grado 3 ó 4 fueron notificadas en ≤ 1% de los pacientes con incidencia baja similar en los cuatro grupos tratados.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"bilirubin\" -> \"bilirrubina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the Phase III dose-optimisation study in chronic phase CML, grade 3 or 4 elevations of transaminases or bilirubin were reported in ≤ 1% of patients with similar low incidence in the four treatment groups.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tbilirubin|||bilirrubina", "en": "In the Phase III dose-optimisation study in chronic phase CML, grade 3 or 4 elevations of transaminases or bilirubin were reported in ≤ 1% of patients with similar low incidence in the four treatment groups.", "es": "En el ensayo Fase III de optimización de la dosis, estudio en fase crónica de LMC, elevaciones de transaminasas o bilirrubina grado 3 ó 4 fueron notificadas en ≤ 1% de los pacientes con incidencia baja similar en los cuatro grupos tratados." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Your doctor has determined the correct dose of Ribavirin Mylan based on how much you or the child you are caring for weighs.\nSpanish: Su médico ha determinado la dosis correcta de Ribavirin Mylan basándose en su peso o en el del niño que está a su cargo.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Your doctor has determined the correct dose of Ribavirin Mylan based on how much you or the child you are caring for weighs.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tdoctor|||médico", "en": "Your doctor has determined the correct dose of Ribavirin Mylan based on how much you or the child you are caring for weighs.", "es": "Su médico ha determinado la dosis correcta de Ribavirin Mylan basándose en su peso o en el del niño que está a su cargo." } }
{ "translation": { "text": "Glossaries:\n\"doctor\" -> \"médico\"\n\"system\" -> \"sistema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Your doctor or nurse will remove the IONSYS system before you leave hospital.\nSpanish: Su médico o enfermero le quitará el sistema IONSYS antes de salir del hospital.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"doctor\" -> \"médico\"\n\"system\" -> \"sistema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Your doctor or nurse will remove the IONSYS system before you leave hospital.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico\tsystem|||sistema", "en": "Your doctor or nurse will remove the IONSYS system before you leave hospital.", "es": "Su médico o enfermero le quitará el sistema IONSYS antes de salir del hospital." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"toxicity\" -> \"toxicidad\"\n\"bone marrow\" -> \"médula ósea\"\n\"hyperplasia\" -> \"hiperplasia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Preclinical data from conventional studies of repeated dose toxicity revealed the expected pharmacological effects including increases in leukocyte count, myeloid hyperplasia in bone marrow, extramedullary haematopoiesis and splenic enlargement.\nSpanish: Los datos preclínicos procedentes de estudios convencionales de toxicidad a dosis repetidas mostraron los efectos farmacológicos esperados incluyendo los aumentos del recuento de leucocitos, hiperplasia mieloide en la médula ósea, hematopoyesis extramedular y aumento del tamaño del bazo.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"toxicity\" -> \"toxicidad\"\n\"bone marrow\" -> \"médula ósea\"\n\"hyperplasia\" -> \"hiperplasia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Preclinical data from conventional studies of repeated dose toxicity revealed the expected pharmacological effects including increases in leukocyte count, myeloid hyperplasia in bone marrow, extramedullary haematopoiesis and splenic enlargement.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\ttoxicity|||toxicidad\tbone marrow|||médula ósea\thyperplasia|||hiperplasia", "en": "Preclinical data from conventional studies of repeated dose toxicity revealed the expected pharmacological effects including increases in leukocyte count, myeloid hyperplasia in bone marrow, extramedullary haematopoiesis and splenic enlargement.", "es": "Los datos preclínicos procedentes de estudios convencionales de toxicidad a dosis repetidas mostraron los efectos farmacológicos esperados incluyendo los aumentos del recuento de leucocitos, hiperplasia mieloide en la médula ósea, hematopoyesis extramedular y aumento del tamaño del bazo." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\n\"kidney\" -> \"riñón\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Depending on the condition of your kidney, your doctor may have to reduce your dose.\nSpanish: Dependiendo del estado de su riñón, su médico puede tener que reducir su dosis.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\n\"kidney\" -> \"riñón\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Depending on the condition of your kidney, your doctor may have to reduce your dose.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tdoctor|||médico\tkidney|||riñón", "en": "Depending on the condition of your kidney, your doctor may have to reduce your dose.", "es": "Dependiendo del estado de su riñón, su médico puede tener que reducir su dosis." } }
{ "translation": { "text": "Glossary:\n\"cough\" -> \"tos\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The most common adverse reactions with the combination were headache (8%), cough (5%), and dizziness (3%).\nSpanish: Las reacciones adversas más frecuentes con la combinaciones fueron cefalea (8%), tos (5%), y mareo (3%).", "en_prompt": "<|im_start|>user\nGlossary:\n\"cough\" -> \"tos\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The most common adverse reactions with the combination were headache (8%), cough (5%), and dizziness (3%).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "cough|||tos", "en": "The most common adverse reactions with the combination were headache (8%), cough (5%), and dizziness (3%).", "es": "Las reacciones adversas más frecuentes con la combinaciones fueron cefalea (8%), tos (5%), y mareo (3%)." } }
{ "translation": { "text": "Glossaries:\n\"efficacy\" -> \"eficacia\"\n\"safety\" -> \"seguridad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Empagliflozin in combination with metformin in drug-naïve patients A factorial design study of 24 weeks duration was conducted to evaluate the efficacy and safety of empagliflozin in drug-naïve patients.\nSpanish: Se realizó un estudio de diseño factorial de 24 semanas de duración para evaluar la eficacia y la seguridad de empagliflozina en pacientes sin tratamiento previo.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"efficacy\" -> \"eficacia\"\n\"safety\" -> \"seguridad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Empagliflozin in combination with metformin in drug-naïve patients A factorial design study of 24 weeks duration was conducted to evaluate the efficacy and safety of empagliflozin in drug-naïve patients.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "efficacy|||eficacia\tsafety|||seguridad", "en": "Empagliflozin in combination with metformin in drug-naïve patients A factorial design study of 24 weeks duration was conducted to evaluate the efficacy and safety of empagliflozin in drug-naïve patients.", "es": "Se realizó un estudio de diseño factorial de 24 semanas de duración para evaluar la eficacia y la seguridad de empagliflozina en pacientes sin tratamiento previo." } }
{ "translation": { "text": "Glossaries:\n\"cell\" -> \"célula\"\n\"ergosterol\" -> \"ergosterol\"\n\"fluconazole\" -> \"fluconazol\"\n\"activity\" -> \"actividad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole.\nSpanish: La acumulación de 14-alfa-metil esteroles se relaciona con la consiguiente pérdida de ergosterol en la membrana de la célula fúngica y puede ser responsable de la actividad antifúngica de fluconazol.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"cell\" -> \"célula\"\n\"ergosterol\" -> \"ergosterol\"\n\"fluconazole\" -> \"fluconazol\"\n\"activity\" -> \"actividad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "cell|||célula\tergosterol|||ergosterol\tfluconazole|||fluconazol\tactivity|||actividad", "en": "The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole.", "es": "La acumulación de 14-alfa-metil esteroles se relaciona con la consiguiente pérdida de ergosterol en la membrana de la célula fúngica y puede ser responsable de la actividad antifúngica de fluconazol." } }
{ "translation": { "text": "Glossary:\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The cells that are affected by Blitzima help to fight infection and you should wait until the infection has passed before you are given Blitzima.\nSpanish: Las células contra las que va dirigido Blitzima ayudan a combatir las infecciones, por lo que debe esperar a que la infección haya pasado antes de utilizar Blitzima.", "en_prompt": "<|im_start|>user\nGlossary:\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The cells that are affected by Blitzima help to fight infection and you should wait until the infection has passed before you are given Blitzima.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "infection|||infección", "en": "The cells that are affected by Blitzima help to fight infection and you should wait until the infection has passed before you are given Blitzima.", "es": "Las células contra las que va dirigido Blitzima ayudan a combatir las infecciones, por lo que debe esperar a que la infección haya pasado antes de utilizar Blitzima." } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"treatment\" -> \"tratamiento\"\n\"hepatitis\" -> \"hepatitis\"\n\"information\" -> \"información\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The European Medicines Agency has deferred the obligation to submit the results of studies with Epclusa in one or more subsets of the paediatric population in the treatment of chronic hepatitis C (see section 4.2 for information on paediatric use).\nSpanish: La Agencia Europea de Medicamentos ha concedido al titular un aplazamiento para presentar los resultados de los estudios realizados con Epclusa en uno o más grupos de la población pediátrica en el tratamiento de la hepatitis C crónica (ver sección 4.2 para consultar la información sobre el uso en la población pediátrica).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"treatment\" -> \"tratamiento\"\n\"hepatitis\" -> \"hepatitis\"\n\"information\" -> \"información\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The European Medicines Agency has deferred the obligation to submit the results of studies with Epclusa in one or more subsets of the paediatric population in the treatment of chronic hepatitis C (see section 4.2 for information on paediatric use).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\ttreatment|||tratamiento\thepatitis|||hepatitis\tinformation|||información\tpopulation|||población", "en": "The European Medicines Agency has deferred the obligation to submit the results of studies with Epclusa in one or more subsets of the paediatric population in the treatment of chronic hepatitis C (see section 4.2 for information on paediatric use).", "es": "La Agencia Europea de Medicamentos ha concedido al titular un aplazamiento para presentar los resultados de los estudios realizados con Epclusa en uno o más grupos de la población pediátrica en el tratamiento de la hepatitis C crónica (ver sección 4.2 para consultar la información sobre el uso en la población pediátrica)." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you are given other medicines as part of your treatment, you should ask your doctor for advice on driving and using machines.\nSpanish: Si está tomando otros medicamentos como parte de su tratamiento, consulte a su médico sobre su capacidad para conducir y utilizar máquinas.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you are given other medicines as part of your treatment, you should ask your doctor for advice on driving and using machines.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tdoctor|||médico", "en": "If you are given other medicines as part of your treatment, you should ask your doctor for advice on driving and using machines.", "es": "Si está tomando otros medicamentos como parte de su tratamiento, consulte a su médico sobre su capacidad para conducir y utilizar máquinas." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"applicant\" -> \"solicitante\"\n\"medicinal product\" -> \"medicamento\"\n\"incontinence\" -> \"incontinencia urinaria\"\n\"urinary incontinence\" -> \"incontinencia urinaria\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The data provided by the applicant show that Enurace 50 is an effective medicinal product for treatment of urinary incontinence in ovariohysterectomised bitches.\nSpanish: Los datos presentados por el solicitante demuestran que Enurace 50 es un medicamento eficaz para el tratamiento de la incontinencia urinaria en perras ovariohisterectomizadas.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"applicant\" -> \"solicitante\"\n\"medicinal product\" -> \"medicamento\"\n\"incontinence\" -> \"incontinencia urinaria\"\n\"urinary incontinence\" -> \"incontinencia urinaria\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The data provided by the applicant show that Enurace 50 is an effective medicinal product for treatment of urinary incontinence in ovariohysterectomised bitches.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tapplicant|||solicitante\tmedicinal product|||medicamento\tincontinence|||incontinencia urinaria\turinary incontinence|||incontinencia urinaria", "en": "The data provided by the applicant show that Enurace 50 is an effective medicinal product for treatment of urinary incontinence in ovariohysterectomised bitches.", "es": "Los datos presentados por el solicitante demuestran que Enurace 50 es un medicamento eficaz para el tratamiento de la incontinencia urinaria en perras ovariohisterectomizadas." } }
{ "translation": { "text": "Glossaries:\n\"fusidic acid\" -> \"ácido fusídico\"\n\"acid\" -> \"ácido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Intravenous administration of fusidic acid:\nSpanish: Administración intravenosa de ácido fusídico:", "en_prompt": "<|im_start|>user\nGlossaries:\n\"fusidic acid\" -> \"ácido fusídico\"\n\"acid\" -> \"ácido\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Intravenous administration of fusidic acid:\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "fusidic acid|||ácido fusídico\tacid|||ácido", "en": "Intravenous administration of fusidic acid:", "es": "Administración intravenosa de ácido fusídico:" } }
{ "translation": { "text": "Glossaries:\n\"tremor\" -> \"temblor\"\n\"anxiety\" -> \"ansiedad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you suddenly stop taking ZYPREXA VELOTAB, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur.\nSpanish: Si deja de tomar ZYPREXA VELOTAB de forma repentina, pueden aparecer síntomas como sudoración, imposibilidad para dormir, temblor, ansiedad, o náuseas y vómitos.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"tremor\" -> \"temblor\"\n\"anxiety\" -> \"ansiedad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you suddenly stop taking ZYPREXA VELOTAB, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "tremor|||temblor\tanxiety|||ansiedad", "en": "If you suddenly stop taking ZYPREXA VELOTAB, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur.", "es": "Si deja de tomar ZYPREXA VELOTAB de forma repentina, pueden aparecer síntomas como sudoración, imposibilidad para dormir, temblor, ansiedad, o náuseas y vómitos." } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"concomitant\" -> \"concomitante\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxes, especially in patients receiving concomitant medicinal products susceptible to induce bleeding (see section 4.8, Haemorrhagic disorders).\nSpanish: Se aconseja a médicos y pacientes que estén atentos a los signos y síntomas de hemorragia, incluyendo petequias y epistaxis, especialmente en pacientes tratados de forma concomitante con otros medicamentos que sean susceptibles de inducir hemorragia (ver sección 4.8, Trastornos hemorrágicos).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"concomitant\" -> \"concomitante\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxes, especially in patients receiving concomitant medicinal products susceptible to induce bleeding (see section 4.8, Haemorrhagic disorders).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\tconcomitant|||concomitante", "en": "Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxes, especially in patients receiving concomitant medicinal products susceptible to induce bleeding (see section 4.8, Haemorrhagic disorders).", "es": "Se aconseja a médicos y pacientes que estén atentos a los signos y síntomas de hemorragia, incluyendo petequias y epistaxis, especialmente en pacientes tratados de forma concomitante con otros medicamentos que sean susceptibles de inducir hemorragia (ver sección 4.8, Trastornos hemorrágicos)." } }
{ "translation": { "text": "Glossaries:\n\"safety profile\" -> \"perfil de seguridad\"\n\"safety\" -> \"seguridad\"\n\"lymphoma\" -> \"linfoma\"\n\"rituximab\" -> \"rituximab\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The overall safety profile of rituximab in non-Hodgkin's lymphoma and CLL is based on data from patients from clinical trials and from post-marketing surveillance.\nSpanish: El perfil de seguridad global de rituximab en linfoma no-Hodgking y leucemia linfática crónica se basa en los datos de pacientes de ensayos clínicos y de los estudios post comercialización.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"safety profile\" -> \"perfil de seguridad\"\n\"safety\" -> \"seguridad\"\n\"lymphoma\" -> \"linfoma\"\n\"rituximab\" -> \"rituximab\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The overall safety profile of rituximab in non-Hodgkin's lymphoma and CLL is based on data from patients from clinical trials and from post-marketing surveillance.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "safety profile|||perfil de seguridad\tsafety|||seguridad\tlymphoma|||linfoma\trituximab|||rituximab", "en": "The overall safety profile of rituximab in non-Hodgkin's lymphoma and CLL is based on data from patients from clinical trials and from post-marketing surveillance.", "es": "El perfil de seguridad global de rituximab en linfoma no-Hodgking y leucemia linfática crónica se basa en los datos de pacientes de ensayos clínicos y de los estudios post comercialización." } }
{ "translation": { "text": "Glossary:\n\"container\" -> \"contenedor\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Put used Needles in a sharps container or a hard plastic container with a secure lid. Do not throw needles directly into your household waste.\nSpanish: • Deposite las Agujas usadas en un contenedor para objetos punzantes o un contenedor de plástico duro provisto de cierre de seguridad.", "en_prompt": "<|im_start|>user\nGlossary:\n\"container\" -> \"contenedor\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Put used Needles in a sharps container or a hard plastic container with a secure lid. Do not throw needles directly into your household waste.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "container|||contenedor", "en": "• Put used Needles in a sharps container or a hard plastic container with a secure lid. Do not throw needles directly into your household waste.", "es": "• Deposite las Agujas usadas en un contenedor para objetos punzantes o un contenedor de plástico duro provisto de cierre de seguridad." } }
{ "translation": { "text": "Glossary:\n\"weight\" -> \"peso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Several patients showed an increase in height (n=7) and weight (n=3) for age Z-score.\nSpanish: Varios pacientes mostraron un aumento de altura (n=7) y peso (n=3) según la puntuación Z para la edad.", "en_prompt": "<|im_start|>user\nGlossary:\n\"weight\" -> \"peso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Several patients showed an increase in height (n=7) and weight (n=3) for age Z-score.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "weight|||peso", "en": "Several patients showed an increase in height (n=7) and weight (n=3) for age Z-score.", "es": "Varios pacientes mostraron un aumento de altura (n=7) y peso (n=3) según la puntuación Z para la edad." } }
{ "translation": { "text": "Glossaries:\n\"agitation\" -> \"agitación\"\n\"tremor\" -> \"temblor\"\n\"hypotonia\" -> \"hipotonía\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.\nSpanish: Se han notificado casos de síntomas de agitación, hipertonía, hipotonía, temblor, somnolencia, dificultad respiratoria o alteraciones alimenticias.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"agitation\" -> \"agitación\"\n\"tremor\" -> \"temblor\"\n\"hypotonia\" -> \"hipotonía\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "agitation|||agitación\ttremor|||temblor\thypotonia|||hipotonía", "en": "There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.", "es": "Se han notificado casos de síntomas de agitación, hipertonía, hipotonía, temblor, somnolencia, dificultad respiratoria o alteraciones alimenticias." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients who were randomised to the placebo treatment group received placebo during the first treatment cycle and TOBI Podhaler in the subsequent two cycles.\nSpanish: Los pacientes que fueron randomizados al grupo de tratamiento con placebo recibieron placebo durante el primer ciclo de tratamiento y TOBI Podhaler en los dos ciclos siguientes.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients who were randomised to the placebo treatment group received placebo during the first treatment cycle and TOBI Podhaler in the subsequent two cycles.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tplacebo|||placebo", "en": "Patients who were randomised to the placebo treatment group received placebo during the first treatment cycle and TOBI Podhaler in the subsequent two cycles.", "es": "Los pacientes que fueron randomizados al grupo de tratamiento con placebo recibieron placebo durante el primer ciclo de tratamiento y TOBI Podhaler en los dos ciclos siguientes." } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The dose of modafinil should be reduced by half in patients with severe hepatic impairment (see section 5.2).\nSpanish: Pacientes con insuficiencia hepática En pacientes con insuficiencia hepática grave se debe reducir la dosis a la mitad (ver sección 5.2).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The dose of modafinil should be reduced by half in patients with severe hepatic impairment (see section 5.2).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\tdose|||dosis", "en": "The dose of modafinil should be reduced by half in patients with severe hepatic impairment (see section 5.2).", "es": "Pacientes con insuficiencia hepática En pacientes con insuficiencia hepática grave se debe reducir la dosis a la mitad (ver sección 5.2)." } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"enfermedad\"\n\"treatment\" -> \"tratamiento\"\n\"mutation\" -> \"mutación\"\n\"prognosis\" -> \"pronóstico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients with AML who have an FLT3 mutation, and whose disease has come back or has not improved following previous treatment, have a poor prognosis and treatment options are limited.\nSpanish: Los pacientes con LMA que presentan una mutación FL3, y cuya enfermedad ha reaparecido o no ha mejorado tras el tratamiento previo, tienen un mal pronóstico y las opciones de tratamiento son limitadas.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"enfermedad\"\n\"treatment\" -> \"tratamiento\"\n\"mutation\" -> \"mutación\"\n\"prognosis\" -> \"pronóstico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients with AML who have an FLT3 mutation, and whose disease has come back or has not improved following previous treatment, have a poor prognosis and treatment options are limited.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||enfermedad\ttreatment|||tratamiento\tmutation|||mutación\tprognosis|||pronóstico", "en": "Patients with AML who have an FLT3 mutation, and whose disease has come back or has not improved following previous treatment, have a poor prognosis and treatment options are limited.", "es": "Los pacientes con LMA que presentan una mutación FL3, y cuya enfermedad ha reaparecido o no ha mejorado tras el tratamiento previo, tienen un mal pronóstico y las opciones de tratamiento son limitadas." } }
{ "translation": { "text": "Glossary:\n\"disease\" -> \"enfermedad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It can also be used in adults at high risk (because of their age or disease) when they are having abdominal surgery or are forced to stay in bed because of an acute illness.\nSpanish: También se puede utilizar en adultos de alto riesgo (por su edad o por su enfermedad) sometidos a cirugía abdominal, o que deban permanecer inmovilizados debido a una enfermedad aguda.", "en_prompt": "<|im_start|>user\nGlossary:\n\"disease\" -> \"enfermedad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It can also be used in adults at high risk (because of their age or disease) when they are having abdominal surgery or are forced to stay in bed because of an acute illness.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||enfermedad", "en": "It can also be used in adults at high risk (because of their age or disease) when they are having abdominal surgery or are forced to stay in bed because of an acute illness.", "es": "También se puede utilizar en adultos de alto riesgo (por su edad o por su enfermedad) sometidos a cirugía abdominal, o que deban permanecer inmovilizados debido a una enfermedad aguda." } }
{ "translation": { "text": "Glossary:\n\"medicinal product\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Therefore, the use of this medicinal product is not recommended during the second and third trimesters of pregnancy.\nSpanish: Por lo tanto, no se recomienda el uso de este medicamento durante el segundo y tercer trimestres de embarazo.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicinal product\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Therefore, the use of this medicinal product is not recommended during the second and third trimesters of pregnancy.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicinal product|||medicamento", "en": "Therefore, the use of this medicinal product is not recommended during the second and third trimesters of pregnancy.", "es": "Por lo tanto, no se recomienda el uso de este medicamento durante el segundo y tercer trimestres de embarazo." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 46% and 38%, of patients on final stable treatment of febuxostat 80 or 120 mg QD, respectively, had complete resolution of the primary palpable tophus from baseline to the Final Visit.\nSpanish: El 46% y 38% de los pacientes con un tratamiento final estable de febuxostat 80 mg y 120 mg 1 vez al día, respectivamente, tuvieron una remisión completa de los principales tofos palpables desde el estado basal hasta la última visita.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 46% and 38%, of patients on final stable treatment of febuxostat 80 or 120 mg QD, respectively, had complete resolution of the primary palpable tophus from baseline to the Final Visit.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento", "en": "46% and 38%, of patients on final stable treatment of febuxostat 80 or 120 mg QD, respectively, had complete resolution of the primary palpable tophus from baseline to the Final Visit.", "es": "El 46% y 38% de los pacientes con un tratamiento final estable de febuxostat 80 mg y 120 mg 1 vez al día, respectivamente, tuvieron una remisión completa de los principales tofos palpables desde el estado basal hasta la última visita." } }
{ "translation": { "text": "Glossaries:\n\"reflux\" -> \"reflujo\"\n\"tachycardia\" -> \"taquicardia\"\n\"oxybutynin\" -> \"oxibutinina\"\n\"lacrimation\" -> \"lagrimeo\"\n\"anorexia\" -> \"anorexia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Adverse reactions known to be associated with anticholinergic therapy, such as oxybutynin, are anorexia, vomiting, reflux oesophagitis, decreased sweating, heat stroke, decreased lacrimation, mydriasis, tachycardia, arrhythmia, disorientation, poor ability to concentrate, fatigue, nightmares, restlessness, convulsion, intraocular hypertension and induction of glaucoma, confusion, anxiety, paranoia, hallucination, photosensitivity, erectile dysfunction.\nSpanish: Las reacciones adversas conocidas del tratamiento anticolinérgico, como oxibutinina, son anorexia, vómitos, esofagitis por reflujo, disminución de la sudoración, golpe de calor, lagrimeo disminuido, midriasis, taquicardia, arritmia, desorientación, poca capacidad de concentración, cansancio,", "en_prompt": "<|im_start|>user\nGlossaries:\n\"reflux\" -> \"reflujo\"\n\"tachycardia\" -> \"taquicardia\"\n\"oxybutynin\" -> \"oxibutinina\"\n\"lacrimation\" -> \"lagrimeo\"\n\"anorexia\" -> \"anorexia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Adverse reactions known to be associated with anticholinergic therapy, such as oxybutynin, are anorexia, vomiting, reflux oesophagitis, decreased sweating, heat stroke, decreased lacrimation, mydriasis, tachycardia, arrhythmia, disorientation, poor ability to concentrate, fatigue, nightmares, restlessness, convulsion, intraocular hypertension and induction of glaucoma, confusion, anxiety, paranoia, hallucination, photosensitivity, erectile dysfunction.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "reflux|||reflujo\ttachycardia|||taquicardia\toxybutynin|||oxibutinina\tlacrimation|||lagrimeo\tanorexia|||anorexia", "en": "Adverse reactions known to be associated with anticholinergic therapy, such as oxybutynin, are anorexia, vomiting, reflux oesophagitis, decreased sweating, heat stroke, decreased lacrimation, mydriasis, tachycardia, arrhythmia, disorientation, poor ability to concentrate, fatigue, nightmares, restlessness, convulsion, intraocular hypertension and induction of glaucoma, confusion, anxiety, paranoia, hallucination, photosensitivity, erectile dysfunction.", "es": "Las reacciones adversas conocidas del tratamiento anticolinérgico, como oxibutinina, son anorexia, vómitos, esofagitis por reflujo, disminución de la sudoración, golpe de calor, lagrimeo disminuido, midriasis, taquicardia, arritmia, desorientación, poca capacidad de concentración, cansancio," } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"metoclopramide\" -> \"metoclopramida\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The evidence indicated that these risks outweighed the benefits of metoclopramide in conditions requiring long-term treatment.\nSpanish: Las pruebas indican que estos riesgos de la metoclopramida son mayores que los beneficios en las afecciones que requieren tratamiento a largo plazo.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"metoclopramide\" -> \"metoclopramida\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The evidence indicated that these risks outweighed the benefits of metoclopramide in conditions requiring long-term treatment.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tmetoclopramide|||metoclopramida", "en": "The evidence indicated that these risks outweighed the benefits of metoclopramide in conditions requiring long-term treatment.", "es": "Las pruebas indican que estos riesgos de la metoclopramida son mayores que los beneficios en las afecciones que requieren tratamiento a largo plazo." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"placebo\" -> \"placebo\"\n\"urinary\" -> \"urinario\"\n\"infection\" -> \"infección\"\n\"infliximab\" -> \"infliximab\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: There was no significant difference between placebo and infliximab for the proportion of patients with sustained closure of all fistulas through week 54, for symptoms such as proctalgia, abscesses and urinary tract infection or for number of newly developed fistulas during treatment.\nSpanish: No hubo diferencia significativa entre placebo e infliximab en cuanto a la proporción de pacientes con cierre sostenido de todas las fístulas hasta la semana 54, en cuanto a síntomas tales como proctalgia, abscesos e infección del tracto urinario o en cuanto al número de fístulas de nueva aparición durante el tratamiento.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"placebo\" -> \"placebo\"\n\"urinary\" -> \"urinario\"\n\"infection\" -> \"infección\"\n\"infliximab\" -> \"infliximab\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: There was no significant difference between placebo and infliximab for the proportion of patients with sustained closure of all fistulas through week 54, for symptoms such as proctalgia, abscesses and urinary tract infection or for number of newly developed fistulas during treatment.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tplacebo|||placebo\turinary|||urinario\tinfection|||infección\tinfliximab|||infliximab", "en": "There was no significant difference between placebo and infliximab for the proportion of patients with sustained closure of all fistulas through week 54, for symptoms such as proctalgia, abscesses and urinary tract infection or for number of newly developed fistulas during treatment.", "es": "No hubo diferencia significativa entre placebo e infliximab en cuanto a la proporción de pacientes con cierre sostenido de todas las fístulas hasta la semana 54, en cuanto a síntomas tales como proctalgia, abscesos e infección del tracto urinario o en cuanto al número de fístulas de nueva aparición durante el tratamiento." } }
{ "translation": { "text": "Glossaries:\n\"octocog alfa\" -> \"octocog alfa\"\n\"injections\" -> \"inyectables\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: PHARMACEUTICAL FORM AND CONTENTS Powder and solvent for solution for injection Contents: 1 vial with 1500 IU octocog alfa, 1 vial with 2 ml sterilised water for injections, 1 BAXJECT II device.\nSpanish: Contenido: 1 vial con 1500 UI de octocog alfa, 1 vial con 2 ml de agua esterilizada para preparaciones inyectables, 1 equipo para reconstitución BAXJECT II.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"octocog alfa\" -> \"octocog alfa\"\n\"injections\" -> \"inyectables\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: PHARMACEUTICAL FORM AND CONTENTS Powder and solvent for solution for injection Contents: 1 vial with 1500 IU octocog alfa, 1 vial with 2 ml sterilised water for injections, 1 BAXJECT II device.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "octocog alfa|||octocog alfa\tinjections|||inyectables", "en": "PHARMACEUTICAL FORM AND CONTENTS Powder and solvent for solution for injection Contents: 1 vial with 1500 IU octocog alfa, 1 vial with 2 ml sterilised water for injections, 1 BAXJECT II device.", "es": "Contenido: 1 vial con 1500 UI de octocog alfa, 1 vial con 2 ml de agua esterilizada para preparaciones inyectables, 1 equipo para reconstitución BAXJECT II." } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"efficacy\" -> \"eficacia\"\n\"eradication\" -> \"erradicación\"\n\"safety\" -> \"seguridad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Protium must not be used in combination treatment for eradication of H. pylori in patients with moderate to severe hepatic dysfunction since currently no data are available on the efficacy and safety of Protium in combination treatment of these patients (see section 4.4).\nSpanish: En pacientes con insuficiencia hepática de moderada a grave no debe utilizarse terapia combinada con Protium para la erradicación de H. pylori, ya que actualmente no hay datos disponibles sobre la eficacia y seguridad de la terapia combinada con Protium en estos pacientes (ver sección 4.4).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"efficacy\" -> \"eficacia\"\n\"eradication\" -> \"erradicación\"\n\"safety\" -> \"seguridad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Protium must not be used in combination treatment for eradication of H. pylori in patients with moderate to severe hepatic dysfunction since currently no data are available on the efficacy and safety of Protium in combination treatment of these patients (see section 4.4).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\tefficacy|||eficacia\teradication|||erradicación\tsafety|||seguridad", "en": "Protium must not be used in combination treatment for eradication of H. pylori in patients with moderate to severe hepatic dysfunction since currently no data are available on the efficacy and safety of Protium in combination treatment of these patients (see section 4.4).", "es": "En pacientes con insuficiencia hepática de moderada a grave no debe utilizarse terapia combinada con Protium para la erradicación de H. pylori, ya que actualmente no hay datos disponibles sobre la eficacia y seguridad de la terapia combinada con Protium en estos pacientes (ver sección 4.4)." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"active substance\" -> \"principio activo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the pregnant rat the AUC for calculated free active substance at this dose was approximately 18 times the human AUC at a 20 mg dose.\nSpanish: El AUC para el principio activo libre en ratas preñadas a esta dosis fue aproximadamente 18 veces el AUC humana para una dosis de 20 mg.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"active substance\" -> \"principio activo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the pregnant rat the AUC for calculated free active substance at this dose was approximately 18 times the human AUC at a 20 mg dose.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tactive substance|||principio activo", "en": "In the pregnant rat the AUC for calculated free active substance at this dose was approximately 18 times the human AUC at a 20 mg dose.", "es": "El AUC para el principio activo libre en ratas preñadas a esta dosis fue aproximadamente 18 veces el AUC humana para una dosis de 20 mg." } }
{ "translation": { "text": "Glossaries:\n\"pharmacokinetics\" -> \"farmacocinética\"\n\"fludarabine\" -> \"fludarabina\"\n\"treosulfan\" -> \"treosulfano\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The effect of treosulfan on the pharmacokinetics of fludarabine is not known.\nSpanish: Se desconoce el efecto de treosulfano en la farmacocinética de fludarabina.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"pharmacokinetics\" -> \"farmacocinética\"\n\"fludarabine\" -> \"fludarabina\"\n\"treosulfan\" -> \"treosulfano\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The effect of treosulfan on the pharmacokinetics of fludarabine is not known.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "pharmacokinetics|||farmacocinética\tfludarabine|||fludarabina\ttreosulfan|||treosulfano", "en": "The effect of treosulfan on the pharmacokinetics of fludarabine is not known.", "es": "Se desconoce el efecto de treosulfano en la farmacocinética de fludarabina." } }
{ "translation": { "text": "Glossary:\n\"heart\" -> \"corazón\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Common (may affect up to 1 in 10 people) - Modification in the heart functioning (the symptoms are a slowing down of the heart rate).\nSpanish: − Modificación del funcionamiento del corazón (los síntomas son un enlentecimiento del ritmo cardíaco).", "en_prompt": "<|im_start|>user\nGlossary:\n\"heart\" -> \"corazón\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Common (may affect up to 1 in 10 people) - Modification in the heart functioning (the symptoms are a slowing down of the heart rate).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "heart|||corazón", "en": "Common (may affect up to 1 in 10 people) - Modification in the heart functioning (the symptoms are a slowing down of the heart rate).", "es": "− Modificación del funcionamiento del corazón (los síntomas son un enlentecimiento del ritmo cardíaco)." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Many of the side effects can be relieved by adjusting the dose.\nSpanish: Muchos se pueden aliviar ajustando la dosis.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Many of the side effects can be relieved by adjusting the dose.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "Many of the side effects can be relieved by adjusting the dose.", "es": "Muchos se pueden aliviar ajustando la dosis." } }
{ "translation": { "text": "Glossary:\n\"priapism\" -> \"priapismo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • A long-lasting and painful erection (priapism).\nSpanish: • Erección de larga duración y dolorosa (priapismo).", "en_prompt": "<|im_start|>user\nGlossary:\n\"priapism\" -> \"priapismo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • A long-lasting and painful erection (priapism).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "priapism|||priapismo", "en": "• A long-lasting and painful erection (priapism).", "es": "• Erección de larga duración y dolorosa (priapismo)." } }
{ "translation": { "text": "Glossary:\n\"impurity\" -> \"impureza\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The limits are based on the maximum daily intake for each impurity derived from animal studies: 96.0 nanograms for NDMA and 26.5 nanograms for NDEA.\nSpanish: Los límites se basan en la ingesta máxima diaria de cada impureza determinada a partir de estudios en animales: 96,0 nanogramos para la NDMA y 26,5 nanogramos para la NDEA.", "en_prompt": "<|im_start|>user\nGlossary:\n\"impurity\" -> \"impureza\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The limits are based on the maximum daily intake for each impurity derived from animal studies: 96.0 nanograms for NDMA and 26.5 nanograms for NDEA.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "impurity|||impureza", "en": "The limits are based on the maximum daily intake for each impurity derived from animal studies: 96.0 nanograms for NDMA and 26.5 nanograms for NDEA.", "es": "Los límites se basan en la ingesta máxima diaria de cada impureza determinada a partir de estudios en animales: 96,0 nanogramos para la NDMA y 26,5 nanogramos para la NDEA." } }
{ "translation": { "text": "Glossary:\n\"extracellular\" -> \"extracelular\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The linear pathway is likely due to extracellular protein degradation by neutrophil elastase and other plasma proteases.\nSpanish: Es probable que la vía lineal se deba a degradación proteica extracelular por la elastasa de los neutrófilos y otras proteasas plasmáticas.", "en_prompt": "<|im_start|>user\nGlossary:\n\"extracellular\" -> \"extracelular\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The linear pathway is likely due to extracellular protein degradation by neutrophil elastase and other plasma proteases.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "extracellular|||extracelular", "en": "The linear pathway is likely due to extracellular protein degradation by neutrophil elastase and other plasma proteases.", "es": "Es probable que la vía lineal se deba a degradación proteica extracelular por la elastasa de los neutrófilos y otras proteasas plasmáticas." } }
{ "translation": { "text": "Glossary:\n\"interaction\" -> \"interacción\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: There have been no formal interaction studies for AVAGLIM.\nSpanish: No se han realizado estudios de interacción con AVAGLIM.", "en_prompt": "<|im_start|>user\nGlossary:\n\"interaction\" -> \"interacción\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: There have been no formal interaction studies for AVAGLIM.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "interaction|||interacción", "en": "There have been no formal interaction studies for AVAGLIM.", "es": "No se han realizado estudios de interacción con AVAGLIM." } }
{ "translation": { "text": "Glossary:\n\"CNS\" -> \"sistema nervioso central\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: CNS changes precede any of the more severe side effects.\nSpanish: Los cambios en el sistema nervioso central, preceden a cualquiera de los efectos adversos más graves.", "en_prompt": "<|im_start|>user\nGlossary:\n\"CNS\" -> \"sistema nervioso central\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: CNS changes precede any of the more severe side effects.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "CNS|||sistema nervioso central", "en": "CNS changes precede any of the more severe side effects.", "es": "Los cambios en el sistema nervioso central, preceden a cualquiera de los efectos adversos más graves." } }
{ "translation": { "text": "Glossaries:\n\"case\" -> \"caso\"\n\"blood test\" -> \"análisis de sangre\"\n\"test\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In either case it should be confirmed by a blood test that Arava has been sufficiently removed from your body and you should then wait for at least another month before you become pregnant.\nSpanish: En cualquier caso, antes de quedarse embarazada, deberá realizarse un análisis de sangre para confirmar que Arava se ha eliminado lo suficiente de su organismo y una vez realizado este análisis, deberá esperar al menos 1 mes antes de quedarse embarazada.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"case\" -> \"caso\"\n\"blood test\" -> \"análisis de sangre\"\n\"test\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In either case it should be confirmed by a blood test that Arava has been sufficiently removed from your body and you should then wait for at least another month before you become pregnant.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "case|||caso\tblood test|||análisis de sangre\ttest|||análisis", "en": "In either case it should be confirmed by a blood test that Arava has been sufficiently removed from your body and you should then wait for at least another month before you become pregnant.", "es": "En cualquier caso, antes de quedarse embarazada, deberá realizarse un análisis de sangre para confirmar que Arava se ha eliminado lo suficiente de su organismo y una vez realizado este análisis, deberá esperar al menos 1 mes antes de quedarse embarazada." } }
{ "translation": { "text": "Glossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Step 2: Choosing an injection site (see Diagram 2)\nSpanish: Paso 2: Elegir un lugar de inyección (ver Figura 2)", "en_prompt": "<|im_start|>user\nGlossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Step 2: Choosing an injection site (see Diagram 2)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injection|||inyección", "en": "Step 2: Choosing an injection site (see Diagram 2)", "es": "Paso 2: Elegir un lugar de inyección (ver Figura 2)" } }
{ "translation": { "text": "Glossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Tell your doctor or nurse immediately if you notice any of the following serious side effects\nSpanish: Avise inmediatamente a su médico o enfermero si experimenta alguno de los siguientes efectos adversos graves:", "en_prompt": "<|im_start|>user\nGlossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Tell your doctor or nurse immediately if you notice any of the following serious side effects\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico", "en": "Tell your doctor or nurse immediately if you notice any of the following serious side effects", "es": "Avise inmediatamente a su médico o enfermero si experimenta alguno de los siguientes efectos adversos graves:" } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 8) Before injecting, read steps A-C to learn correct way to administer dose.\nSpanish: 8) Antes de proceder a la inyección, lea los pasos 8 A-C para aprender la forma correcta de A. Prepárese para administrar una dosis", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 8) Before injecting, read steps A-C to learn correct way to administer dose.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "8) Before injecting, read steps A-C to learn correct way to administer dose.", "es": "8) Antes de proceder a la inyección, lea los pasos 8 A-C para aprender la forma correcta de A. Prepárese para administrar una dosis" } }
{ "translation": { "text": "Glossaries:\n\"response\" -> \"respuesta\"\n\"index\" -> \"índice\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In anti-JCV antibody positive TYSABRI treated patients who have not used prior immunosuppressants the level of anti-JCV antibody response (index) is associated with the level of risk for PML.\nSpanish: En los pacientes tratados con TYSABRI con anticuerpos anti-VJC positivos y que no han recibido tratamiento inmunosupresor previo, el nivel de respuesta de los anticuerpos anti-VJC (índice) está asociado al nivel de riesgo de LMP.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"response\" -> \"respuesta\"\n\"index\" -> \"índice\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In anti-JCV antibody positive TYSABRI treated patients who have not used prior immunosuppressants the level of anti-JCV antibody response (index) is associated with the level of risk for PML.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "response|||respuesta\tindex|||índice", "en": "In anti-JCV antibody positive TYSABRI treated patients who have not used prior immunosuppressants the level of anti-JCV antibody response (index) is associated with the level of risk for PML.", "es": "En los pacientes tratados con TYSABRI con anticuerpos anti-VJC positivos y que no han recibido tratamiento inmunosupresor previo, el nivel de respuesta de los anticuerpos anti-VJC (índice) está asociado al nivel de riesgo de LMP." } }
{ "translation": { "text": "Glossary:\n\"creatine\" -> \"creatina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Common (may affect up to 1 in 10 people) • Increase of an enzyme in your blood (blood creatine phosphokinase).\nSpanish: Frecuentes (pueden afectar hasta 1 de cada 10 personas) • Aumento de una enzima de la sangre (creatina-fosfocinasa sanguínea).", "en_prompt": "<|im_start|>user\nGlossary:\n\"creatine\" -> \"creatina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Common (may affect up to 1 in 10 people) • Increase of an enzyme in your blood (blood creatine phosphokinase).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "creatine|||creatina", "en": "Common (may affect up to 1 in 10 people) • Increase of an enzyme in your blood (blood creatine phosphokinase).", "es": "Frecuentes (pueden afectar hasta 1 de cada 10 personas) • Aumento de una enzima de la sangre (creatina-fosfocinasa sanguínea)." } }
{ "translation": { "text": "Glossary:\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: NAME OF THE MEDICINAL PRODUCT Zoledronic acid medac 4 mg/100 ml solution for infusion\nSpanish: NOMBRE DEL MEDICAMENTO Ácido zoledrónico medac 4 mg/100 ml solución para perfusión", "en_prompt": "<|im_start|>user\nGlossary:\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: NAME OF THE MEDICINAL PRODUCT Zoledronic acid medac 4 mg/100 ml solution for infusion\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfusión", "en": "NAME OF THE MEDICINAL PRODUCT Zoledronic acid medac 4 mg/100 ml solution for infusion", "es": "NOMBRE DEL MEDICAMENTO Ácido zoledrónico medac 4 mg/100 ml solución para perfusión" } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"Pregnancy\" -> \"Embarazo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: (See section “Pregnancy and breastfeeding”).\nSpanish: Ver sección “Embarazo y lactancia”).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"Pregnancy\" -> \"Embarazo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: (See section “Pregnancy and breastfeeding”).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\tPregnancy|||Embarazo", "en": "(See section “Pregnancy and breastfeeding”).", "es": "Ver sección “Embarazo y lactancia”)." } }
{ "translation": { "text": "Glossary:\n\"in vitro\" -> \"in vitro\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Vandetanib inhibits EGFR-dependent cell proliferation and cell survival in vitro.\nSpanish: Vandetanib inhibe la proliferación celular EGFR dependiente y la supervivencia celular in vitro.", "en_prompt": "<|im_start|>user\nGlossary:\n\"in vitro\" -> \"in vitro\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Vandetanib inhibits EGFR-dependent cell proliferation and cell survival in vitro.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "in vitro|||in vitro", "en": "Vandetanib inhibits EGFR-dependent cell proliferation and cell survival in vitro.", "es": "Vandetanib inhibe la proliferación celular EGFR dependiente y la supervivencia celular in vitro." } }
{ "translation": { "text": "Glossaries:\n\"tissue\" -> \"tejido\"\n\"lesion\" -> \"lesión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Skin and subcutaneous tissue disorders rash, acne uncommon photosensitivity reaction, hyperhidrosis, seborrhoea, skin lesion, rash pruritic, Stevens-Johnson syndrome/toxic epidermal necrolysis rare pruritus, urticaria not known\nSpanish: Trastornos de la piel y del tejido subcutáneo erupción, acné poco frecuentes reacción de fotosensibilidad, hiperhidrosis, seborrea, lesión de la piel, erupción prurítica, síndrome de Stevens-Johnson/necrolisis epidérmica tóxica raras prurito, urticaria no conocida", "en_prompt": "<|im_start|>user\nGlossaries:\n\"tissue\" -> \"tejido\"\n\"lesion\" -> \"lesión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Skin and subcutaneous tissue disorders rash, acne uncommon photosensitivity reaction, hyperhidrosis, seborrhoea, skin lesion, rash pruritic, Stevens-Johnson syndrome/toxic epidermal necrolysis rare pruritus, urticaria not known\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "tissue|||tejido\tlesion|||lesión", "en": "Skin and subcutaneous tissue disorders rash, acne uncommon photosensitivity reaction, hyperhidrosis, seborrhoea, skin lesion, rash pruritic, Stevens-Johnson syndrome/toxic epidermal necrolysis rare pruritus, urticaria not known", "es": "Trastornos de la piel y del tejido subcutáneo erupción, acné poco frecuentes reacción de fotosensibilidad, hiperhidrosis, seborrea, lesión de la piel, erupción prurítica, síndrome de Stevens-Johnson/necrolisis epidérmica tóxica raras prurito, urticaria no conocida" } }
{ "translation": { "text": "Glossary:\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not store any unused portion of the infusion solution for reuse.\nSpanish: No conservar ninguna porción no utilizada de solución para perfusión para su reutilización.", "en_prompt": "<|im_start|>user\nGlossary:\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not store any unused portion of the infusion solution for reuse.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfusión", "en": "Do not store any unused portion of the infusion solution for reuse.", "es": "No conservar ninguna porción no utilizada de solución para perfusión para su reutilización." } }
{ "translation": { "text": "Glossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The majority of skin and subcutaneous adverse reactions were associated with the injection site.\nSpanish: Reacciones adversas de la piel y del tejido subcutáneo La mayoría de las reacciones adversas cutáneas y del tejido subcutáneo se relacionaron con el lugar de la inyección.", "en_prompt": "<|im_start|>user\nGlossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The majority of skin and subcutaneous adverse reactions were associated with the injection site.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injection|||inyección", "en": "The majority of skin and subcutaneous adverse reactions were associated with the injection site.", "es": "Reacciones adversas de la piel y del tejido subcutáneo La mayoría de las reacciones adversas cutáneas y del tejido subcutáneo se relacionaron con el lugar de la inyección." } }
{ "translation": { "text": "Glossaries:\n\"immune system\" -> \"sistema inmunitario\"\n\"system\" -> \"sistema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The immune system has the ability to recognise foreign proteins and react against them.\nSpanish: El sistema inmunitario tiene la capacidad de reconocer las proteínas extrañas y reaccionar contra ellas.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"immune system\" -> \"sistema inmunitario\"\n\"system\" -> \"sistema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The immune system has the ability to recognise foreign proteins and react against them.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "immune system|||sistema inmunitario\tsystem|||sistema", "en": "The immune system has the ability to recognise foreign proteins and react against them.", "es": "El sistema inmunitario tiene la capacidad de reconocer las proteínas extrañas y reaccionar contra ellas." } }
{ "translation": { "text": "Glossaries:\n\"dermatitis\" -> \"dermatitis\"\n\"safety\" -> \"seguridad\"\n\"atopic dermatitis\" -> \"dermatitis atópica\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The safety and benefits of Dupixent are not yet known in children and adolescents with atopic dermatitis below the age of 12.\nSpanish: No se conocen todavía la seguridad y beneficios de Dupixent en niños y adolescentes menores de 12 años con dermatitis atópica.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dermatitis\" -> \"dermatitis\"\n\"safety\" -> \"seguridad\"\n\"atopic dermatitis\" -> \"dermatitis atópica\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The safety and benefits of Dupixent are not yet known in children and adolescents with atopic dermatitis below the age of 12.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dermatitis|||dermatitis\tsafety|||seguridad\tatopic dermatitis|||dermatitis atópica", "en": "The safety and benefits of Dupixent are not yet known in children and adolescents with atopic dermatitis below the age of 12.", "es": "No se conocen todavía la seguridad y beneficios de Dupixent en niños y adolescentes menores de 12 años con dermatitis atópica." } }
{ "translation": { "text": "Glossaries:\n\"follow-up\" -> \"seguimiento\"\n\"MS\" -> \"esclerosis múltiple\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: There are follow-up data under controlled clinical conditions for patients with relapsing-remitting MS for up to 5 years and for patients with secondary progressive MS for up to 3 years.\nSpanish: Se dispone de datos de seguimiento de ensayos clínicos controlados de pacientes con EM (esclerosis múltiple) remitenterecidivante durante un máximo de 5 años y de pacientes con EM secundaria progresiva durante un máximo de 3 años.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"follow-up\" -> \"seguimiento\"\n\"MS\" -> \"esclerosis múltiple\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: There are follow-up data under controlled clinical conditions for patients with relapsing-remitting MS for up to 5 years and for patients with secondary progressive MS for up to 3 years.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "follow-up|||seguimiento\tMS|||esclerosis múltiple", "en": "There are follow-up data under controlled clinical conditions for patients with relapsing-remitting MS for up to 5 years and for patients with secondary progressive MS for up to 3 years.", "es": "Se dispone de datos de seguimiento de ensayos clínicos controlados de pacientes con EM (esclerosis múltiple) remitenterecidivante durante un máximo de 5 años y de pacientes con EM secundaria progresiva durante un máximo de 3 años." } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"enfermedad\"\n\"MS\" -> \"esclerosis múltiple\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Mayzent was effective at delaying the progression of secondary progressive MS in patients with active disease; however, the beneficial effects of the medicine were not demonstrated in patients without an active disease.\nSpanish: Mayzent fue eficaz a la hora de retrasar la progresión de la esclerosis múltiple secundaria progresiva en pacientes con una enfermedad activa.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"enfermedad\"\n\"MS\" -> \"esclerosis múltiple\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Mayzent was effective at delaying the progression of secondary progressive MS in patients with active disease; however, the beneficial effects of the medicine were not demonstrated in patients without an active disease.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||enfermedad\tMS|||esclerosis múltiple", "en": "Mayzent was effective at delaying the progression of secondary progressive MS in patients with active disease; however, the beneficial effects of the medicine were not demonstrated in patients without an active disease.", "es": "Mayzent fue eficaz a la hora de retrasar la progresión de la esclerosis múltiple secundaria progresiva en pacientes con una enfermedad activa." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: These effects will gradually reduce as treatment is continued.\nSpanish: Estos efectos se reducirán progresivamente mientras continúe el tratamiento.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: These effects will gradually reduce as treatment is continued.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento", "en": "These effects will gradually reduce as treatment is continued.", "es": "Estos efectos se reducirán progresivamente mientras continúe el tratamiento." } }
{ "translation": { "text": "Glossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Advise your doctor if you have a history of recurrent infections or other conditions that increase the risk of infections.\nSpanish: Informe a su médico si tiene antecedentes de infecciones recurrentes u otras patologías o factores que aumenten el riesgo de infecciones.", "en_prompt": "<|im_start|>user\nGlossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Advise your doctor if you have a history of recurrent infections or other conditions that increase the risk of infections.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico", "en": "Advise your doctor if you have a history of recurrent infections or other conditions that increase the risk of infections.", "es": "Informe a su médico si tiene antecedentes de infecciones recurrentes u otras patologías o factores que aumenten el riesgo de infecciones." } }
{ "translation": { "text": "Glossaries:\n\"doctor\" -> \"médico\"\n\"reconstitution\" -> \"reconstitución\"\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: This card will also include pictures of the relevant syringe sizes on which the doctor can draw a line to indicate on the volume of water for injection to use for reconstitution and the volume of reconstituted solution to inject.\nSpanish: Esta tarjeta también incluye imágenes de los tamaños de jeringas relevantes en las que el médico puede dibujar una línea para indicar el volumen de agua para la inyección a utilizar para la reconstitución y el volumen de solución reconstituida a inyectarse.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"doctor\" -> \"médico\"\n\"reconstitution\" -> \"reconstitución\"\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: This card will also include pictures of the relevant syringe sizes on which the doctor can draw a line to indicate on the volume of water for injection to use for reconstitution and the volume of reconstituted solution to inject.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico\treconstitution|||reconstitución\tinjection|||inyección", "en": "This card will also include pictures of the relevant syringe sizes on which the doctor can draw a line to indicate on the volume of water for injection to use for reconstitution and the volume of reconstituted solution to inject.", "es": "Esta tarjeta también incluye imágenes de los tamaños de jeringas relevantes en las que el médico puede dibujar una línea para indicar el volumen de agua para la inyección a utilizar para la reconstitución y el volumen de solución reconstituida a inyectarse." } }
{ "translation": { "text": "Glossary:\n\"monotherapy\" -> \"monoterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In treated patients who completed titration and started withdrawing antiepileptic medicinal products (284 and 99 respectively), monotherapy was maintained in 71.5 % and 70.7 % of patients respectively for 57-105 days (median 71 days), over the targeted observation period of 70 days.\nSpanish: En los pacientes tratados que completaron el ajuste de dosis y comenzaron la retirada de los medicamentos antiepilépticos (284 y 99 respectivamente), se mantuvo la monoterapia en el 71,5 % y 70,7 % de pacientes respectivamente durante 57 - 105 días (mediana de 71 días), sobre el período de observación estipulado de 70 días.", "en_prompt": "<|im_start|>user\nGlossary:\n\"monotherapy\" -> \"monoterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In treated patients who completed titration and started withdrawing antiepileptic medicinal products (284 and 99 respectively), monotherapy was maintained in 71.5 % and 70.7 % of patients respectively for 57-105 days (median 71 days), over the targeted observation period of 70 days.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "monotherapy|||monoterapia", "en": "In treated patients who completed titration and started withdrawing antiepileptic medicinal products (284 and 99 respectively), monotherapy was maintained in 71.5 % and 70.7 % of patients respectively for 57-105 days (median 71 days), over the targeted observation period of 70 days.", "es": "En los pacientes tratados que completaron el ajuste de dosis y comenzaron la retirada de los medicamentos antiepilépticos (284 y 99 respectivamente), se mantuvo la monoterapia en el 71,5 % y 70,7 % de pacientes respectivamente durante 57 - 105 días (mediana de 71 días), sobre el período de observación estipulado de 70 días." } }
{ "translation": { "text": "Glossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Step 4 Press and hold the injection button to remove excess liquid\nSpanish: Paso 4 Pulse y mantenga presionado el botón de inyección para eliminar el exceso de líquido", "en_prompt": "<|im_start|>user\nGlossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Step 4 Press and hold the injection button to remove excess liquid\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injection|||inyección", "en": "Step 4 Press and hold the injection button to remove excess liquid", "es": "Paso 4 Pulse y mantenga presionado el botón de inyección para eliminar el exceso de líquido" } }
{ "translation": { "text": "Glossaries:\n\"medicine\" -> \"medicamento\"\n\"expiry date\" -> \"fecha de caducidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}.\nSpanish: No utilice este medicamento después de la fecha de caducidad que aparece en el frasco y en la caja después de {EXP}.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"medicine\" -> \"medicamento\"\n\"expiry date\" -> \"fecha de caducidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicamento\texpiry date|||fecha de caducidad", "en": "Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}.", "es": "No utilice este medicamento después de la fecha de caducidad que aparece en el frasco y en la caja después de {EXP}." } }
{ "translation": { "text": "Glossaries:\n\"cancer\" -> \"cáncer\"\n\"focal\" -> \"focal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For small lesions (<1 cm diameter) focal uptake greater than blood pool should be considered suspicious for cancer.\nSpanish: Para lesiones pequeñas (diámetro < 1 cm), una captación focal mayor que para el conjunto sanguíneo debe considerarse sospechosa de cáncer.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"cancer\" -> \"cáncer\"\n\"focal\" -> \"focal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For small lesions (<1 cm diameter) focal uptake greater than blood pool should be considered suspicious for cancer.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "cancer|||cáncer\tfocal|||focal", "en": "For small lesions (<1 cm diameter) focal uptake greater than blood pool should be considered suspicious for cancer.", "es": "Para lesiones pequeñas (diámetro < 1 cm), una captación focal mayor que para el conjunto sanguíneo debe considerarse sospechosa de cáncer." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Upon recovery, Alunbrig may either be resumed at the next lower dose per Table 1 or permanently discontinued.\nSpanish: Cuando el paciente se recupere, se puede reanudar el tratamiento con Alunbrig con la siguiente dosis inferior de acuerdo con la Tabla 1 o suspender de forma permanente.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Upon recovery, Alunbrig may either be resumed at the next lower dose per Table 1 or permanently discontinued.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "Upon recovery, Alunbrig may either be resumed at the next lower dose per Table 1 or permanently discontinued.", "es": "Cuando el paciente se recupere, se puede reanudar el tratamiento con Alunbrig con la siguiente dosis inferior de acuerdo con la Tabla 1 o suspender de forma permanente." } }
{ "translation": { "text": "Glossary:\n\"erythropoietin\" -> \"eritropoyetina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • adults and children over one year of age with anaemia caused by long-term kidney failure, when the body does not produce enough of the natural hormone erythropoietin,\nSpanish: • adultos y niños de más de un año de edad con anemia causada por insuficiencia renal de larga duración, cuando el organismo no produce la suficiente hormona natural eritropoyetina;", "en_prompt": "<|im_start|>user\nGlossary:\n\"erythropoietin\" -> \"eritropoyetina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • adults and children over one year of age with anaemia caused by long-term kidney failure, when the body does not produce enough of the natural hormone erythropoietin,\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "erythropoietin|||eritropoyetina", "en": "• adults and children over one year of age with anaemia caused by long-term kidney failure, when the body does not produce enough of the natural hormone erythropoietin,", "es": "• adultos y niños de más de un año de edad con anemia causada por insuficiencia renal de larga duración, cuando el organismo no produce la suficiente hormona natural eritropoyetina;" } }
{ "translation": { "text": "Glossaries:\n\"release\" -> \"liberación\"\n\"S\" -> \"S\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: PHARMACEUTICAL FORM AND CONTENTS 28 Prolonged-release tablets 30 Prolonged-release tablets 100 Prolonged-release tablets METHOD AND ROUTE(S) OF ADMINISTRATION Oral use.\nSpanish: FORMA FARMACÉUTICA Y CONTENIDO DEL ENVASE 28 comprimidos de liberación prolongada 30 comprimidos de liberación prolongada 100 comprimidos de liberación prolongada FORMA Y VÍA(S) DE ADMINISTRACIÓN Vía oral.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"release\" -> \"liberación\"\n\"S\" -> \"S\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: PHARMACEUTICAL FORM AND CONTENTS 28 Prolonged-release tablets 30 Prolonged-release tablets 100 Prolonged-release tablets METHOD AND ROUTE(S) OF ADMINISTRATION Oral use.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "release|||liberación\tS|||S", "en": "PHARMACEUTICAL FORM AND CONTENTS 28 Prolonged-release tablets 30 Prolonged-release tablets 100 Prolonged-release tablets METHOD AND ROUTE(S) OF ADMINISTRATION Oral use.", "es": "FORMA FARMACÉUTICA Y CONTENIDO DEL ENVASE 28 comprimidos de liberación prolongada 30 comprimidos de liberación prolongada 100 comprimidos de liberación prolongada FORMA Y VÍA(S) DE ADMINISTRACIÓN Vía oral." } }
{ "translation": { "text": "Glossary:\n\"efficacy\" -> \"eficacia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No clinical efficacy study has been done in subjects from 17 to 45 years from endemic areas.\nSpanish: Datos de eficacia clínica para sujetos de 17 a 45 años de edad en zonas endémicas No se han llevado a cabo estudios de eficacia clínica en sujetos de 17 a 45 años de edad de zonas endémicas.", "en_prompt": "<|im_start|>user\nGlossary:\n\"efficacy\" -> \"eficacia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No clinical efficacy study has been done in subjects from 17 to 45 years from endemic areas.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "efficacy|||eficacia", "en": "No clinical efficacy study has been done in subjects from 17 to 45 years from endemic areas.", "es": "Datos de eficacia clínica para sujetos de 17 a 45 años de edad en zonas endémicas No se han llevado a cabo estudios de eficacia clínica en sujetos de 17 a 45 años de edad de zonas endémicas." } }
{ "translation": { "text": "Glossaries:\n\"fluorouracil\" -> \"fluorouracilo\"\n\"paclitaxel\" -> \"paclitaxel\"\n\"epirubicin\" -> \"epirubicina\"\n\"cyclophosphamide\" -> \"ciclofosfamida\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: There is limited data on pharmacokinetic interactions with chemotherapeutic agents other than doxorubicin, epirubicin, cyclophosphamide, 5-fluorouracil and paclitaxel.\nSpanish: Existen datos limitados sobre interacciones farmacocinéticas con agentes quimioterápicos aparte de doxorubicina, epirubicina, ciclofosfamida, 5-fluorouracilo y paclitaxel.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"fluorouracil\" -> \"fluorouracilo\"\n\"paclitaxel\" -> \"paclitaxel\"\n\"epirubicin\" -> \"epirubicina\"\n\"cyclophosphamide\" -> \"ciclofosfamida\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: There is limited data on pharmacokinetic interactions with chemotherapeutic agents other than doxorubicin, epirubicin, cyclophosphamide, 5-fluorouracil and paclitaxel.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "fluorouracil|||fluorouracilo\tpaclitaxel|||paclitaxel\tepirubicin|||epirubicina\tcyclophosphamide|||ciclofosfamida", "en": "There is limited data on pharmacokinetic interactions with chemotherapeutic agents other than doxorubicin, epirubicin, cyclophosphamide, 5-fluorouracil and paclitaxel.", "es": "Existen datos limitados sobre interacciones farmacocinéticas con agentes quimioterápicos aparte de doxorubicina, epirubicina, ciclofosfamida, 5-fluorouracilo y paclitaxel." } }
{ "translation": { "text": "Glossary:\n\"inhibition\" -> \"inhibición\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The mechanism is UGT1A1 inhibition.\nSpanish: El mecanismo es la inhibición de la UGT1A1.", "en_prompt": "<|im_start|>user\nGlossary:\n\"inhibition\" -> \"inhibición\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The mechanism is UGT1A1 inhibition.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "inhibition|||inhibición", "en": "The mechanism is UGT1A1 inhibition.", "es": "El mecanismo es la inhibición de la UGT1A1." } }
{ "translation": { "text": "Glossaries:\n\"interim analysis\" -> \"análisis intermedio\"\n\"analysis\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: This interim analysis showed a TTP risk reduction of 45 % (95 % CI; 29-57 %, p < 0.0001) for patients treated with combination therapy of bortezomib and pegylated liposomal doxorubicin.\nSpanish: Este análisis intermedio mostró una reducción del riesgo de TTP del 45 % (IC 95 %: 29-57 %, p < 0,0001) en los pacientes tratados con la combinación de bortezomib y doxorubicina liposomal pegilada.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"interim analysis\" -> \"análisis intermedio\"\n\"analysis\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: This interim analysis showed a TTP risk reduction of 45 % (95 % CI; 29-57 %, p < 0.0001) for patients treated with combination therapy of bortezomib and pegylated liposomal doxorubicin.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "interim analysis|||análisis intermedio\tanalysis|||análisis", "en": "This interim analysis showed a TTP risk reduction of 45 % (95 % CI; 29-57 %, p < 0.0001) for patients treated with combination therapy of bortezomib and pegylated liposomal doxorubicin.", "es": "Este análisis intermedio mostró una reducción del riesgo de TTP del 45 % (IC 95 %: 29-57 %, p < 0,0001) en los pacientes tratados con la combinación de bortezomib y doxorubicina liposomal pegilada." } }
{ "translation": { "text": "Glossaries:\n\"injections\" -> \"inyectables\"\n\"pemetrexed\" -> \"pemetrexed\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Reconstitute each 100 mg vial with 4.2 ml of sterile water for injections, resulting in a solution containing 25 mg/ml pemetrexed.\nSpanish: Reconstituya cada vial de 100 mg con 4,2 ml de agua estéril para inyectables para obtener una solución que contenga 25 mg/ml de pemetrexed.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"injections\" -> \"inyectables\"\n\"pemetrexed\" -> \"pemetrexed\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Reconstitute each 100 mg vial with 4.2 ml of sterile water for injections, resulting in a solution containing 25 mg/ml pemetrexed.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injections|||inyectables\tpemetrexed|||pemetrexed", "en": "Reconstitute each 100 mg vial with 4.2 ml of sterile water for injections, resulting in a solution containing 25 mg/ml pemetrexed.", "es": "Reconstituya cada vial de 100 mg con 4,2 ml de agua estéril para inyectables para obtener una solución que contenga 25 mg/ml de pemetrexed." } }
{ "translation": { "text": "Glossary:\n\"pioglitazone\" -> \"pioglitazona\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Food had no effect on the AUC and Cmax of pioglitazone when Glubrava was administered to healthy volunteers.\nSpanish: La ingesta de alimentos no tiene efecto sobre el área bajo la curva (AUC) y los niveles plasmáticos máximos (Cmax) de la pioglitazona cuando Glubrava se administró a voluntarios sanos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"pioglitazone\" -> \"pioglitazona\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Food had no effect on the AUC and Cmax of pioglitazone when Glubrava was administered to healthy volunteers.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "pioglitazone|||pioglitazona", "en": "Food had no effect on the AUC and Cmax of pioglitazone when Glubrava was administered to healthy volunteers.", "es": "La ingesta de alimentos no tiene efecto sobre el área bajo la curva (AUC) y los niveles plasmáticos máximos (Cmax) de la pioglitazona cuando Glubrava se administró a voluntarios sanos." } }
{ "translation": { "text": "Glossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hold the syringe firmly by the finger grip.\nSpanish: Sujete firmemente la jeringa por la empuñadura.", "en_prompt": "<|im_start|>user\nGlossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hold the syringe firmly by the finger grip.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "syringe|||jeringa", "en": "Hold the syringe firmly by the finger grip.", "es": "Sujete firmemente la jeringa por la empuñadura." } }
{ "translation": { "text": "Glossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Filter Onpattro through a sterile 0.45 micron polyethersulfone (PES) syringe filter into a sterile container.\nSpanish: • Filtre Onpattro con un filtro de jeringa de polietersulfona (PES) estéril de 0,45 micrómetros a un recipiente estéril.", "en_prompt": "<|im_start|>user\nGlossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Filter Onpattro through a sterile 0.45 micron polyethersulfone (PES) syringe filter into a sterile container.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "syringe|||jeringa", "en": "• Filter Onpattro through a sterile 0.45 micron polyethersulfone (PES) syringe filter into a sterile container.", "es": "• Filtre Onpattro con un filtro de jeringa de polietersulfona (PES) estéril de 0,45 micrómetros a un recipiente estéril." } }
{ "translation": { "text": "Glossary:\n\"clopidogrel\" -> \"clopidogrel\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =\nSpanish: En los pacientes que fueron incluidos en el ensayo por haber sufrido únicamente un IAM reciente, clopidogrel fue numéricamente inferior pero no estadísticamente diferente a AAS (RRR = - 4,0%; IC: - 22,5 a 11,7 [p=0,639]).", "en_prompt": "<|im_start|>user\nGlossary:\n\"clopidogrel\" -> \"clopidogrel\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "clopidogrel|||clopidogrel", "en": "In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =", "es": "En los pacientes que fueron incluidos en el ensayo por haber sufrido únicamente un IAM reciente, clopidogrel fue numéricamente inferior pero no estadísticamente diferente a AAS (RRR = - 4,0%; IC: - 22,5 a 11,7 [p=0,639])." } }
{ "translation": { "text": "Glossaries:\n\"fever\" -> \"fiebre\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Get an infection and/or a fever.\nSpanish: • Sufre una infección y/o fiebre.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"fever\" -> \"fiebre\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Get an infection and/or a fever.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "fever|||fiebre\tinfection|||infección", "en": "• Get an infection and/or a fever.", "es": "• Sufre una infección y/o fiebre." } }
{ "translation": { "text": "Glossaries:\n\"system\" -> \"sistema\"\n\"information\" -> \"información\"\n\"risk management system\" -> \"sistema de gestión de riesgos\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.\nSpanish: • Cuando se modifique el sistema de gestión de riesgos especialmente como resultado de una nueva información disponible que pueda conllevar cambios relevantes en el perfil beneficio/riesgo, o como resultado de la consecución de un hito importante (farmacovigilancia o minimización de riesgos).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"system\" -> \"sistema\"\n\"information\" -> \"información\"\n\"risk management system\" -> \"sistema de gestión de riesgos\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "system|||sistema\tinformation|||información\trisk management system|||sistema de gestión de riesgos", "en": "• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.", "es": "• Cuando se modifique el sistema de gestión de riesgos especialmente como resultado de una nueva información disponible que pueda conllevar cambios relevantes en el perfil beneficio/riesgo, o como resultado de la consecución de un hito importante (farmacovigilancia o minimización de riesgos)." } }
{ "translation": { "text": "Glossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Smoking induces CYP1A2 and has been shown to decrease the bioavailability of agomelatine, especially in heavy smokers (> 15 cigarettes/day) (see section 5.2).\nSpanish: especialmente en fumadores severos (≥ 15 cigarrillos/día) (ver sección 5.2).", "en_prompt": "<|im_start|>user\nGlossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Smoking induces CYP1A2 and has been shown to decrease the bioavailability of agomelatine, especially in heavy smokers (> 15 cigarettes/day) (see section 5.2).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección", "en": "Smoking induces CYP1A2 and has been shown to decrease the bioavailability of agomelatine, especially in heavy smokers (> 15 cigarettes/day) (see section 5.2).", "es": "especialmente en fumadores severos (≥ 15 cigarrillos/día) (ver sección 5.2)." } }
{ "translation": { "text": "Glossaries:\n\"seroconversion\" -> \"seroconversión\"\n\"factor\" -> \"factor\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in the adults measured by Single Radial Haemolysis (SRH) assay was as follows:\nSpanish: La tasa de seroprotección*, la tasa de seroconversión* y el factor de seroconversión** de los anticuerpos anti-HA frente a H5N1 A/Vietnam/1194/2004 en adultos medidos mediante el ensayo de hemólisis radial simple (SRH) fue como sigue:", "en_prompt": "<|im_start|>user\nGlossaries:\n\"seroconversion\" -> \"seroconversión\"\n\"factor\" -> \"factor\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in the adults measured by Single Radial Haemolysis (SRH) assay was as follows:\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "seroconversion|||seroconversión\tfactor|||factor", "en": "The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in the adults measured by Single Radial Haemolysis (SRH) assay was as follows:", "es": "La tasa de seroprotección*, la tasa de seroconversión* y el factor de seroconversión** de los anticuerpos anti-HA frente a H5N1 A/Vietnam/1194/2004 en adultos medidos mediante el ensayo de hemólisis radial simple (SRH) fue como sigue:" } }
{ "translation": { "text": "Glossaries:\n\"nevirapine\" -> \"nevirapina\"\n\"lamivudine\" -> \"lamivudina\"\n\"distribution\" -> \"distribución\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No changes to lamivudine apparent clearance and volume of distribution, suggesting no induction effect of nevirapine on lamivudine clearance.\nSpanish: No hay cambios en el aclaramiento aparente ni en el volumen de distribución de lamivudina, lo que sugiere que nevirapina no ejerce efecto de inducción sobre el aclaramiento de lamivudina.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"nevirapine\" -> \"nevirapina\"\n\"lamivudine\" -> \"lamivudina\"\n\"distribution\" -> \"distribución\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No changes to lamivudine apparent clearance and volume of distribution, suggesting no induction effect of nevirapine on lamivudine clearance.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "nevirapine|||nevirapina\tlamivudine|||lamivudina\tdistribution|||distribución", "en": "No changes to lamivudine apparent clearance and volume of distribution, suggesting no induction effect of nevirapine on lamivudine clearance.", "es": "No hay cambios en el aclaramiento aparente ni en el volumen de distribución de lamivudina, lo que sugiere que nevirapina no ejerce efecto de inducción sobre el aclaramiento de lamivudina." } }
{ "translation": { "text": "Glossaries:\n\"medicine\" -> \"medicamento\"\n\"treatment\" -> \"tratamiento\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: How long to continue your treatment with Seebri Breezhaler - Keep using this medicine for as long as your doctor tells you.\nSpanish: Cuánto tiempo debe continuar su tratamiento con Seebri Breezhaler - Continúe usando su tratamiento con este medicamento durante el tiempo que su médico le indique.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"medicine\" -> \"medicamento\"\n\"treatment\" -> \"tratamiento\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: How long to continue your treatment with Seebri Breezhaler - Keep using this medicine for as long as your doctor tells you.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicamento\ttreatment|||tratamiento\tdoctor|||médico", "en": "How long to continue your treatment with Seebri Breezhaler - Keep using this medicine for as long as your doctor tells you.", "es": "Cuánto tiempo debe continuar su tratamiento con Seebri Breezhaler - Continúe usando su tratamiento con este medicamento durante el tiempo que su médico le indique." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"patient\" -> \"paciente\"\n\"weight\" -> \"peso\"\n\"retention\" -> \"retención\"\n\"evaluation\" -> \"evaluación\"\n\"oedema\" -> \"edema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • That treatment with Volibris causes peripheral oedema and fluid retention o If a patient develops clinically significant peripheral oedema, with or without associated weight gain, carry out further evaluation to determine the cause and if appropriate consider discontinuation of Volibris.\nSpanish: • El tratamiento con Volibris causa edema periférico y retención de fluidos o Si un paciente desarrolla edema periférico clínicamente relevante, con o sin aumento de peso, se debe realizar una evaluación adicional para determinar la causa y si es conveniente se interrumpirá el tratamiento con Volibris.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"patient\" -> \"paciente\"\n\"weight\" -> \"peso\"\n\"retention\" -> \"retención\"\n\"evaluation\" -> \"evaluación\"\n\"oedema\" -> \"edema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • That treatment with Volibris causes peripheral oedema and fluid retention o If a patient develops clinically significant peripheral oedema, with or without associated weight gain, carry out further evaluation to determine the cause and if appropriate consider discontinuation of Volibris.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tpatient|||paciente\tweight|||peso\tretention|||retención\tevaluation|||evaluación\toedema|||edema", "en": "• That treatment with Volibris causes peripheral oedema and fluid retention o If a patient develops clinically significant peripheral oedema, with or without associated weight gain, carry out further evaluation to determine the cause and if appropriate consider discontinuation of Volibris.", "es": "• El tratamiento con Volibris causa edema periférico y retención de fluidos o Si un paciente desarrolla edema periférico clínicamente relevante, con o sin aumento de peso, se debe realizar una evaluación adicional para determinar la causa y si es conveniente se interrumpirá el tratamiento con Volibris." } }
{ "translation": { "text": "Glossaries:\n\"creatinine\" -> \"creatinina\"\n\"release\" -> \"liberación\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The treatment of patients with a creatinine clearance below 30 ml/min with Oprymea prolonged release tablets is not recommended as no data are available for this patient population.\nSpanish: No se recomienda administrar Oprymea comprimidos de liberación prolongada a pacientes con un aclaramiento de creatinina inferior a 30 ml/min debido a que no hay datos disponibles para esta población de pacientes.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"creatinine\" -> \"creatinina\"\n\"release\" -> \"liberación\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The treatment of patients with a creatinine clearance below 30 ml/min with Oprymea prolonged release tablets is not recommended as no data are available for this patient population.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "creatinine|||creatinina\trelease|||liberación\tpopulation|||población", "en": "The treatment of patients with a creatinine clearance below 30 ml/min with Oprymea prolonged release tablets is not recommended as no data are available for this patient population.", "es": "No se recomienda administrar Oprymea comprimidos de liberación prolongada a pacientes con un aclaramiento de creatinina inferior a 30 ml/min debido a que no hay datos disponibles para esta población de pacientes." } }
{ "translation": { "text": "Glossary:\n\"palonosetron\" -> \"palonosetrón\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Interaction between oral netupitant and oral palonosetron:\nSpanish: Interacción entre netupitant administrado por vía oral y palonosetrón administrado por vía oral:", "en_prompt": "<|im_start|>user\nGlossary:\n\"palonosetron\" -> \"palonosetrón\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Interaction between oral netupitant and oral palonosetron:\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "palonosetron|||palonosetrón", "en": "Interaction between oral netupitant and oral palonosetron:", "es": "Interacción entre netupitant administrado por vía oral y palonosetrón administrado por vía oral:" } }
{ "translation": { "text": "Glossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The most common side effects reported are a reaction and pain at the injection site.\nSpanish: Los efectos secundarios más habituales notificados son reacción y dolor en el lugar de la inyección.", "en_prompt": "<|im_start|>user\nGlossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The most common side effects reported are a reaction and pain at the injection site.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injection|||inyección", "en": "The most common side effects reported are a reaction and pain at the injection site.", "es": "Los efectos secundarios más habituales notificados son reacción y dolor en el lugar de la inyección." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients who received ZIMULTI 20 mg for one year were re-randomized to ZIMULTI 20 mg or placebo.\nSpanish: Los pacientes que recibieron ZIMULTI 20 mg durante un año fueron reasignados aleatoriamente a ZIMULTI 20 mg o a placebo.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients who received ZIMULTI 20 mg for one year were re-randomized to ZIMULTI 20 mg or placebo.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Patients who received ZIMULTI 20 mg for one year were re-randomized to ZIMULTI 20 mg or placebo.", "es": "Los pacientes que recibieron ZIMULTI 20 mg durante un año fueron reasignados aleatoriamente a ZIMULTI 20 mg o a placebo." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys.\nSpanish: Su médico puede prescribir otro régimen de dosificación y/o dosis diferentes si usted tiene problemas en los riñones.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tdoctor|||médico", "en": "Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys.", "es": "Su médico puede prescribir otro régimen de dosificación y/o dosis diferentes si usted tiene problemas en los riñones." } }
{ "translation": { "text": "Glossary:\n\"docetaxel\" -> \"docetaxel\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The premix solution contains 10 mg/ml docetaxel and should be used immediately after preparation.\nSpanish: La solución premezcla contiene 10 mg/ml de docetaxel y debe ser utilizada inmediatamente después de la preparación.", "en_prompt": "<|im_start|>user\nGlossary:\n\"docetaxel\" -> \"docetaxel\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The premix solution contains 10 mg/ml docetaxel and should be used immediately after preparation.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "docetaxel|||docetaxel", "en": "The premix solution contains 10 mg/ml docetaxel and should be used immediately after preparation.", "es": "La solución premezcla contiene 10 mg/ml de docetaxel y debe ser utilizada inmediatamente después de la preparación." } }
{ "translation": { "text": "Glossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Co-administration with products containing St. John's wort (Hypericum perforatum) (see section 4.5).\nSpanish: Administración conjunta con productos que contengan hierba de San Juan (Hypericum perforatum) (ver sección 4.5).", "en_prompt": "<|im_start|>user\nGlossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Co-administration with products containing St. John's wort (Hypericum perforatum) (see section 4.5).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección", "en": "Co-administration with products containing St. John's wort (Hypericum perforatum) (see section 4.5).", "es": "Administración conjunta con productos que contengan hierba de San Juan (Hypericum perforatum) (ver sección 4.5)." } }
{ "translation": { "text": "Glossary:\n\"sleeplessness\" -> \"insomnio\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Uncommon: Tingling sensation (pins and needles) and/or numbness, changes in taste (in very rare cases loss of taste), confusion and disorientation, sleep problems (predominately sleeplessness), shaking, sensation of dizziness (spinning or falling over), sleepiness\nSpanish: Poco frecuente: Sensación de hormigueo (de alfileres y agujas) y/o entumecimiento, alteración del gusto (en casos muy raros, pérdida del gusto), confusión y desorientación, trastornos del sueño (predominantemente insomnio), temblores, sensación de vértigo (de que todo gira y de caerse), somnolencia", "en_prompt": "<|im_start|>user\nGlossary:\n\"sleeplessness\" -> \"insomnio\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Uncommon: Tingling sensation (pins and needles) and/or numbness, changes in taste (in very rare cases loss of taste), confusion and disorientation, sleep problems (predominately sleeplessness), shaking, sensation of dizziness (spinning or falling over), sleepiness\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "sleeplessness|||insomnio", "en": "Uncommon: Tingling sensation (pins and needles) and/or numbness, changes in taste (in very rare cases loss of taste), confusion and disorientation, sleep problems (predominately sleeplessness), shaking, sensation of dizziness (spinning or falling over), sleepiness", "es": "Poco frecuente: Sensación de hormigueo (de alfileres y agujas) y/o entumecimiento, alteración del gusto (en casos muy raros, pérdida del gusto), confusión y desorientación, trastornos del sueño (predominantemente insomnio), temblores, sensación de vértigo (de que todo gira y de caerse), somnolencia" } }
{ "translation": { "text": "Glossaries:\n\"monotherapy\" -> \"monoterapia\"\n\"oedema\" -> \"edema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Pulmonary oedema was reported in two patients (0.3%) receiving tivozanib as initial therapy in the five core RCC monotherapy studies.\nSpanish: Se notificó edema pulmonar en dos pacientes (0,3%) que recibieron tivozanib como tratamiento inicial en los cinco estudios pivotales de monoterapia en el CCR.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"monotherapy\" -> \"monoterapia\"\n\"oedema\" -> \"edema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Pulmonary oedema was reported in two patients (0.3%) receiving tivozanib as initial therapy in the five core RCC monotherapy studies.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "monotherapy|||monoterapia\toedema|||edema", "en": "Pulmonary oedema was reported in two patients (0.3%) receiving tivozanib as initial therapy in the five core RCC monotherapy studies.", "es": "Se notificó edema pulmonar en dos pacientes (0,3%) que recibieron tivozanib como tratamiento inicial en los cinco estudios pivotales de monoterapia en el CCR." } }
{ "translation": { "text": "Glossaries:\n\"powder\" -> \"polvo\"\n\"product\" -> \"producto\"\n\"lyophilised\" -> \"liofilizado\"\n\"sodium chloride\" -> \"cloruro de sodio\"\n\"lyophilised product\" -> \"producto liofilizado\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Cubicin given as 30 or 60-minute intravenous infusion A 50 mg/ml concentration of Cubicin 350 mg powder for infusion is obtained by reconstituting the lyophilised product with 7 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.\nSpanish: Cubicin administrado como perfusión intravenosa durante 30 ó 60 minutos Reconstituyendo el producto liofilizado con 7 ml de una solución inyectable con 9 mg/ml de cloruro de sodio (0,9%), se puede obtener una concentración de 50 mg/ml de Cubicin 350 mg polvo para perfusión.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"powder\" -> \"polvo\"\n\"product\" -> \"producto\"\n\"lyophilised\" -> \"liofilizado\"\n\"sodium chloride\" -> \"cloruro de sodio\"\n\"lyophilised product\" -> \"producto liofilizado\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Cubicin given as 30 or 60-minute intravenous infusion A 50 mg/ml concentration of Cubicin 350 mg powder for infusion is obtained by reconstituting the lyophilised product with 7 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "powder|||polvo\tproduct|||producto\tlyophilised|||liofilizado\tsodium chloride|||cloruro de sodio\tlyophilised product|||producto liofilizado\tinfusion|||perfusión", "en": "Cubicin given as 30 or 60-minute intravenous infusion A 50 mg/ml concentration of Cubicin 350 mg powder for infusion is obtained by reconstituting the lyophilised product with 7 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.", "es": "Cubicin administrado como perfusión intravenosa durante 30 ó 60 minutos Reconstituyendo el producto liofilizado con 7 ml de una solución inyectable con 9 mg/ml de cloruro de sodio (0,9%), se puede obtener una concentración de 50 mg/ml de Cubicin 350 mg polvo para perfusión." } }
{ "translation": { "text": "Glossaries:\n\"weight\" -> \"peso\"\n\"oedema\" -> \"edema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve.\nSpanish: Se deben controlar los signos y síntomas de insuficiencia cardiaca, aumento de peso o edema, especialmente en casos con disminución de la reserva cardiaca.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"weight\" -> \"peso\"\n\"oedema\" -> \"edema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "weight|||peso\toedema|||edema", "en": "Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve.", "es": "Se deben controlar los signos y síntomas de insuficiencia cardiaca, aumento de peso o edema, especialmente en casos con disminución de la reserva cardiaca." } }
{ "translation": { "text": "Glossaries:\n\"vaccination\" -> \"vacunación\"\n\"influenza\" -> \"influenza\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 2nd scheme - vaccination against equine influenza and tetanus:\nSpanish: 2ª Pauta vacunal - vacunación contra la influenza equina y el tétanos:", "en_prompt": "<|im_start|>user\nGlossaries:\n\"vaccination\" -> \"vacunación\"\n\"influenza\" -> \"influenza\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 2nd scheme - vaccination against equine influenza and tetanus:\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "vaccination|||vacunación\tinfluenza|||influenza", "en": "2nd scheme - vaccination against equine influenza and tetanus:", "es": "2ª Pauta vacunal - vacunación contra la influenza equina y el tétanos:" } }
{ "translation": { "text": "Glossaries:\n\"doctor\" -> \"médico\"\n\"heartburn\" -> \"ardor de estómago\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients with long-term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals.\nSpanish: Los pacientes con síntomas prolongados recurrentes de indigestión o ardor de estómago deben visitar a su médico en intervalos regulares.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"doctor\" -> \"médico\"\n\"heartburn\" -> \"ardor de estómago\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients with long-term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico\theartburn|||ardor de estómago", "en": "Patients with long-term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals.", "es": "Los pacientes con síntomas prolongados recurrentes de indigestión o ardor de estómago deben visitar a su médico en intervalos regulares." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The educational programme is aimed at providing information that helps identify patients eligible for therapy, understand how ponatinib should be used safely, the risks for patients and the important adverse reactions for which monitoring and dose adjustment are recommended.\nSpanish: El programa formativo tiene como objetivos ofrecer información que ayude a identificar a los pacientes que pueden optar al tratamiento y comprender cómo se debe usar ponatinib de forma segura, los riesgos para los pacientes y las importantes reacciones adversas para las que se recomiendan vigilancia y ajustes de la dosis.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The educational programme is aimed at providing information that helps identify patients eligible for therapy, understand how ponatinib should be used safely, the risks for patients and the important adverse reactions for which monitoring and dose adjustment are recommended.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tinformation|||información", "en": "The educational programme is aimed at providing information that helps identify patients eligible for therapy, understand how ponatinib should be used safely, the risks for patients and the important adverse reactions for which monitoring and dose adjustment are recommended.", "es": "El programa formativo tiene como objetivos ofrecer información que ayude a identificar a los pacientes que pueden optar al tratamiento y comprender cómo se debe usar ponatinib de forma segura, los riesgos para los pacientes y las importantes reacciones adversas para las que se recomiendan vigilancia y ajustes de la dosis." } }
{ "translation": { "text": "Glossaries:\n\"vertebral\" -> \"vertebral\"\n\"fracture\" -> \"fractura\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: New clinical vertebral fracture over 3 years\nSpanish: Nueva fractura vertebral clínica durante los 3 años", "en_prompt": "<|im_start|>user\nGlossaries:\n\"vertebral\" -> \"vertebral\"\n\"fracture\" -> \"fractura\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: New clinical vertebral fracture over 3 years\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "vertebral|||vertebral\tfracture|||fractura", "en": "New clinical vertebral fracture over 3 years", "es": "Nueva fractura vertebral clínica durante los 3 años" } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\n\"response\" -> \"respuesta\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Your doctor may change the dose and frequency of dosing depending on your blood tests, your general condition and your response to DOCETAXEL KABI.\nSpanish: Su médico puede cambiar la dosis y frecuencia de la administración dependiendo de sus análisis de sangre, su estado general y su respuesta a DOCETAXEL KABI.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\n\"response\" -> \"respuesta\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Your doctor may change the dose and frequency of dosing depending on your blood tests, your general condition and your response to DOCETAXEL KABI.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tdoctor|||médico\tresponse|||respuesta", "en": "Your doctor may change the dose and frequency of dosing depending on your blood tests, your general condition and your response to DOCETAXEL KABI.", "es": "Su médico puede cambiar la dosis y frecuencia de la administración dependiendo de sus análisis de sangre, su estado general y su respuesta a DOCETAXEL KABI." } }
{ "translation": { "text": "Glossaries:\n\"medicine\" -> \"medicamento\"\n\"interferon\" -> \"interferón\"\n\"multiple sclerosis\" -> \"esclerosis múltiple\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Extavia is a type of medicine known as interferon used to treat multiple sclerosis.\nSpanish: Extavia es un tipo de medicamento conocido como interferón, utilizado en el tratamiento de la esclerosis múltiple.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"medicine\" -> \"medicamento\"\n\"interferon\" -> \"interferón\"\n\"multiple sclerosis\" -> \"esclerosis múltiple\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Extavia is a type of medicine known as interferon used to treat multiple sclerosis.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicamento\tinterferon|||interferón\tmultiple sclerosis|||esclerosis múltiple", "en": "Extavia is a type of medicine known as interferon used to treat multiple sclerosis.", "es": "Extavia es un tipo de medicamento conocido como interferón, utilizado en el tratamiento de la esclerosis múltiple." } }
{ "translation": { "text": "Glossary:\n\"product\" -> \"producto\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The reference product is authorised in Belgium since 1985.\nSpanish: El producto de referencia está autorizado en Bélgica desde 1985.", "en_prompt": "<|im_start|>user\nGlossary:\n\"product\" -> \"producto\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The reference product is authorised in Belgium since 1985.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "product|||producto", "en": "The reference product is authorised in Belgium since 1985.", "es": "El producto de referencia está autorizado en Bélgica desde 1985." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you need more information about your animal's medical condition or treatment, contact your veterinarian.\nSpanish: Si necesita más información sobre la enfermedad de su animal o el tratamiento de la misma, pregunte a su veterinario.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you need more information about your animal's medical condition or treatment, contact your veterinarian.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tinformation|||información", "en": "If you need more information about your animal's medical condition or treatment, contact your veterinarian.", "es": "Si necesita más información sobre la enfermedad de su animal o el tratamiento de la misma, pregunte a su veterinario." } }
{ "translation": { "text": "Glossary:\n\"exposure\" -> \"exposición\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The data described below reflect the exposure to SPRYCEL as single-agent therapy at all doses tested in clinical studies (N=2,900), including 324 adult patients with newly diagnosed chronic phase CML, 2,388 adult patients with imatinib-resistant or -intolerant chronic or advanced phase CML or Ph+ ALL, and 188 paediatric patients.\nSpanish: Los datos descritos abajo reflejan la exposición de SPRYCEL como tratamiento único a todas las dosis evaluadas en los ensayos clínicos (N=2.900) incluyendo 324 pacientes adultos con LMC en fase crónica de nuevo diagnóstico, 2.388 pacientes adultos con LMC de fase avanzada o crónica resistentes o intolerantes a imatinib o LLA Ph+, y 188 pacientes pediátricos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"exposure\" -> \"exposición\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The data described below reflect the exposure to SPRYCEL as single-agent therapy at all doses tested in clinical studies (N=2,900), including 324 adult patients with newly diagnosed chronic phase CML, 2,388 adult patients with imatinib-resistant or -intolerant chronic or advanced phase CML or Ph+ ALL, and 188 paediatric patients.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||exposición", "en": "The data described below reflect the exposure to SPRYCEL as single-agent therapy at all doses tested in clinical studies (N=2,900), including 324 adult patients with newly diagnosed chronic phase CML, 2,388 adult patients with imatinib-resistant or -intolerant chronic or advanced phase CML or Ph+ ALL, and 188 paediatric patients.", "es": "Los datos descritos abajo reflejan la exposición de SPRYCEL como tratamiento único a todas las dosis evaluadas en los ensayos clínicos (N=2.900) incluyendo 324 pacientes adultos con LMC en fase crónica de nuevo diagnóstico, 2.388 pacientes adultos con LMC de fase avanzada o crónica resistentes o intolerantes a imatinib o LLA Ph+, y 188 pacientes pediátricos." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"analysis\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In a retrospective analysis, 91% (234/258) of patients on nilotinib 300 mg twice daily achieved BCR-ABL levels ≤10% at 3 months of treatment compared to 67% (176/264) of patients on imatinib 400 mg once daily.\nSpanish: En un análisis retrospectivo, el 91% de los pacientes (234/258) tratados con nilotinib 300 mg dos veces al día alcanzaron los niveles de BCR-ABL ≤10% a los 3 meses de tratamiento comparado al 67% de los pacientes (176/264) tratados con imatinib 400 mg una vez al día.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"analysis\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In a retrospective analysis, 91% (234/258) of patients on nilotinib 300 mg twice daily achieved BCR-ABL levels ≤10% at 3 months of treatment compared to 67% (176/264) of patients on imatinib 400 mg once daily.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tanalysis|||análisis", "en": "In a retrospective analysis, 91% (234/258) of patients on nilotinib 300 mg twice daily achieved BCR-ABL levels ≤10% at 3 months of treatment compared to 67% (176/264) of patients on imatinib 400 mg once daily.", "es": "En un análisis retrospectivo, el 91% de los pacientes (234/258) tratados con nilotinib 300 mg dos veces al día alcanzaron los niveles de BCR-ABL ≤10% a los 3 meses de tratamiento comparado al 67% de los pacientes (176/264) tratados con imatinib 400 mg una vez al día." } }
{ "translation": { "text": "Glossary:\n\"urine\" -> \"orina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: To detect this, your baby's stools and urine may be tested to determine if there is any blood present in them.\nSpanish: A fin de detectar esto, se podrán analizar las heces y la orina de su bebé para determinar la presencia de sangre en los mismos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"urine\" -> \"orina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: To detect this, your baby's stools and urine may be tested to determine if there is any blood present in them.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "urine|||orina", "en": "To detect this, your baby's stools and urine may be tested to determine if there is any blood present in them.", "es": "A fin de detectar esto, se podrán analizar las heces y la orina de su bebé para determinar la presencia de sangre en los mismos." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"adverse event\" -> \"acontecimiento adverso\"\n\"safety profile\" -> \"perfil de seguridad\"\n\"safety\" -> \"seguridad\"\n\"diarrhoea\" -> \"diarrea\"\n\"therapeutic dose\" -> \"dosis terapéutica\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In a study in healthy volunteers receiving a single dose of 2,897 micrograms (up to 10-fold the recommended therapeutic dose) the safety profile in these subjects was consistent with that in the overall population, with diarrhoea being the most commonly reported adverse event.\nSpanish: En un estudio llevado a cabo con voluntarios sanos que recibieron una dosis única de 2897 microgramos (hasta diez veces la dosis terapéutica recomendada), el perfil de seguridad de estos sujetos fue similar al de la población global tratada, siendo la diarrea el acontecimiento adverso comunicado con mayor frecuencia.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"adverse event\" -> \"acontecimiento adverso\"\n\"safety profile\" -> \"perfil de seguridad\"\n\"safety\" -> \"seguridad\"\n\"diarrhoea\" -> \"diarrea\"\n\"therapeutic dose\" -> \"dosis terapéutica\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In a study in healthy volunteers receiving a single dose of 2,897 micrograms (up to 10-fold the recommended therapeutic dose) the safety profile in these subjects was consistent with that in the overall population, with diarrhoea being the most commonly reported adverse event.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tadverse event|||acontecimiento adverso\tsafety profile|||perfil de seguridad\tsafety|||seguridad\tdiarrhoea|||diarrea\ttherapeutic dose|||dosis terapéutica\tpopulation|||población", "en": "In a study in healthy volunteers receiving a single dose of 2,897 micrograms (up to 10-fold the recommended therapeutic dose) the safety profile in these subjects was consistent with that in the overall population, with diarrhoea being the most commonly reported adverse event.", "es": "En un estudio llevado a cabo con voluntarios sanos que recibieron una dosis única de 2897 microgramos (hasta diez veces la dosis terapéutica recomendada), el perfil de seguridad de estos sujetos fue similar al de la población global tratada, siendo la diarrea el acontecimiento adverso comunicado con mayor frecuencia." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"urine\" -> \"orina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: C-labeled tedizolid phosphate under fasted conditions, the majority of elimination occurred via the liver with 81.5% of the radioactive dose recovered in faeces and 18% in urine, with most of the elimination (>85%) occurring within 96 hours.\nSpanish: C en ayunas, la mayor parte de la eliminación se produjo por vía hepática, con un 81,5 % de la dosis radioactiva recuperada en las heces y un 18 % en orina; la mayor parte de la eliminación (> 85%) se produjo dentro de las 96 horas.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"urine\" -> \"orina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: C-labeled tedizolid phosphate under fasted conditions, the majority of elimination occurred via the liver with 81.5% of the radioactive dose recovered in faeces and 18% in urine, with most of the elimination (>85%) occurring within 96 hours.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\turine|||orina", "en": "C-labeled tedizolid phosphate under fasted conditions, the majority of elimination occurred via the liver with 81.5% of the radioactive dose recovered in faeces and 18% in urine, with most of the elimination (>85%) occurring within 96 hours.", "es": "C en ayunas, la mayor parte de la eliminación se produjo por vía hepática, con un 81,5 % de la dosis radioactiva recuperada en las heces y un 18 % en orina; la mayor parte de la eliminación (> 85%) se produjo dentro de las 96 horas." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"analysis\" -> \"análisis\"\n\"test\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: With regard to the between-group analysis, the treatment with Spherox passed the test of non-inferiority compared with microfracture (Δ of 5.7 with lower bound of CI equal to -1.0 at the 12 months assessment, Δ of 6.1 with lower bound of CI equal to -0.4 at the 24 months assessment, results for KOOS at 36 months were consistent with the earlier time points).\nSpanish: En lo que respecta al análisis entre grupos, el tratamiento con Spherox pasó la prueba de no inferioridad en comparación con las microfracturas (Δ de 5,7 con un límite inferior del IC igual a -1,0 en la evaluación a los 12 meses y Δ de 6,1 con un límite inferior del IC igual a -0,4 en la evaluación a los 24 meses; los resultados en la puntuación KOOS al cabo de 36 meses fueron congruentes con los de los anteriores puntos temporales).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"analysis\" -> \"análisis\"\n\"test\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: With regard to the between-group analysis, the treatment with Spherox passed the test of non-inferiority compared with microfracture (Δ of 5.7 with lower bound of CI equal to -1.0 at the 12 months assessment, Δ of 6.1 with lower bound of CI equal to -0.4 at the 24 months assessment, results for KOOS at 36 months were consistent with the earlier time points).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tanalysis|||análisis\ttest|||análisis", "en": "With regard to the between-group analysis, the treatment with Spherox passed the test of non-inferiority compared with microfracture (Δ of 5.7 with lower bound of CI equal to -1.0 at the 12 months assessment, Δ of 6.1 with lower bound of CI equal to -0.4 at the 24 months assessment, results for KOOS at 36 months were consistent with the earlier time points).", "es": "En lo que respecta al análisis entre grupos, el tratamiento con Spherox pasó la prueba de no inferioridad en comparación con las microfracturas (Δ de 5,7 con un límite inferior del IC igual a -1,0 en la evaluación a los 12 meses y Δ de 6,1 con un límite inferior del IC igual a -0,4 en la evaluación a los 24 meses; los resultados en la puntuación KOOS al cabo de 36 meses fueron congruentes con los de los anteriores puntos temporales)." } }
{ "translation": { "text": "Glossaries:\n\"G-CSF\" -> \"G-CSF\"\n\"derivatives\" -> \"derivados\"\n\"oedema\" -> \"edema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Capillary leak syndrome has been reported after administration of G-CSF or derivatives and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration.\nSpanish: Se ha notificado síndrome de fuga capilar después de la administración de G-CSF o de sus derivados, que se caracteriza por hipotensión, hipoalbuminemia, edema y hemoconcentración.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"G-CSF\" -> \"G-CSF\"\n\"derivatives\" -> \"derivados\"\n\"oedema\" -> \"edema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Capillary leak syndrome has been reported after administration of G-CSF or derivatives and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "G-CSF|||G-CSF\tderivatives|||derivados\toedema|||edema", "en": "Capillary leak syndrome has been reported after administration of G-CSF or derivatives and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration.", "es": "Se ha notificado síndrome de fuga capilar después de la administración de G-CSF o de sus derivados, que se caracteriza por hipotensión, hipoalbuminemia, edema y hemoconcentración." } }
{ "translation": { "text": "Glossary:\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Detailed information is available on the website of {name of MS/Agency}>\nSpanish: La información detallada sobre este medicamento está disponible en la página web de: {nombre del Estado Miembro/Agencia}", "en_prompt": "<|im_start|>user\nGlossary:\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Detailed information is available on the website of {name of MS/Agency}>\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "information|||información", "en": "Detailed information is available on the website of {name of MS/Agency}>", "es": "La información detallada sobre este medicamento está disponible en la página web de: {nombre del Estado Miembro/Agencia}" } }
{ "translation": { "text": "Glossaries:\n\"reconstitution\" -> \"reconstitución\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For intravenous use as infusion, after reconstitution and dilution.\nSpanish: Para uso intravenoso como perfusión, tras la reconstitución y dilución.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"reconstitution\" -> \"reconstitución\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For intravenous use as infusion, after reconstitution and dilution.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "reconstitution|||reconstitución\tinfusion|||perfusión", "en": "For intravenous use as infusion, after reconstitution and dilution.", "es": "Para uso intravenoso como perfusión, tras la reconstitución y dilución." } }
{ "translation": { "text": "Glossary:\n\"ribavirin\" -> \"ribavirina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: During clinical trials with Viekirax and dasabuvir with or without ribavirin, transient elevations of ALT to greater than 5 times the upper limit of normal occurred in approximately 1% of subjects (35 of 3,039).\nSpanish: Durante los ensayos clínicos con Viekirax y dasabuvir con o sin ribavirina, se produjeron elevaciones de ALT transitorias de más de 5 veces el límite superior normal, en aproximadamente el 1 % de los sujetos (35 de 3.039).", "en_prompt": "<|im_start|>user\nGlossary:\n\"ribavirin\" -> \"ribavirina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: During clinical trials with Viekirax and dasabuvir with or without ribavirin, transient elevations of ALT to greater than 5 times the upper limit of normal occurred in approximately 1% of subjects (35 of 3,039).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "ribavirin|||ribavirina", "en": "During clinical trials with Viekirax and dasabuvir with or without ribavirin, transient elevations of ALT to greater than 5 times the upper limit of normal occurred in approximately 1% of subjects (35 of 3,039).", "es": "Durante los ensayos clínicos con Viekirax y dasabuvir con o sin ribavirina, se produjeron elevaciones de ALT transitorias de más de 5 veces el límite superior normal, en aproximadamente el 1 % de los sujetos (35 de 3.039)." } }
{ "translation": { "text": "Glossary:\n\"system\" -> \"sistema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).\nSpanish: Las reacciones adversas se categorizan conforme al sistema de clasificación por órganos, usando el siguiente convenio: muy frecuentes (≥ 1/10), frecuentes (de ≥ 1/100 a < 1/10), poco frecuentes (de ≥ 1/1.000 a < 1/100), raras (de ≥ 1/10.000 a < 1/1.000), muy raras (< 1/10.000), frecuencia no conocida (no puede estimarse a partir de los datos disponibles).", "en_prompt": "<|im_start|>user\nGlossary:\n\"system\" -> \"sistema\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "system|||sistema", "en": "Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).", "es": "Las reacciones adversas se categorizan conforme al sistema de clasificación por órganos, usando el siguiente convenio: muy frecuentes (≥ 1/10), frecuentes (de ≥ 1/100 a < 1/10), poco frecuentes (de ≥ 1/1.000 a < 1/100), raras (de ≥ 1/10.000 a < 1/1.000), muy raras (< 1/10.000), frecuencia no conocida (no puede estimarse a partir de los datos disponibles)." } }
{ "translation": { "text": "Glossaries:\n\"fluticasone\" -> \"fluticasona\"\n\"renal\" -> \"renal\"\n\"renal clearance\" -> \"aclaramiento renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The renal clearance of fluticasone propionate is negligible.\nSpanish: El aclaramiento renal del propionato de fluticasona es insignificante.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"fluticasone\" -> \"fluticasona\"\n\"renal\" -> \"renal\"\n\"renal clearance\" -> \"aclaramiento renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The renal clearance of fluticasone propionate is negligible.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "fluticasone|||fluticasona\trenal|||renal\trenal clearance|||aclaramiento renal", "en": "The renal clearance of fluticasone propionate is negligible.", "es": "El aclaramiento renal del propionato de fluticasona es insignificante." } }
{ "translation": { "text": "Glossaries:\n\"inflammation\" -> \"inflamación\"\n\"post-operative\" -> \"postoperatorio\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Acticam is efficacious in alleviating the inflammation and pain in both acute and chronic musculoskeletal disorders and reducing the post operative pain following orthopaedic and soft tissue surgery in dogs and in reducing the post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats.\nSpanish: Acticam es eficaz en el alivio de la inflamación y el dolor en trastornos musculoesqueléticos agudos y crónicos y la reducción del dolor postoperatorio tras cirugía ortopédica y de tejidos blandos en perros y en la reducción del dolor postoperatorio después de una ovariohisterectomía o cirugía menor de tejidos blandos en gatos.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"inflammation\" -> \"inflamación\"\n\"post-operative\" -> \"postoperatorio\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Acticam is efficacious in alleviating the inflammation and pain in both acute and chronic musculoskeletal disorders and reducing the post operative pain following orthopaedic and soft tissue surgery in dogs and in reducing the post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "inflammation|||inflamación\tpost-operative|||postoperatorio", "en": "Acticam is efficacious in alleviating the inflammation and pain in both acute and chronic musculoskeletal disorders and reducing the post operative pain following orthopaedic and soft tissue surgery in dogs and in reducing the post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats.", "es": "Acticam es eficaz en el alivio de la inflamación y el dolor en trastornos musculoesqueléticos agudos y crónicos y la reducción del dolor postoperatorio tras cirugía ortopédica y de tejidos blandos en perros y en la reducción del dolor postoperatorio después de una ovariohisterectomía o cirugía menor de tejidos blandos en gatos." } }
{ "translation": { "text": "Glossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Xofigo is administered as an intravenous injection and is thus 100% bioavailable.\nSpanish: Xofigo se administra en forma de inyección intravenosa, por lo que su biodisponibilidad es del 100%.", "en_prompt": "<|im_start|>user\nGlossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Xofigo is administered as an intravenous injection and is thus 100% bioavailable.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injection|||inyección", "en": "Xofigo is administered as an intravenous injection and is thus 100% bioavailable.", "es": "Xofigo se administra en forma de inyección intravenosa, por lo que su biodisponibilidad es del 100%." } }
{ "translation": { "text": "Glossaries:\n\"melphalan\" -> \"melfalán\"\n\"efficacy\" -> \"eficacia\"\n\"myeloma\" -> \"mieloma\"\n\"bendamustine\" -> \"bendamustina\"\n\"randomised\" -> \"aleatorizado\"\n\"chemotherapy\" -> \"quimioterapia\"\n\"prednisone\" -> \"prednisona\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The Applicant provided data from a prospective, multi-centre randomised controlled pivotal trial comparing the efficacy of first-line chemotherapy with bendamustine and prednisone (BP) to melphalan and prednisone therapy (MP) in patients with previously untreated multiple myeloma.\nSpanish: El solicitante presentó los datos procedentes de un ensayo fundamental prospectivo, multicéntrico, aleatorizado y controlado para comparar la eficacia de la quimioterapia de primera línea con bendamustina y prednisona (BP) frente a melfalán y prednisona (MP) en pacientes con mieloma múltiple no tratado previamente.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"melphalan\" -> \"melfalán\"\n\"efficacy\" -> \"eficacia\"\n\"myeloma\" -> \"mieloma\"\n\"bendamustine\" -> \"bendamustina\"\n\"randomised\" -> \"aleatorizado\"\n\"chemotherapy\" -> \"quimioterapia\"\n\"prednisone\" -> \"prednisona\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The Applicant provided data from a prospective, multi-centre randomised controlled pivotal trial comparing the efficacy of first-line chemotherapy with bendamustine and prednisone (BP) to melphalan and prednisone therapy (MP) in patients with previously untreated multiple myeloma.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "melphalan|||melfalán\tefficacy|||eficacia\tmyeloma|||mieloma\tbendamustine|||bendamustina\trandomised|||aleatorizado\tchemotherapy|||quimioterapia\tprednisone|||prednisona", "en": "The Applicant provided data from a prospective, multi-centre randomised controlled pivotal trial comparing the efficacy of first-line chemotherapy with bendamustine and prednisone (BP) to melphalan and prednisone therapy (MP) in patients with previously untreated multiple myeloma.", "es": "El solicitante presentó los datos procedentes de un ensayo fundamental prospectivo, multicéntrico, aleatorizado y controlado para comparar la eficacia de la quimioterapia de primera línea con bendamustina y prednisona (BP) frente a melfalán y prednisona (MP) en pacientes con mieloma múltiple no tratado previamente." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"case\" -> \"caso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In case of very severe infections the dose can be increased up to a maximum daily dose of 1200 mg (400 mg thrice daily).\nSpanish: En el caso de infecciones muy graves, la dosis puede aumentarse hasta una dosis máxima diaria de 1200 mg (400 mg tres veces al día).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"case\" -> \"caso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In case of very severe infections the dose can be increased up to a maximum daily dose of 1200 mg (400 mg thrice daily).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tcase|||caso", "en": "In case of very severe infections the dose can be increased up to a maximum daily dose of 1200 mg (400 mg thrice daily).", "es": "En el caso de infecciones muy graves, la dosis puede aumentarse hasta una dosis máxima diaria de 1200 mg (400 mg tres veces al día)." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients taking Instanyl were allowed to take a second spray 10 minutes after the first dose if there had been insufficient pain relief.\nSpanish: Se autorizó a los pacientes que tomaban Instanyl aplicar un segundo aerosol al cabo de 10 minutos después de la primera dosis, en caso de insuficiente alivio del dolor.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients taking Instanyl were allowed to take a second spray 10 minutes after the first dose if there had been insufficient pain relief.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "Patients taking Instanyl were allowed to take a second spray 10 minutes after the first dose if there had been insufficient pain relief.", "es": "Se autorizó a los pacientes que tomaban Instanyl aplicar un segundo aerosol al cabo de 10 minutos después de la primera dosis, en caso de insuficiente alivio del dolor." } }
{ "translation": { "text": "Glossaries:\n\"fatigue\" -> \"fatiga\"\n\"weight\" -> \"peso\"\n\"anorexia\" -> \"anorexia\"\n\"hypoglycaemia\" -> \"hipoglucemia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: All patients should be monitored and informed about the signs and symptoms associated with hypocortisolism (e.g. weakness, fatigue, anorexia, nausea, vomiting, weight-loss, hypotension, hyponatraemia, hyperkalaemia and/or hypoglycaemia).\nSpanish: Se debe hacer un seguimiento de todos los pacientes, así como informar, a todos los pacientes, acerca de los signos y síntomas asociados al hipocortisolismo (por ejemplo, debilidad, fatiga, anorexia, náuseas, vómitos, pérdida de peso, hipotensión, hiponatremia, hiperpotasiemia e/o hipoglucemia).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"fatigue\" -> \"fatiga\"\n\"weight\" -> \"peso\"\n\"anorexia\" -> \"anorexia\"\n\"hypoglycaemia\" -> \"hipoglucemia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: All patients should be monitored and informed about the signs and symptoms associated with hypocortisolism (e.g. weakness, fatigue, anorexia, nausea, vomiting, weight-loss, hypotension, hyponatraemia, hyperkalaemia and/or hypoglycaemia).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "fatigue|||fatiga\tweight|||peso\tanorexia|||anorexia\thypoglycaemia|||hipoglucemia", "en": "All patients should be monitored and informed about the signs and symptoms associated with hypocortisolism (e.g. weakness, fatigue, anorexia, nausea, vomiting, weight-loss, hypotension, hyponatraemia, hyperkalaemia and/or hypoglycaemia).", "es": "Se debe hacer un seguimiento de todos los pacientes, así como informar, a todos los pacientes, acerca de los signos y síntomas asociados al hipocortisolismo (por ejemplo, debilidad, fatiga, anorexia, náuseas, vómitos, pérdida de peso, hipotensión, hiponatremia, hiperpotasiemia e/o hipoglucemia)." } }
{ "translation": { "text": "Glossary:\n\"monitoring\" -> \"seguimiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No additional monitoring is required.\nSpanish: No es necesario efectuar ningún seguimiento adicional.", "en_prompt": "<|im_start|>user\nGlossary:\n\"monitoring\" -> \"seguimiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No additional monitoring is required.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "monitoring|||seguimiento", "en": "No additional monitoring is required.", "es": "No es necesario efectuar ningún seguimiento adicional." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"effects\" -> \"efecto\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • if Norvir is used to boost the effects of certain other anti-HIV medicines the typical dose for adults is 1 to 2 tablets once or twice daily.\nSpanish: • si se utiliza Norvir para potenciar el efecto de otros medicamentos anti-VIH, la dosis para adultos es de 1 a 2 comprimidos una o dos veces al día.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"effects\" -> \"efecto\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • if Norvir is used to boost the effects of certain other anti-HIV medicines the typical dose for adults is 1 to 2 tablets once or twice daily.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\teffects|||efecto", "en": "• if Norvir is used to boost the effects of certain other anti-HIV medicines the typical dose for adults is 1 to 2 tablets once or twice daily.", "es": "• si se utiliza Norvir para potenciar el efecto de otros medicamentos anti-VIH, la dosis para adultos es de 1 a 2 comprimidos una o dos veces al día." } }
{ "translation": { "text": "Glossaries:\n\"antiretroviral\" -> \"antirretroviral\"\n\"exposure\" -> \"exposición\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The pharmacokinetic data demonstrate that total exposure (AUC) to rilpivirine as a part of an antiretroviral regimen was approximately 30% lower during pregnancy compared with postpartum (6-12 weeks).\nSpanish: Los datos farmacocinéticos demuestran que la exposición total (AUC) a rilpivirina como parte de una pauta de tratamiento antirretroviral fue aproximadamente un 30 % inferior durante el embarazo en comparación con el posparto (6-12 semanas).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"antiretroviral\" -> \"antirretroviral\"\n\"exposure\" -> \"exposición\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The pharmacokinetic data demonstrate that total exposure (AUC) to rilpivirine as a part of an antiretroviral regimen was approximately 30% lower during pregnancy compared with postpartum (6-12 weeks).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "antiretroviral|||antirretroviral\texposure|||exposición", "en": "The pharmacokinetic data demonstrate that total exposure (AUC) to rilpivirine as a part of an antiretroviral regimen was approximately 30% lower during pregnancy compared with postpartum (6-12 weeks).", "es": "Los datos farmacocinéticos demuestran que la exposición total (AUC) a rilpivirina como parte de una pauta de tratamiento antirretroviral fue aproximadamente un 30 % inferior durante el embarazo en comparación con el posparto (6-12 semanas)." } }
{ "translation": { "text": "Glossaries:\n\"diabetes\" -> \"diabetes\"\n\"diabetes mellitus\" -> \"diabetes\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Table 1 Result from two 26-weeks' trials in type 2 diabetes mellitus with Ryzodeg given once daily\nSpanish: Tabla 1 Resultado de dos ensayos de 26 semanas de duración en pacientes con diabetes mellitus tipo 2 con Ryzodeg administrado una vez al día", "en_prompt": "<|im_start|>user\nGlossaries:\n\"diabetes\" -> \"diabetes\"\n\"diabetes mellitus\" -> \"diabetes\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Table 1 Result from two 26-weeks' trials in type 2 diabetes mellitus with Ryzodeg given once daily\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "diabetes|||diabetes\tdiabetes mellitus|||diabetes", "en": "Table 1 Result from two 26-weeks' trials in type 2 diabetes mellitus with Ryzodeg given once daily", "es": "Tabla 1 Resultado de dos ensayos de 26 semanas de duración en pacientes con diabetes mellitus tipo 2 con Ryzodeg administrado una vez al día" } }
{ "translation": { "text": "Glossaries:\n\"therapy\" -> \"terapia\"\n\"tuberculosis\" -> \"tuberculosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If active tuberculosis is diagnosed, Erelzi therapy must not be initiated.\nSpanish: No se debe iniciar la terapia con Erelzi si se diagnostica una tuberculosis activa.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"therapy\" -> \"terapia\"\n\"tuberculosis\" -> \"tuberculosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If active tuberculosis is diagnosed, Erelzi therapy must not be initiated.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "therapy|||terapia\ttuberculosis|||tuberculosis", "en": "If active tuberculosis is diagnosed, Erelzi therapy must not be initiated.", "es": "No se debe iniciar la terapia con Erelzi si se diagnostica una tuberculosis activa." } }
{ "translation": { "text": "Glossary:\n\"heart\" -> \"corazón\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For [Invented name] be aware of the following: - If you are taking [Invented name] and other medicines that affect your heart there is an increased risk for altering your heartbeat.\nSpanish: Con [Denominación de fantasía] debe tener en cuenta lo siguiente: - Si está tomando [Denominación de fantasía] y otros medicamentos que afecten al corazón, existe un riesgo mayor de que se produzcan alteraciones de los latidos cardiacos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"heart\" -> \"corazón\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For [Invented name] be aware of the following: - If you are taking [Invented name] and other medicines that affect your heart there is an increased risk for altering your heartbeat.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "heart|||corazón", "en": "For [Invented name] be aware of the following: - If you are taking [Invented name] and other medicines that affect your heart there is an increased risk for altering your heartbeat.", "es": "Con [Denominación de fantasía] debe tener en cuenta lo siguiente: - Si está tomando [Denominación de fantasía] y otros medicamentos que afecten al corazón, existe un riesgo mayor de que se produzcan alteraciones de los latidos cardiacos." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"oedema\" -> \"edema\"\n\"congestive heart failure\" -> \"insuficiencia cardíaca congestiva\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: INDICATION(S) For treatment of clinical signs, including oedema and effusion, related to congestive heart failure.\nSpanish: Para el tratamiento de los signos clínicos, incluyendo edema y derrame relacionados con la insuficiencia cardíaca congestiva.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"oedema\" -> \"edema\"\n\"congestive heart failure\" -> \"insuficiencia cardíaca congestiva\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: INDICATION(S) For treatment of clinical signs, including oedema and effusion, related to congestive heart failure.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\toedema|||edema\tcongestive heart failure|||insuficiencia cardíaca congestiva", "en": "INDICATION(S) For treatment of clinical signs, including oedema and effusion, related to congestive heart failure.", "es": "Para el tratamiento de los signos clínicos, incluyendo edema y derrame relacionados con la insuficiencia cardíaca congestiva." } }
{ "translation": { "text": "Glossaries:\n\"system\" -> \"sistema\"\n\"ATC code\" -> \"código ATC\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Pharmacotherapeutic group: Other respiratory system products; ATC code: R07AX31\nSpanish: Grupo farmacoterapéutico: Otros productos del sistema respiratorio; código ATC: R07AX31", "en_prompt": "<|im_start|>user\nGlossaries:\n\"system\" -> \"sistema\"\n\"ATC code\" -> \"código ATC\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Pharmacotherapeutic group: Other respiratory system products; ATC code: R07AX31\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "system|||sistema\tATC code|||código ATC", "en": "Pharmacotherapeutic group: Other respiratory system products; ATC code: R07AX31", "es": "Grupo farmacoterapéutico: Otros productos del sistema respiratorio; código ATC: R07AX31" } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"vaccine\" -> \"vacuna\"\n\"vaccine strain\" -> \"cepa de la vacuna\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: monograph 01/2008:0587 is not directly applicable, the vaccine strain was shown to be compliant with its section 2.4.1 “safety”.\nSpanish: 01/2008:0587 no es directamente aplicable, se ha demostrado que la cepa de la vacuna cumple lo establecido en su sección 2.4.1 «Seguridad».", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"vaccine\" -> \"vacuna\"\n\"vaccine strain\" -> \"cepa de la vacuna\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: monograph 01/2008:0587 is not directly applicable, the vaccine strain was shown to be compliant with its section 2.4.1 “safety”.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\tvaccine|||vacuna\tvaccine strain|||cepa de la vacuna", "en": "monograph 01/2008:0587 is not directly applicable, the vaccine strain was shown to be compliant with its section 2.4.1 “safety”.", "es": "01/2008:0587 no es directamente aplicable, se ha demostrado que la cepa de la vacuna cumple lo establecido en su sección 2.4.1 «Seguridad»." } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"creatinine\" -> \"creatinina\"\n\"efficacy\" -> \"eficacia\"\n\"safety\" -> \"seguridad\"\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance <30 mL/min, see section 5.2).\nSpanish: No se han evaluado completamente la eficacia y la seguridad en pacientes con insuficiencia renal grave (aclaramiento de creatinina <30 ml/min, ver sección 5.2).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"creatinine\" -> \"creatinina\"\n\"efficacy\" -> \"eficacia\"\n\"safety\" -> \"seguridad\"\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance <30 mL/min, see section 5.2).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\tcreatinine|||creatinina\tefficacy|||eficacia\tsafety|||seguridad\trenal|||renal", "en": "The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance <30 mL/min, see section 5.2).", "es": "No se han evaluado completamente la eficacia y la seguridad en pacientes con insuficiencia renal grave (aclaramiento de creatinina <30 ml/min, ver sección 5.2)." } }
{ "translation": { "text": "Glossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: They must be taken with food (see section 5.2).\nSpanish: Se deben tomar con alimentos (ver sección 5.2).", "en_prompt": "<|im_start|>user\nGlossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: They must be taken with food (see section 5.2).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección", "en": "They must be taken with food (see section 5.2).", "es": "Se deben tomar con alimentos (ver sección 5.2)." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"fluconazole\" -> \"fluconazol\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Indinavir and fluconazole can be co-administered without dose adjustment.\nSpanish: Indinavir y fluconazol pueden coadministrarse sin ajuste de dosis.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"fluconazole\" -> \"fluconazol\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Indinavir and fluconazole can be co-administered without dose adjustment.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tfluconazole|||fluconazol", "en": "Indinavir and fluconazole can be co-administered without dose adjustment.", "es": "Indinavir y fluconazol pueden coadministrarse sin ajuste de dosis." } }
{ "translation": { "text": "Glossary:\n\"obstruction\" -> \"obstrucción\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Venoocclusive liver disease (sinusoidal obstruction syndrome) (3% [pre-HSCT]d)\nSpanish: Enfermedad venooclusiva hepática (síndrome de obstrucción sinusoidal) (3% [pre-TCMH]", "en_prompt": "<|im_start|>user\nGlossary:\n\"obstruction\" -> \"obstrucción\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Venoocclusive liver disease (sinusoidal obstruction syndrome) (3% [pre-HSCT]d)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "obstruction|||obstrucción", "en": "Venoocclusive liver disease (sinusoidal obstruction syndrome) (3% [pre-HSCT]d)", "es": "Enfermedad venooclusiva hepática (síndrome de obstrucción sinusoidal) (3% [pre-TCMH]" } }
{ "translation": { "text": "Glossary:\n\"diarrhoea\" -> \"diarrea\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Common: Nausea, vomiting, abdominal pain or cramps, diarrhoea Rare: Pancreatitis, elevations in serum amylase\nSpanish: Frecuentes: Náuseas, vómitos, dolor o calambres abdominales, diarrea.", "en_prompt": "<|im_start|>user\nGlossary:\n\"diarrhoea\" -> \"diarrea\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Common: Nausea, vomiting, abdominal pain or cramps, diarrhoea Rare: Pancreatitis, elevations in serum amylase\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "diarrhoea|||diarrea", "en": "Common: Nausea, vomiting, abdominal pain or cramps, diarrhoea Rare: Pancreatitis, elevations in serum amylase", "es": "Frecuentes: Náuseas, vómitos, dolor o calambres abdominales, diarrea." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"medicinal product\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If these toxicities persist or recur following two dose reductions, discontinue the medicinal product.\nSpanish: Si estas toxicidades persisten o reaparecen después de dos reducciones de dosis, se debe suspender el tratamiento con este medicamento.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"medicinal product\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If these toxicities persist or recur following two dose reductions, discontinue the medicinal product.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tmedicinal product|||medicamento", "en": "If these toxicities persist or recur following two dose reductions, discontinue the medicinal product.", "es": "Si estas toxicidades persisten o reaparecen después de dos reducciones de dosis, se debe suspender el tratamiento con este medicamento." } }
{ "translation": { "text": "Glossaries:\n\"factor\" -> \"factor\"\n\"model\" -> \"modelo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: a Adjusted for donor type as factor, and risk group and centre as strata using Cox regression model.\nSpanish: a Ajustado por tipo de donante como factor, y grupo de riesgo y centro como estratos según el modelo de regresión de Cox.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"factor\" -> \"factor\"\n\"model\" -> \"modelo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: a Adjusted for donor type as factor, and risk group and centre as strata using Cox regression model.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "factor|||factor\tmodel|||modelo", "en": "a Adjusted for donor type as factor, and risk group and centre as strata using Cox regression model.", "es": "a Ajustado por tipo de donante como factor, y grupo de riesgo y centro como estratos según el modelo de regresión de Cox." } }
{ "translation": { "text": "Glossaries:\n\"inhibition\" -> \"inhibición\"\n\"growth\" -> \"crecimiento\"\n\"treatment\" -> \"tratamiento\"\n\"irreversible\" -> \"irreversible\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients.\nSpanish: Al decidir no aplazar el tratamiento hasta la edad adulta, es importante considerar que el tratamiento de combinación indujo inhibición del crecimiento, que puede ser irreversible en algunos pacientes.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"inhibition\" -> \"inhibición\"\n\"growth\" -> \"crecimiento\"\n\"treatment\" -> \"tratamiento\"\n\"irreversible\" -> \"irreversible\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "inhibition|||inhibición\tgrowth|||crecimiento\ttreatment|||tratamiento\tirreversible|||irreversible", "en": "When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients.", "es": "Al decidir no aplazar el tratamiento hasta la edad adulta, es importante considerar que el tratamiento de combinación indujo inhibición del crecimiento, que puede ser irreversible en algunos pacientes." } }
{ "translation": { "text": "Glossaries:\n\"factor\" -> \"factor\"\n\"torsade de pointes\" -> \"torsade de pointes\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Rivastigmine may cause bradycardia which constitutes a risk factor in the occurrence of torsade de pointes, predominantly in patients with risk factors.\nSpanish: La rivastigmina puede provocar bradicardia, la cual constituye un factor de riesgo en la aparición de torsade de pointes, preferentemente en pacientes con factores de riesgo.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"factor\" -> \"factor\"\n\"torsade de pointes\" -> \"torsade de pointes\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Rivastigmine may cause bradycardia which constitutes a risk factor in the occurrence of torsade de pointes, predominantly in patients with risk factors.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "factor|||factor\ttorsade de pointes|||torsade de pointes", "en": "Rivastigmine may cause bradycardia which constitutes a risk factor in the occurrence of torsade de pointes, predominantly in patients with risk factors.", "es": "La rivastigmina puede provocar bradicardia, la cual constituye un factor de riesgo en la aparición de torsade de pointes, preferentemente en pacientes con factores de riesgo." } }
{ "translation": { "text": "Glossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Intestinal angioedema has been reported in patients treated with ACE inhibitors including TRITAZIDE (see section 4.8).\nSpanish: Se han notificado casos de angioedema intestinal en pacientes tratados con inhibidores de la ECA, incluido TRITAZIDE (ver sección 4.8).", "en_prompt": "<|im_start|>user\nGlossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Intestinal angioedema has been reported in patients treated with ACE inhibitors including TRITAZIDE (see section 4.8).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección", "en": "Intestinal angioedema has been reported in patients treated with ACE inhibitors including TRITAZIDE (see section 4.8).", "es": "Se han notificado casos de angioedema intestinal en pacientes tratados con inhibidores de la ECA, incluido TRITAZIDE (ver sección 4.8)." } }
{ "translation": { "text": "Glossary:\n\"diabetes\" -> \"diabetes\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Insuman was effective for both type 1 and type 2 diabetes.\nSpanish: Insuman es eficaz tanto para la diabetes de tipo 1 como para la diabetes de tipo 2.", "en_prompt": "<|im_start|>user\nGlossary:\n\"diabetes\" -> \"diabetes\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Insuman was effective for both type 1 and type 2 diabetes.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "diabetes|||diabetes", "en": "Insuman was effective for both type 1 and type 2 diabetes.", "es": "Insuman es eficaz tanto para la diabetes de tipo 1 como para la diabetes de tipo 2." } }
{ "translation": { "text": "Glossary:\n\"suspension\" -> \"suspensión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 250 mg oral suspension (in single dose sachets)\nSpanish: 250 mg suspensión oral (en sobres monodosis)", "en_prompt": "<|im_start|>user\nGlossary:\n\"suspension\" -> \"suspensión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 250 mg oral suspension (in single dose sachets)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "suspension|||suspensión", "en": "250 mg oral suspension (in single dose sachets)", "es": "250 mg suspensión oral (en sobres monodosis)" } }
{ "translation": { "text": "Glossaries:\n\"dropper bottle\" -> \"frasco cuentagotas\"\n\"dropper\" -> \"cuentagotas\"\n\"eye\" -> \"ojo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Invert the dropper bottle or prepare the device allowing a single drop to form at the tip and fall freely into the open eye, gently flooding it.\nSpanish: Dar la vuelta al frasco cuentagotas o preparar el dispositivo y dejar que se forme una sola gota en el extremo y que caiga libremente en el ojo abierto, inundándolo suavemente.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dropper bottle\" -> \"frasco cuentagotas\"\n\"dropper\" -> \"cuentagotas\"\n\"eye\" -> \"ojo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Invert the dropper bottle or prepare the device allowing a single drop to form at the tip and fall freely into the open eye, gently flooding it.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dropper bottle|||frasco cuentagotas\tdropper|||cuentagotas\teye|||ojo", "en": "Invert the dropper bottle or prepare the device allowing a single drop to form at the tip and fall freely into the open eye, gently flooding it.", "es": "Dar la vuelta al frasco cuentagotas o preparar el dispositivo y dejar que se forme una sola gota en el extremo y que caiga libremente en el ojo abierto, inundándolo suavemente." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"SmPC\" -> \"RCP\"\n\"product\" -> \"producto\"\n\"weight\" -> \"peso\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The CMDh amended the product information accordingly, revising the wording of Section 4.2 of the SmPC as follows: “In adults and children over 40 kg in weight, the maximum daily dose is 100 mg per day” and clarifying the wording of the recommendation in children up to 40 kg in weight.\nSpanish: El CMDh modificó la información sobre el producto en consonancia, mediante la revisión del redactado de la sección 4.2 del RCP de la siguiente manera: «En adultos y niños de más de 40 kg de peso, la dosis máxima diaria es de 100 mg» y aclarando el texto de la recomendación para niños de hasta 40 kg de peso.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"SmPC\" -> \"RCP\"\n\"product\" -> \"producto\"\n\"weight\" -> \"peso\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The CMDh amended the product information accordingly, revising the wording of Section 4.2 of the SmPC as follows: “In adults and children over 40 kg in weight, the maximum daily dose is 100 mg per day” and clarifying the wording of the recommendation in children up to 40 kg in weight.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tSmPC|||RCP\tproduct|||producto\tweight|||peso\tinformation|||información", "en": "The CMDh amended the product information accordingly, revising the wording of Section 4.2 of the SmPC as follows: “In adults and children over 40 kg in weight, the maximum daily dose is 100 mg per day” and clarifying the wording of the recommendation in children up to 40 kg in weight.", "es": "El CMDh modificó la información sobre el producto en consonancia, mediante la revisión del redactado de la sección 4.2 del RCP de la siguiente manera: «En adultos y niños de más de 40 kg de peso, la dosis máxima diaria es de 100 mg» y aclarando el texto de la recomendación para niños de hasta 40 kg de peso." } }
{ "translation": { "text": "Glossary:\n\"spleen\" -> \"bazo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Therefore, spleen size should be carefully monitored (e.g. clinical examination, ultrasound).\nSpanish: Por lo tanto, se debe controlar cuidadosamente el tamaño del bazo (p. ej., exploración clínica o ecográfica).", "en_prompt": "<|im_start|>user\nGlossary:\n\"spleen\" -> \"bazo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Therefore, spleen size should be carefully monitored (e.g. clinical examination, ultrasound).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "spleen|||bazo", "en": "Therefore, spleen size should be carefully monitored (e.g. clinical examination, ultrasound).", "es": "Por lo tanto, se debe controlar cuidadosamente el tamaño del bazo (p. ej., exploración clínica o ecográfica)." } }
{ "translation": { "text": "Glossaries:\n\"impact\" -> \"impacto\"\n\"suspension\" -> \"suspensión\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The PRAC has considered all elements expressed in relation to the impact of a suspension of the marketing authorisation for HES solutions for infusion on a potential unmet medical need at national level, including comments submitted by the MAHs in writing and at oral explanations, responses from Member States and other stakeholders' views.\nSpanish: El PRAC ha examinado todos los elementos expresados en relación con el impacto de una suspensión de la autorización de comercialización de las soluciones para perfusión de AHE en una posible necesidad médica no satisfecha a escala nacional, incluidos los comentarios presentados por los TAC", "en_prompt": "<|im_start|>user\nGlossaries:\n\"impact\" -> \"impacto\"\n\"suspension\" -> \"suspensión\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The PRAC has considered all elements expressed in relation to the impact of a suspension of the marketing authorisation for HES solutions for infusion on a potential unmet medical need at national level, including comments submitted by the MAHs in writing and at oral explanations, responses from Member States and other stakeholders' views.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "impact|||impacto\tsuspension|||suspensión\tinfusion|||perfusión", "en": "The PRAC has considered all elements expressed in relation to the impact of a suspension of the marketing authorisation for HES solutions for infusion on a potential unmet medical need at national level, including comments submitted by the MAHs in writing and at oral explanations, responses from Member States and other stakeholders' views.", "es": "El PRAC ha examinado todos los elementos expresados en relación con el impacto de una suspensión de la autorización de comercialización de las soluciones para perfusión de AHE en una posible necesidad médica no satisfecha a escala nacional, incluidos los comentarios presentados por los TAC" } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In patients considered at high risk treatment with TYSABRI should only be continued if the benefits outweigh the risks.\nSpanish: En los pacientes considerados de alto riesgo, el tratamiento con TYSABRI únicamente debe mantenerse si los beneficios son mayores que los riesgos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratamiento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In patients considered at high risk treatment with TYSABRI should only be continued if the benefits outweigh the risks.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento", "en": "In patients considered at high risk treatment with TYSABRI should only be continued if the benefits outweigh the risks.", "es": "En los pacientes considerados de alto riesgo, el tratamiento con TYSABRI únicamente debe mantenerse si los beneficios son mayores que los riesgos." } }
{ "translation": { "text": "Glossary:\n\"nevirapine\" -> \"nevirapina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Dosing of nevirapine at 150 mg/m2 BID (after a two-week lead in at 150 mg/m2 QD) produced geometric mean or mean trough nevirapine concentrations between 4-6 μg/ml (as targeted from adult data).\nSpanish: cada día) produjo concentraciones medias geométricas o concentraciones valle medias de nevirapina de 4-6 microgramos/ml (como se había previsto a partir de los datos en adultos).", "en_prompt": "<|im_start|>user\nGlossary:\n\"nevirapine\" -> \"nevirapina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Dosing of nevirapine at 150 mg/m2 BID (after a two-week lead in at 150 mg/m2 QD) produced geometric mean or mean trough nevirapine concentrations between 4-6 μg/ml (as targeted from adult data).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "nevirapine|||nevirapina", "en": "Dosing of nevirapine at 150 mg/m2 BID (after a two-week lead in at 150 mg/m2 QD) produced geometric mean or mean trough nevirapine concentrations between 4-6 μg/ml (as targeted from adult data).", "es": "cada día) produjo concentraciones medias geométricas o concentraciones valle medias de nevirapina de 4-6 microgramos/ml (como se había previsto a partir de los datos en adultos)." } }
{ "translation": { "text": "Glossaries:\n\"efficacy\" -> \"eficacia\"\n\"indication\" -> \"indicación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The CHMP accepted that some evidence of efficacy in this indication has been provided, mainly by the study by Tsakalakos et al.\nSpanish: El CHMP aceptó que se han aportado algunas pruebas sobre la eficacia en esta indicación, principalmente en el estudio de Tsakalakos et al.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"efficacy\" -> \"eficacia\"\n\"indication\" -> \"indicación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The CHMP accepted that some evidence of efficacy in this indication has been provided, mainly by the study by Tsakalakos et al.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "efficacy|||eficacia\tindication|||indicación", "en": "The CHMP accepted that some evidence of efficacy in this indication has been provided, mainly by the study by Tsakalakos et al.", "es": "El CHMP aceptó que se han aportado algunas pruebas sobre la eficacia en esta indicación, principalmente en el estudio de Tsakalakos et al." } }
{ "translation": { "text": "Glossary:\n\"activity\" -> \"actividad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Atorvastatin produces a profound and sustained increase in LDL receptor activity coupled with a beneficial change in the quality of circulating LDL particles.\nSpanish: Atorvastatina produce un profundo y sostenido aumento en la actividad de los receptores para la LDL, junto con una modificación beneficiosa en la calidad de las LDL circulantes.", "en_prompt": "<|im_start|>user\nGlossary:\n\"activity\" -> \"actividad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Atorvastatin produces a profound and sustained increase in LDL receptor activity coupled with a beneficial change in the quality of circulating LDL particles.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "activity|||actividad", "en": "Atorvastatin produces a profound and sustained increase in LDL receptor activity coupled with a beneficial change in the quality of circulating LDL particles.", "es": "Atorvastatina produce un profundo y sostenido aumento en la actividad de los receptores para la LDL, junto con una modificación beneficiosa en la calidad de las LDL circulantes." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"weight\" -> \"peso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The dose should be recalculated every 3 months based on changes in body weight, or more often if necessary.\nSpanish: La dosis se debe volver a calcular cada 3 meses en función de los cambios en el peso corporal, o más a menudo si es necesario.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"weight\" -> \"peso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The dose should be recalculated every 3 months based on changes in body weight, or more often if necessary.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tweight|||peso", "en": "The dose should be recalculated every 3 months based on changes in body weight, or more often if necessary.", "es": "La dosis se debe volver a calcular cada 3 meses en función de los cambios en el peso corporal, o más a menudo si es necesario." } }
{ "translation": { "text": "Glossaries:\n\"fenofibrate\" -> \"fenofibrato\"\n\"dose\" -> \"dosis\"\n\"acid\" -> \"ácido\"\n\"simvastatin\" -> \"simvastatina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In one study the AUC of the simvastatin acid (SVA), a major active metabolite of simvastatin, was reduced by 42% (90% CI 24%-56%) when a single dose of 40 mg simvastatin was combined with repeated administration of fenofibrate 160 mg.\nSpanish: En un estudio la AUC del ácido de simvastatina (SVA), un metabolito activo principal de la simvastatina, se redujo en un 42% (90% CI 24%-56%) cuando se combinó una única dosis de simvastatina 40 mg con la administración repetida de fenofibrato 160 mg.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"fenofibrate\" -> \"fenofibrato\"\n\"dose\" -> \"dosis\"\n\"acid\" -> \"ácido\"\n\"simvastatin\" -> \"simvastatina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In one study the AUC of the simvastatin acid (SVA), a major active metabolite of simvastatin, was reduced by 42% (90% CI 24%-56%) when a single dose of 40 mg simvastatin was combined with repeated administration of fenofibrate 160 mg.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "fenofibrate|||fenofibrato\tdose|||dosis\tacid|||ácido\tsimvastatin|||simvastatina", "en": "In one study the AUC of the simvastatin acid (SVA), a major active metabolite of simvastatin, was reduced by 42% (90% CI 24%-56%) when a single dose of 40 mg simvastatin was combined with repeated administration of fenofibrate 160 mg.", "es": "En un estudio la AUC del ácido de simvastatina (SVA), un metabolito activo principal de la simvastatina, se redujo en un 42% (90% CI 24%-56%) cuando se combinó una única dosis de simvastatina 40 mg con la administración repetida de fenofibrato 160 mg." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"daptomycin\" -> \"daptomicina\"\n\"pharmacokinetics\" -> \"farmacocinética\"\n\"infusion\" -> \"perfusión\"\n\"tobramycin\" -> \"tobramicina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Although small changes in the pharmacokinetics of daptomycin and tobramycin were observed during coadministration by intravenous infusion over a 30-minute period using a daptomycin dose of 2 mg/kg, the changes were not statistically significant.\nSpanish: Aunque se observaron pequeños cambios en la farmacocinética de daptomicina y tobramicina durante la administración concomitante por perfusión intravenosa durante un período de 30 minutos utilizando una dosis de daptomicina de 2 mg/kg, los cambios no fueron estadísticamente significativos.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"daptomycin\" -> \"daptomicina\"\n\"pharmacokinetics\" -> \"farmacocinética\"\n\"infusion\" -> \"perfusión\"\n\"tobramycin\" -> \"tobramicina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Although small changes in the pharmacokinetics of daptomycin and tobramycin were observed during coadministration by intravenous infusion over a 30-minute period using a daptomycin dose of 2 mg/kg, the changes were not statistically significant.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tdaptomycin|||daptomicina\tpharmacokinetics|||farmacocinética\tinfusion|||perfusión\ttobramycin|||tobramicina", "en": "Although small changes in the pharmacokinetics of daptomycin and tobramycin were observed during coadministration by intravenous infusion over a 30-minute period using a daptomycin dose of 2 mg/kg, the changes were not statistically significant.", "es": "Aunque se observaron pequeños cambios en la farmacocinética de daptomicina y tobramicina durante la administración concomitante por perfusión intravenosa durante un período de 30 minutos utilizando una dosis de daptomicina de 2 mg/kg, los cambios no fueron estadísticamente significativos." } }
{ "translation": { "text": "Glossaries:\n\"agent\" -> \"agente\"\n\"antibacterial agent\" -> \"antibacteriano\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Doripenem is a synthetic carbapenem antibacterial agent.\nSpanish: Mecanismo de acción El doripenem es un agente antibacteriano derivado sintético del carbapenem.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"agent\" -> \"agente\"\n\"antibacterial agent\" -> \"antibacteriano\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Doripenem is a synthetic carbapenem antibacterial agent.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "agent|||agente\tantibacterial agent|||antibacteriano", "en": "Doripenem is a synthetic carbapenem antibacterial agent.", "es": "Mecanismo de acción El doripenem es un agente antibacteriano derivado sintético del carbapenem." } }
{ "translation": { "text": "Glossary:\n\"toxicity\" -> \"toxicidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Reproductive and developmental toxicity studies have not been conducted with niraparib.\nSpanish: No se han hecho estudios de toxicidad para la reproducción y para el desarrollo con el niraparib.", "en_prompt": "<|im_start|>user\nGlossary:\n\"toxicity\" -> \"toxicidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Reproductive and developmental toxicity studies have not been conducted with niraparib.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "toxicity|||toxicidad", "en": "Reproductive and developmental toxicity studies have not been conducted with niraparib.", "es": "No se han hecho estudios de toxicidad para la reproducción y para el desarrollo con el niraparib." } }
{ "translation": { "text": "Glossaries:\n\"efficacy\" -> \"eficacia\"\n\"safety\" -> \"seguridad\"\n\"randomised\" -> \"aleatorizado\"\n\"oedema\" -> \"edema\"\n\"double\" -> \"doble\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The safety and efficacy of Eylea were assessed in a randomised, multi-centre, double-masked, activecontrolled study in patients with macular oedema secondary to BRVO (VIBRANT) which included Hemi-Retinal Vein Occlusion.\nSpanish: Se evaluó la seguridad y eficacia de Eylea en un estudio aleatorizado, multicéntrico, doble ciego y controlado con tratamiento activo en pacientes con edema macular secundario a ORVR (VIBRANT), que incluye oclusión venosa hemirretiniana.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"efficacy\" -> \"eficacia\"\n\"safety\" -> \"seguridad\"\n\"randomised\" -> \"aleatorizado\"\n\"oedema\" -> \"edema\"\n\"double\" -> \"doble\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The safety and efficacy of Eylea were assessed in a randomised, multi-centre, double-masked, activecontrolled study in patients with macular oedema secondary to BRVO (VIBRANT) which included Hemi-Retinal Vein Occlusion.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "efficacy|||eficacia\tsafety|||seguridad\trandomised|||aleatorizado\toedema|||edema\tdouble|||doble", "en": "The safety and efficacy of Eylea were assessed in a randomised, multi-centre, double-masked, activecontrolled study in patients with macular oedema secondary to BRVO (VIBRANT) which included Hemi-Retinal Vein Occlusion.", "es": "Se evaluó la seguridad y eficacia de Eylea en un estudio aleatorizado, multicéntrico, doble ciego y controlado con tratamiento activo en pacientes con edema macular secundario a ORVR (VIBRANT), que incluye oclusión venosa hemirretiniana." } }
{ "translation": { "text": "Glossaries:\n\"safety\" -> \"seguridad\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The safety population consisted of 168 patients in the Remsima subcutaneous group and 175 patients in the Remsima intravenous group.\nSpanish: La población de seguridad constaba de 168 pacientes en el grupo de Remsima subcutáneo y 175 pacientes en el grupo de Remsima intravenoso.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"safety\" -> \"seguridad\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The safety population consisted of 168 patients in the Remsima subcutaneous group and 175 patients in the Remsima intravenous group.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "safety|||seguridad\tpopulation|||población", "en": "The safety population consisted of 168 patients in the Remsima subcutaneous group and 175 patients in the Remsima intravenous group.", "es": "La población de seguridad constaba de 168 pacientes en el grupo de Remsima subcutáneo y 175 pacientes en el grupo de Remsima intravenoso." } }
{ "translation": { "text": "Glossary:\n\"contact\" -> \"contacto\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: People who are hypersensitive (allergic) to iron compounds or toltrazuril should avoid contact with Baycox Iron.\nSpanish: Las personas hipersensibles (alérgicas) a los compuestos de hierro deben evitar el contacto con Baycox Iron.", "en_prompt": "<|im_start|>user\nGlossary:\n\"contact\" -> \"contacto\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: People who are hypersensitive (allergic) to iron compounds or toltrazuril should avoid contact with Baycox Iron.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "contact|||contacto", "en": "People who are hypersensitive (allergic) to iron compounds or toltrazuril should avoid contact with Baycox Iron.", "es": "Las personas hipersensibles (alérgicas) a los compuestos de hierro deben evitar el contacto con Baycox Iron." } }
{ "translation": { "text": "Glossary:\n\"absence\" -> \"ausencia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Elevations in LFTs may develop in the absence of clinical symptoms.\nSpanish: Se pueden presentar elevaciones de las PFH en ausencia de síntomas clínicos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"absence\" -> \"ausencia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Elevations in LFTs may develop in the absence of clinical symptoms.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "absence|||ausencia", "en": "Elevations in LFTs may develop in the absence of clinical symptoms.", "es": "Se pueden presentar elevaciones de las PFH en ausencia de síntomas clínicos." } }
{ "translation": { "text": "Glossaries:\n\"fluorouracil\" -> \"fluorouracilo\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 5-fluorouracil IV bolus/infusion, each on days 1 and 2\nSpanish: Leucovorina los días 1 y 2 5-fluorouracilo IV en bolo/perfusión, cada uno los días 1 y 2", "en_prompt": "<|im_start|>user\nGlossaries:\n\"fluorouracil\" -> \"fluorouracilo\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 5-fluorouracil IV bolus/infusion, each on days 1 and 2\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "fluorouracil|||fluorouracilo\tinfusion|||perfusión", "en": "5-fluorouracil IV bolus/infusion, each on days 1 and 2", "es": "Leucovorina los días 1 y 2 5-fluorouracilo IV en bolo/perfusión, cada uno los días 1 y 2" } }
{ "translation": { "text": "Glossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Each ml of the diluted solution contains approximately 3.5 mg of sodium (sodium chloride 9 mg/ml (0.9 %) solution for injection), 0.64 mg sodium (5 % glucose solution for injection) or 3.2 mg sodium (Lactated Ringers solution for injection).\nSpanish: Cada ml de la solución diluida contiene aproximadamente 3,5 mg de sodio (9 mg/ml de cloruro sódico solución para inyección (0,9 %)), 0,64 mg de sodio (5 % solución de glucosa inyectable) o 3,2 mg de sodio (solución inyectable Ringer lactato).", "en_prompt": "<|im_start|>user\nGlossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Each ml of the diluted solution contains approximately 3.5 mg of sodium (sodium chloride 9 mg/ml (0.9 %) solution for injection), 0.64 mg sodium (5 % glucose solution for injection) or 3.2 mg sodium (Lactated Ringers solution for injection).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injection|||inyección", "en": "Each ml of the diluted solution contains approximately 3.5 mg of sodium (sodium chloride 9 mg/ml (0.9 %) solution for injection), 0.64 mg sodium (5 % glucose solution for injection) or 3.2 mg sodium (Lactated Ringers solution for injection).", "es": "Cada ml de la solución diluida contiene aproximadamente 3,5 mg de sodio (9 mg/ml de cloruro sódico solución para inyección (0,9 %)), 0,64 mg de sodio (5 % solución de glucosa inyectable) o 3,2 mg de sodio (solución inyectable Ringer lactato)." } }
{ "translation": { "text": "Glossary:\n\"holder\" -> \"titular\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The marketing authorisation holder is Glaxo Group Ltd.\nSpanish: El titular de la Autorización de Comercialización es Glaxo Group Ltd.", "en_prompt": "<|im_start|>user\nGlossary:\n\"holder\" -> \"titular\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The marketing authorisation holder is Glaxo Group Ltd.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "holder|||titular", "en": "The marketing authorisation holder is Glaxo Group Ltd.", "es": "El titular de la Autorización de Comercialización es Glaxo Group Ltd." } }
{ "translation": { "text": "Glossary:\n\"disease\" -> \"enfermedad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A reduction in risk of objective disease progression was seen across most patient groups but was most evident in those at highest risk of disease progression.\nSpanish: En la mayoría de los subgrupos de pacientes se observó una disminución en el riesgo de progresión objetiva de la enfermedad, pero fue más evidente en aquellos con mayor riesgo de progresión de la enfermedad.", "en_prompt": "<|im_start|>user\nGlossary:\n\"disease\" -> \"enfermedad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A reduction in risk of objective disease progression was seen across most patient groups but was most evident in those at highest risk of disease progression.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||enfermedad", "en": "A reduction in risk of objective disease progression was seen across most patient groups but was most evident in those at highest risk of disease progression.", "es": "En la mayoría de los subgrupos de pacientes se observó una disminución en el riesgo de progresión objetiva de la enfermedad, pero fue más evidente en aquellos con mayor riesgo de progresión de la enfermedad." } }
{ "translation": { "text": "Glossaries:\n\"carbamazepine\" -> \"carbamazepina\"\n\"exposure\" -> \"exposición\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No change in exposure to carbamazepine or its metabolite carbamazepine-epoxide was noted.\nSpanish: No se observó ningún cambio en la exposición a la carbamazepina ni a su metabolito, el epóxido de carbamazepina.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"carbamazepine\" -> \"carbamazepina\"\n\"exposure\" -> \"exposición\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: No change in exposure to carbamazepine or its metabolite carbamazepine-epoxide was noted.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "carbamazepine|||carbamazepina\texposure|||exposición", "en": "No change in exposure to carbamazepine or its metabolite carbamazepine-epoxide was noted.", "es": "No se observó ningún cambio en la exposición a la carbamazepina ni a su metabolito, el epóxido de carbamazepina." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • An oral syringe is provided with Jylamvo and it is important that only this syringe is used to withdraw the dose.\nSpanish: • Jylamvo se proporciona con una jeringa para uso oral y es importante limitarse a utilizar esta jeringa para extraer la dosis.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • An oral syringe is provided with Jylamvo and it is important that only this syringe is used to withdraw the dose.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tsyringe|||jeringa", "en": "• An oral syringe is provided with Jylamvo and it is important that only this syringe is used to withdraw the dose.", "es": "• Jylamvo se proporciona con una jeringa para uso oral y es importante limitarse a utilizar esta jeringa para extraer la dosis." } }
{ "translation": { "text": "Glossary:\n\"saquinavir\" -> \"saquinavir\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Also included are serious and non-serious adverse reactions from post-marketing spontaneous reports for which a causal relationship to saquinavir cannot be excluded.\nSpanish: También se incluyen reacciones adversas graves y no graves obtenidas de notificaciones espontáneas en la fase de post-comercialización, para las cuales no se puede excluir una relación causal con saquinavir.", "en_prompt": "<|im_start|>user\nGlossary:\n\"saquinavir\" -> \"saquinavir\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Also included are serious and non-serious adverse reactions from post-marketing spontaneous reports for which a causal relationship to saquinavir cannot be excluded.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "saquinavir|||saquinavir", "en": "Also included are serious and non-serious adverse reactions from post-marketing spontaneous reports for which a causal relationship to saquinavir cannot be excluded.", "es": "También se incluyen reacciones adversas graves y no graves obtenidas de notificaciones espontáneas en la fase de post-comercialización, para las cuales no se puede excluir una relación causal con saquinavir." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the treatment of hypercalcaemia caused by tumours, Bondronat is given over 2 hours as an infusion of either 2 or 4 mg, depending on how severe the hypercalcaemia is.\nSpanish: En el tratamiento de la hipercalcemia provocada por tumores, Bondronat se administra durante 2 horas en forma de perfusión de 2 o 4 mg, dependiendo de la gravedad de la hipercalcemia.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the treatment of hypercalcaemia caused by tumours, Bondronat is given over 2 hours as an infusion of either 2 or 4 mg, depending on how severe the hypercalcaemia is.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tinfusion|||perfusión", "en": "In the treatment of hypercalcaemia caused by tumours, Bondronat is given over 2 hours as an infusion of either 2 or 4 mg, depending on how severe the hypercalcaemia is.", "es": "En el tratamiento de la hipercalcemia provocada por tumores, Bondronat se administra durante 2 horas en forma de perfusión de 2 o 4 mg, dependiendo de la gravedad de la hipercalcemia." } }
{ "translation": { "text": "Glossaries:\n\"inhibition\" -> \"inhibición\"\n\"growth\" -> \"crecimiento\"\n\"factor\" -> \"factor\"\n\"vascular\" -> \"vascular\"\n\"inhibitor\" -> \"inhibidores\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the clinical trial, the overall frequency of non-ocular haemorrhages, an adverse event potentially related to systemic VEGF (vascular endothelial growth factor) inhibition, was slightly increased in intravitreal VEGF inhibitor-treated patients.\nSpanish: En el estudio clínico, la frecuencia general de las hemorragias no oculares, un potencial efecto adverso relacionado con la inhibición sistémica de VEGF (factor del crecimiento endotelial vascular), aumentó ligeramente en los pacientes tratados con inhibidores de VEGF intravítreo.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"inhibition\" -> \"inhibición\"\n\"growth\" -> \"crecimiento\"\n\"factor\" -> \"factor\"\n\"vascular\" -> \"vascular\"\n\"inhibitor\" -> \"inhibidores\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the clinical trial, the overall frequency of non-ocular haemorrhages, an adverse event potentially related to systemic VEGF (vascular endothelial growth factor) inhibition, was slightly increased in intravitreal VEGF inhibitor-treated patients.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "inhibition|||inhibición\tgrowth|||crecimiento\tfactor|||factor\tvascular|||vascular\tinhibitor|||inhibidores", "en": "In the clinical trial, the overall frequency of non-ocular haemorrhages, an adverse event potentially related to systemic VEGF (vascular endothelial growth factor) inhibition, was slightly increased in intravitreal VEGF inhibitor-treated patients.", "es": "En el estudio clínico, la frecuencia general de las hemorragias no oculares, un potencial efecto adverso relacionado con la inhibición sistémica de VEGF (factor del crecimiento endotelial vascular), aumentó ligeramente en los pacientes tratados con inhibidores de VEGF intravítreo." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\n\"concomitant\" -> \"concomitante\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: However if your doctor does prescribe Effentora together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor.\nSpanish: No obstante, si su médico le prescribe Effentora con medicamentos sedantes, la dosis y la duración del tratamiento concomitante deben ser limitadas por su médico.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\n\"concomitant\" -> \"concomitante\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: However if your doctor does prescribe Effentora together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tdose|||dosis\tdoctor|||médico\tconcomitant|||concomitante", "en": "However if your doctor does prescribe Effentora together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor.", "es": "No obstante, si su médico le prescribe Effentora con medicamentos sedantes, la dosis y la duración del tratamiento concomitante deben ser limitadas por su médico." } }
{ "translation": { "text": "Glossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not touch the syringe tip under the syringe cap.\nSpanish: No toque la punta de la jeringa bajo el capuchón de jeringa.", "en_prompt": "<|im_start|>user\nGlossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Do not touch the syringe tip under the syringe cap.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "syringe|||jeringa", "en": "Do not touch the syringe tip under the syringe cap.", "es": "No toque la punta de la jeringa bajo el capuchón de jeringa." } }
{ "translation": { "text": "Glossaries:\n\"antiretroviral\" -> \"antirretroviral\"\n\"efficacy\" -> \"eficacia\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Although study 542 showed no statistically significant differences between the two regimens in efficacy in a predominantly antiretroviral naïve patient population, the significance of these findings for antiretroviral experienced patients is unknown.\nSpanish: Aunque el ensayo 542 no mostró diferencias significativas de eficacia entre los dos regímenes en una población de pacientes predominantemente naïve a la terapia antirretroviral, se desconoce el significado de estos hallazgos para los pacientes que hayan recibido tratamiento antirretroviral previo.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"antiretroviral\" -> \"antirretroviral\"\n\"efficacy\" -> \"eficacia\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Although study 542 showed no statistically significant differences between the two regimens in efficacy in a predominantly antiretroviral naïve patient population, the significance of these findings for antiretroviral experienced patients is unknown.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "antiretroviral|||antirretroviral\tefficacy|||eficacia\tpopulation|||población", "en": "Although study 542 showed no statistically significant differences between the two regimens in efficacy in a predominantly antiretroviral naïve patient population, the significance of these findings for antiretroviral experienced patients is unknown.", "es": "Aunque el ensayo 542 no mostró diferencias significativas de eficacia entre los dos regímenes en una población de pacientes predominantemente naïve a la terapia antirretroviral, se desconoce el significado de estos hallazgos para los pacientes que hayan recibido tratamiento antirretroviral previo." } }
{ "translation": { "text": "Glossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 3.2 Hold the vial adapter, insert the syringe tip into it and screw to connect.\nSpanish: 3.2 Sostenga el adaptador del vial firmemente, inserte la punta de la jeringa en el adaptador del vial y enrósquela para conectarla.", "en_prompt": "<|im_start|>user\nGlossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: 3.2 Hold the vial adapter, insert the syringe tip into it and screw to connect.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "syringe|||jeringa", "en": "3.2 Hold the vial adapter, insert the syringe tip into it and screw to connect.", "es": "3.2 Sostenga el adaptador del vial firmemente, inserte la punta de la jeringa en el adaptador del vial y enrósquela para conectarla." } }
{ "translation": { "text": "Glossaries:\n\"insulin\" -> \"insulina\"\n\"suspension\" -> \"suspensión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Each cartridge contains 300 IU of human insulin in 3 ml suspension for injection.\nSpanish: Cada cartucho contiene 300 UI de insulina humana en 3 ml de suspensión inyectable.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"insulin\" -> \"insulina\"\n\"suspension\" -> \"suspensión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Each cartridge contains 300 IU of human insulin in 3 ml suspension for injection.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "insulin|||insulina\tsuspension|||suspensión", "en": "Each cartridge contains 300 IU of human insulin in 3 ml suspension for injection.", "es": "Cada cartucho contiene 300 UI de insulina humana en 3 ml de suspensión inyectable." } }
{ "translation": { "text": "Glossaries:\n\"inflammation\" -> \"inflamación\"\n\"kidney\" -> \"riñón\"\n\"urine\" -> \"orina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • inflammation of the kidney, passing a lot of urine and feeling thirsty,\nSpanish: • inflamación del riñón, aumento del volumen de orina y sensación de sed,", "en_prompt": "<|im_start|>user\nGlossaries:\n\"inflammation\" -> \"inflamación\"\n\"kidney\" -> \"riñón\"\n\"urine\" -> \"orina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • inflammation of the kidney, passing a lot of urine and feeling thirsty,\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "inflammation|||inflamación\tkidney|||riñón\turine|||orina", "en": "• inflammation of the kidney, passing a lot of urine and feeling thirsty,", "es": "• inflamación del riñón, aumento del volumen de orina y sensación de sed," } }
{ "translation": { "text": "Glossaries:\n\"agent\" -> \"agente\"\n\"antiretroviral\" -> \"antirretroviral\"\n\"antiretroviral agent\" -> \"antirretroviral\"\n\"atovaquone\" -> \"atovacuona\"\n\"decrease\" -> \"descenso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent induces glucuronidation and as a result is expected to decrease the plasma concentrations of atovaquone.\nSpanish: Ritonavir dosificado como potenciador farmacocinético o como agente antirretroviral induce la glucuronidación y como resultado se espera un descenso de las concentraciones plasmáticas de atovacuona.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"agent\" -> \"agente\"\n\"antiretroviral\" -> \"antirretroviral\"\n\"antiretroviral agent\" -> \"antirretroviral\"\n\"atovaquone\" -> \"atovacuona\"\n\"decrease\" -> \"descenso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent induces glucuronidation and as a result is expected to decrease the plasma concentrations of atovaquone.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "agent|||agente\tantiretroviral|||antirretroviral\tantiretroviral agent|||antirretroviral\tatovaquone|||atovacuona\tdecrease|||descenso", "en": "Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent induces glucuronidation and as a result is expected to decrease the plasma concentrations of atovaquone.", "es": "Ritonavir dosificado como potenciador farmacocinético o como agente antirretroviral induce la glucuronidación y como resultado se espera un descenso de las concentraciones plasmáticas de atovacuona." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"urinary bladder\" -> \"vejiga urinaria\"\n\"bladder\" -> \"vejiga\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It did not reveal any test item-related lesions in any of the examined organs, in particular in the urinary bladder, in both the single-dose and the repeat-dose studies.\nSpanish: No se observó ninguna lesión asociada al estudio en ninguno de los órganos examinados, especialmente en la vejiga urinaria, tanto para el estudio de dosis única como de dosis repetida.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"urinary bladder\" -> \"vejiga urinaria\"\n\"bladder\" -> \"vejiga\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It did not reveal any test item-related lesions in any of the examined organs, in particular in the urinary bladder, in both the single-dose and the repeat-dose studies.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\turinary bladder|||vejiga urinaria\tbladder|||vejiga", "en": "It did not reveal any test item-related lesions in any of the examined organs, in particular in the urinary bladder, in both the single-dose and the repeat-dose studies.", "es": "No se observó ninguna lesión asociada al estudio en ninguno de los órganos examinados, especialmente en la vejiga urinaria, tanto para el estudio de dosis única como de dosis repetida." } }
{ "translation": { "text": "Glossaries:\n\"bladder\" -> \"vejiga\"\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The most common side effects with Lifmior (seen in more than 1 patient in 10) are injection site reactions (including bleeding, bruising, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections).\nSpanish: Los efectos adversos más frecuentes de Lifmior (observados en más de 1 de cada 10 pacientes) son reacciones en el lugar de la inyección (sangrados, hematomas, enrojecimiento, picor, dolor e hinchazón) e infecciones (resfriados e infecciones pulmonares, de la vejiga y de la piel).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"bladder\" -> \"vejiga\"\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The most common side effects with Lifmior (seen in more than 1 patient in 10) are injection site reactions (including bleeding, bruising, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "bladder|||vejiga\tinjection|||inyección", "en": "The most common side effects with Lifmior (seen in more than 1 patient in 10) are injection site reactions (including bleeding, bruising, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections).", "es": "Los efectos adversos más frecuentes de Lifmior (observados en más de 1 de cada 10 pacientes) son reacciones en el lugar de la inyección (sangrados, hematomas, enrojecimiento, picor, dolor e hinchazón) e infecciones (resfriados e infecciones pulmonares, de la vejiga y de la piel)." } }
{ "translation": { "text": "Glossaries:\n\"tachycardia\" -> \"taquicardia\"\n\"syncope\" -> \"síncope\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Common ( ≥ 1/100 to < 1/10): Bradycardia with or without hypotension or syncope, tachycardia.\nSpanish: Frecuentes (≥1/100 a <1/10): bradicardia con o sin hipotensión o síncope, taquicardia.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"tachycardia\" -> \"taquicardia\"\n\"syncope\" -> \"síncope\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Common ( ≥ 1/100 to < 1/10): Bradycardia with or without hypotension or syncope, tachycardia.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "tachycardia|||taquicardia\tsyncope|||síncope", "en": "Common ( ≥ 1/100 to < 1/10): Bradycardia with or without hypotension or syncope, tachycardia.", "es": "Frecuentes (≥1/100 a <1/10): bradicardia con o sin hipotensión o síncope, taquicardia." } }
{ "translation": { "text": "Glossary:\n\"cancer\" -> \"cáncer\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: As expected, the risk of cancer increases when excluding the four studies with no events.\nSpanish: Como cabía esperar, el riesgo de cáncer aumenta cuando se excluyen los cuatro estudios sin acontecimientos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"cancer\" -> \"cáncer\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: As expected, the risk of cancer increases when excluding the four studies with no events.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "cancer|||cáncer", "en": "As expected, the risk of cancer increases when excluding the four studies with no events.", "es": "Como cabía esperar, el riesgo de cáncer aumenta cuando se excluyen los cuatro estudios sin acontecimientos." } }
{ "translation": { "text": "Glossary:\n\"S\" -> \"S\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: MARKETING AUTHORISATION NUMBER(S) EU/1/12/770/004\nSpanish: NÚMERO(S) DE AUTORIZACIÓN DE COMERCIALIZACIÓN EU/1/12/770/004", "en_prompt": "<|im_start|>user\nGlossary:\n\"S\" -> \"S\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: MARKETING AUTHORISATION NUMBER(S) EU/1/12/770/004\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "S|||S", "en": "MARKETING AUTHORISATION NUMBER(S) EU/1/12/770/004", "es": "NÚMERO(S) DE AUTORIZACIÓN DE COMERCIALIZACIÓN EU/1/12/770/004" } }
{ "translation": { "text": "Glossaries:\n\"lacrimal\" -> \"lagrimal\"\n\"vision\" -> \"visión\"\n\"discharge\" -> \"secreción\"\n\"disorder\" -> \"trastorno\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • eye discharge, blurred vision, lacrimal disorder\nSpanish: • secreción ocular, visión borrosa, trastorno lagrimal", "en_prompt": "<|im_start|>user\nGlossaries:\n\"lacrimal\" -> \"lagrimal\"\n\"vision\" -> \"visión\"\n\"discharge\" -> \"secreción\"\n\"disorder\" -> \"trastorno\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • eye discharge, blurred vision, lacrimal disorder\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "lacrimal|||lagrimal\tvision|||visión\tdischarge|||secreción\tdisorder|||trastorno", "en": "• eye discharge, blurred vision, lacrimal disorder", "es": "• secreción ocular, visión borrosa, trastorno lagrimal" } }
{ "translation": { "text": "Glossary:\n\"powder\" -> \"polvo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Eperzan 30 mg powder and solvent for solution for injection Eperzan 50 mg powder and solvent for solution for injection\nSpanish: Eperzan 30 mg polvo y disolvente para solución inyectable Eperzan 50 mg polvo y disolvente para solución inyectable", "en_prompt": "<|im_start|>user\nGlossary:\n\"powder\" -> \"polvo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Eperzan 30 mg powder and solvent for solution for injection Eperzan 50 mg powder and solvent for solution for injection\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "powder|||polvo", "en": "Eperzan 30 mg powder and solvent for solution for injection Eperzan 50 mg powder and solvent for solution for injection", "es": "Eperzan 30 mg polvo y disolvente para solución inyectable Eperzan 50 mg polvo y disolvente para solución inyectable" } }
{ "translation": { "text": "Glossaries:\n\"interferon\" -> \"interferón\"\n\"interferon alfa\" -> \"interferón alfa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Usual dosage to be used with interferon alfa-2b or peginterferon alfa-2b in children above 3 years of age and adolescents\nSpanish: Dosis habitual para ser utilizada con interferón alfa-2b o peginterferón alfa-2b en niños a partir de 3 años de edad y en adolescentes", "en_prompt": "<|im_start|>user\nGlossaries:\n\"interferon\" -> \"interferón\"\n\"interferon alfa\" -> \"interferón alfa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Usual dosage to be used with interferon alfa-2b or peginterferon alfa-2b in children above 3 years of age and adolescents\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "interferon|||interferón\tinterferon alfa|||interferón alfa", "en": "Usual dosage to be used with interferon alfa-2b or peginterferon alfa-2b in children above 3 years of age and adolescents", "es": "Dosis habitual para ser utilizada con interferón alfa-2b o peginterferón alfa-2b en niños a partir de 3 años de edad y en adolescentes" } }
{ "translation": { "text": "Glossaries:\n\"weight\" -> \"peso\"\n\"expected\" -> \"esperado\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It is estimated that approximately half of the mean improvement in HbA1c in patients receiving rimonabant 20 mg was beyond that expected from weight loss alone.\nSpanish: Se estima que aproximadamente la mitad de las medias de la mejora en la HbA1c en pacientes que recibieron rimonabant 20 mg fue más allá de lo esperado en cuanto a pérdida sólo de peso.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"weight\" -> \"peso\"\n\"expected\" -> \"esperado\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It is estimated that approximately half of the mean improvement in HbA1c in patients receiving rimonabant 20 mg was beyond that expected from weight loss alone.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "weight|||peso\texpected|||esperado", "en": "It is estimated that approximately half of the mean improvement in HbA1c in patients receiving rimonabant 20 mg was beyond that expected from weight loss alone.", "es": "Se estima que aproximadamente la mitad de las medias de la mejora en la HbA1c en pacientes que recibieron rimonabant 20 mg fue más allá de lo esperado en cuanto a pérdida sólo de peso." } }
{ "translation": { "text": "Glossary:\n\"HBV\" -> \"VHB\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Of the 10 patients who were not HBV suppressed at baseline (HBV DNA ≥ 29 IU/mL), 7 became suppressed, 2 remained detectable, and 1 had missing data.\nSpanish: De los 10 pacientes que no presentaron supresión del VHB en el momento basal (ADN del VHB ≥ 29 UI/ml), 7 pacientes lograron supresión, el ADN del VHB se mantuvo detectable en 2 pacientes y hubo ausencia de datos en 1 paciente.", "en_prompt": "<|im_start|>user\nGlossary:\n\"HBV\" -> \"VHB\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Of the 10 patients who were not HBV suppressed at baseline (HBV DNA ≥ 29 IU/mL), 7 became suppressed, 2 remained detectable, and 1 had missing data.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "HBV|||VHB", "en": "Of the 10 patients who were not HBV suppressed at baseline (HBV DNA ≥ 29 IU/mL), 7 became suppressed, 2 remained detectable, and 1 had missing data.", "es": "De los 10 pacientes que no presentaron supresión del VHB en el momento basal (ADN del VHB ≥ 29 UI/ml), 7 pacientes lograron supresión, el ADN del VHB se mantuvo detectable en 2 pacientes y hubo ausencia de datos en 1 paciente." } }
{ "translation": { "text": "Glossaries:\n\"exposure\" -> \"exposición\"\n\"prevention\" -> \"prevención\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A pregnancy prevention programme will be implemented accordingly to prevent valproate exposure during pregnancy given that significant risk of lifelong harm is associated with its use.\nSpanish: Se aplicará un programa de prevención del embarazo según corresponda para evitar la exposición al valproato durante la gestación, ya que su uso se asocia a un riesgo considerable de sufrir daños de por vida.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"exposure\" -> \"exposición\"\n\"prevention\" -> \"prevención\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A pregnancy prevention programme will be implemented accordingly to prevent valproate exposure during pregnancy given that significant risk of lifelong harm is associated with its use.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||exposición\tprevention|||prevención", "en": "A pregnancy prevention programme will be implemented accordingly to prevent valproate exposure during pregnancy given that significant risk of lifelong harm is associated with its use.", "es": "Se aplicará un programa de prevención del embarazo según corresponda para evitar la exposición al valproato durante la gestación, ya que su uso se asocia a un riesgo considerable de sufrir daños de por vida." } }
{ "translation": { "text": "Glossary:\n\"efficacy\" -> \"eficacia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Secondary efficacy endpoints were all consistent with the primary endpoint and no difference was detected for OS between patients treated with erlotinib 300 mg and 150 mg daily (HR 1.03, 95% CI 0.80 to 1.32).\nSpanish: Todos los objetivos de eficacia secundarios fueron consistentes con los primarios y no hubo diferencias en la SG de los pacientes tratados con erlotinib 300 mg y 150 mg diarios (HR 1.03, 95% CI 0.80 to 1.32) Los datos de seguridad fueron comparables entre las dosis de 300 mg y 150 mg, sin embargo hubo un amento numérico en la incidencia de rash, enfermedad pulmonar intersticial y diarrea en pacientes que recibieron la dosis alta de erlotinib.", "en_prompt": "<|im_start|>user\nGlossary:\n\"efficacy\" -> \"eficacia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Secondary efficacy endpoints were all consistent with the primary endpoint and no difference was detected for OS between patients treated with erlotinib 300 mg and 150 mg daily (HR 1.03, 95% CI 0.80 to 1.32).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "efficacy|||eficacia", "en": "Secondary efficacy endpoints were all consistent with the primary endpoint and no difference was detected for OS between patients treated with erlotinib 300 mg and 150 mg daily (HR 1.03, 95% CI 0.80 to 1.32).", "es": "Todos los objetivos de eficacia secundarios fueron consistentes con los primarios y no hubo diferencias en la SG de los pacientes tratados con erlotinib 300 mg y 150 mg diarios (HR 1.03, 95% CI 0.80 to 1.32) Los datos de seguridad fueron comparables entre las dosis de 300 mg y 150 mg, sin embargo hubo un amento numérico en la incidencia de rash, enfermedad pulmonar intersticial y diarrea en pacientes que recibieron la dosis alta de erlotinib." } }
{ "translation": { "text": "Glossary:\n\"medicinal product\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hepatic impairment This medicinal product must not be used in patients with hepatic impairment (see sections 4.3, 4.4 and\nSpanish: Insuficiencia hepática Este medicamento no debe usarse en pacientes con insuficiencia hepática (ver secciones 4.3, 4.4 y", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicinal product\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hepatic impairment This medicinal product must not be used in patients with hepatic impairment (see sections 4.3, 4.4 and\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicinal product|||medicamento", "en": "Hepatic impairment This medicinal product must not be used in patients with hepatic impairment (see sections 4.3, 4.4 and", "es": "Insuficiencia hepática Este medicamento no debe usarse en pacientes con insuficiencia hepática (ver secciones 4.3, 4.4 y" } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"dose\" -> \"dosis\"\n\"toxicity\" -> \"toxicidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Haematological toxicity is dose-related and full blood count including platelets should be determined regularly (see section 4.2).\nSpanish: La toxicidad hematológica está relacionada con la dosis y, por tanto, se debe determinar regularmente el recuento sanguíneo global, incluyendo plaquetas (ver sección 4.2).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"dose\" -> \"dosis\"\n\"toxicity\" -> \"toxicidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Haematological toxicity is dose-related and full blood count including platelets should be determined regularly (see section 4.2).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\tdose|||dosis\ttoxicity|||toxicidad", "en": "Haematological toxicity is dose-related and full blood count including platelets should be determined regularly (see section 4.2).", "es": "La toxicidad hematológica está relacionada con la dosis y, por tanto, se debe determinar regularmente el recuento sanguíneo global, incluyendo plaquetas (ver sección 4.2)." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"inhibitor\" -> \"inhibidores\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you have been taking an ACE inhibitor, wait for 36 hours after taking the last dose before you start to take Entresto (see “Other medicines and Entresto”).\nSpanish: Si ha estado tomando inhibidores de la ECA, espere 36 horas después de haber tomado la última dosis antes de empezar a tomar Entresto (ver “Otros medicamentos y Entresto”).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"inhibitor\" -> \"inhibidores\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: If you have been taking an ACE inhibitor, wait for 36 hours after taking the last dose before you start to take Entresto (see “Other medicines and Entresto”).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tinhibitor|||inhibidores", "en": "If you have been taking an ACE inhibitor, wait for 36 hours after taking the last dose before you start to take Entresto (see “Other medicines and Entresto”).", "es": "Si ha estado tomando inhibidores de la ECA, espere 36 horas después de haber tomado la última dosis antes de empezar a tomar Entresto (ver “Otros medicamentos y Entresto”)." } }
{ "translation": { "text": "Glossaries:\n\"contact\" -> \"contacto\"\n\"case\" -> \"caso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In case of accidental contact (skin, eye), wash thoroughly with water.\nSpanish: En caso de contacto accidental (piel, ojos), lávese con agua abundante.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"contact\" -> \"contacto\"\n\"case\" -> \"caso\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In case of accidental contact (skin, eye), wash thoroughly with water.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "contact|||contacto\tcase|||caso", "en": "In case of accidental contact (skin, eye), wash thoroughly with water.", "es": "En caso de contacto accidental (piel, ojos), lávese con agua abundante." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"viral\" -> \"viral\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: c: Patients with genotype 3 low viral load (< 600,000 IU/ml) were to receive 24 weeks of treatment while those with genotype 3 and high viral load (≥ 600,000 IU/ml) were to receive 48 weeks of treatment.\nSpanish: c: Pacientes de genotipo 3 con baja carga viral (< 600.000 UI/ml) recibieron el tratamiento 24 semanas mientras aquellos de genotipo 3 y alta carga viral (≥ 600.000 UI/ml) recibieron el tratamiento 48 semanas.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"viral\" -> \"viral\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: c: Patients with genotype 3 low viral load (< 600,000 IU/ml) were to receive 24 weeks of treatment while those with genotype 3 and high viral load (≥ 600,000 IU/ml) were to receive 48 weeks of treatment.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tviral|||viral", "en": "c: Patients with genotype 3 low viral load (< 600,000 IU/ml) were to receive 24 weeks of treatment while those with genotype 3 and high viral load (≥ 600,000 IU/ml) were to receive 48 weeks of treatment.", "es": "c: Pacientes de genotipo 3 con baja carga viral (< 600.000 UI/ml) recibieron el tratamiento 24 semanas mientras aquellos de genotipo 3 y alta carga viral (≥ 600.000 UI/ml) recibieron el tratamiento 48 semanas." } }
{ "translation": { "text": "Glossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Where should you give your injection?\nSpanish: ¿Dónde debe ponerse la inyección?", "en_prompt": "<|im_start|>user\nGlossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Where should you give your injection?\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injection|||inyección", "en": "Where should you give your injection?", "es": "¿Dónde debe ponerse la inyección?" } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"dose\" -> \"dosis\"\n\"cancer\" -> \"cáncer\"\n\"chemotherapy\" -> \"quimioterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Udenyca is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines).\nSpanish: Udenyca se administra en una dosis única de 6 mg inyectada bajo la piel al menos 24 horas después del final de cada ciclo de quimioterapia (tratamiento con medicamentos contra el cáncer).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"dose\" -> \"dosis\"\n\"cancer\" -> \"cáncer\"\n\"chemotherapy\" -> \"quimioterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Udenyca is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tdose|||dosis\tcancer|||cáncer\tchemotherapy|||quimioterapia", "en": "Udenyca is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines).", "es": "Udenyca se administra en una dosis única de 6 mg inyectada bajo la piel al menos 24 horas después del final de cada ciclo de quimioterapia (tratamiento con medicamentos contra el cáncer)." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"fluconazole\" -> \"fluconazol\"\n\"syndrome\" -> \"Síndrome\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, during treatment with fluconazole.\nSpanish: Raramente, algunos pacientes han desarrollado reacciones cutáneas exfoliativas, como Síndrome de Stevens-Johnson y necrolisis epidérmica tóxica, durante el tratamiento con fluconazol.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"fluconazole\" -> \"fluconazol\"\n\"syndrome\" -> \"Síndrome\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, during treatment with fluconazole.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tfluconazole|||fluconazol\tsyndrome|||Síndrome", "en": "Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, during treatment with fluconazole.", "es": "Raramente, algunos pacientes han desarrollado reacciones cutáneas exfoliativas, como Síndrome de Stevens-Johnson y necrolisis epidérmica tóxica, durante el tratamiento con fluconazol." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The dose can be reduced if not tolerated (see section 4.2 and 5.2).\nSpanish: La dosis puede reducirse si no es bien tolerada (ver secciones 4.2 y", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The dose can be reduced if not tolerated (see section 4.2 and 5.2).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "The dose can be reduced if not tolerated (see section 4.2 and 5.2).", "es": "La dosis puede reducirse si no es bien tolerada (ver secciones 4.2 y" } }
{ "translation": { "text": "Glossary:\n\"injections\" -> \"inyectables\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Sodium chloride, borax and water for injections.\nSpanish: Cloruro de sodio, borato de sodio y agua para preparaciones inyectables.", "en_prompt": "<|im_start|>user\nGlossary:\n\"injections\" -> \"inyectables\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Sodium chloride, borax and water for injections.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injections|||inyectables", "en": "Sodium chloride, borax and water for injections.", "es": "Cloruro de sodio, borato de sodio y agua para preparaciones inyectables." } }
{ "translation": { "text": "Glossaries:\n\"sign\" -> \"signo\"\n\"infection\" -> \"infección\"\n\"mofetil\" -> \"mofetilo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: These changes may suggest a ‘left shift' in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive mycophenolate mofetil.\nSpanish: En un análisis de sangre, estos cambios pueden mostrar una “desviación a la izquierda” en la madurez de los neutrófilos, lo cual se puede interpretar erróneamente como un signo de infección en pacientes inmunodeprimidos como los tratados con micofenolato mofetilo.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"sign\" -> \"signo\"\n\"infection\" -> \"infección\"\n\"mofetil\" -> \"mofetilo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: These changes may suggest a ‘left shift' in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive mycophenolate mofetil.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "sign|||signo\tinfection|||infección\tmofetil|||mofetilo", "en": "These changes may suggest a ‘left shift' in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive mycophenolate mofetil.", "es": "En un análisis de sangre, estos cambios pueden mostrar una “desviación a la izquierda” en la madurez de los neutrófilos, lo cual se puede interpretar erróneamente como un signo de infección en pacientes inmunodeprimidos como los tratados con micofenolato mofetilo." } }
{ "translation": { "text": "Glossaries:\n\"doctor\" -> \"médico\"\n\"inject\" -> \"inyectar\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Please read the instructions at the end of this leaflet on how to inject Nplate, as discussed with your doctor.\nSpanish: Por favor, lea las instrucciones al final de este prospecto sobre cómo inyectar Nplate, tal como ha comentado con su médico.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"doctor\" -> \"médico\"\n\"inject\" -> \"inyectar\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Please read the instructions at the end of this leaflet on how to inject Nplate, as discussed with your doctor.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico\tinject|||inyectar", "en": "Please read the instructions at the end of this leaflet on how to inject Nplate, as discussed with your doctor.", "es": "Por favor, lea las instrucciones al final de este prospecto sobre cómo inyectar Nplate, tal como ha comentado con su médico." } }
{ "translation": { "text": "Glossary:\n\"protocol\" -> \"protocolo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The final study protocol will be submitted within 60 days from Commission decision to MSs/RMS to be finally agreed prior to starting the study.\nSpanish: El protocolo final del estudio se presentará en el plazo de 60 días desde la decisión de la Comisión a los EM/RMS para su acuerdo final antes del inicio del estudio.", "en_prompt": "<|im_start|>user\nGlossary:\n\"protocol\" -> \"protocolo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The final study protocol will be submitted within 60 days from Commission decision to MSs/RMS to be finally agreed prior to starting the study.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "protocol|||protocolo", "en": "The final study protocol will be submitted within 60 days from Commission decision to MSs/RMS to be finally agreed prior to starting the study.", "es": "El protocolo final del estudio se presentará en el plazo de 60 días desde la decisión de la Comisión a los EM/RMS para su acuerdo final antes del inicio del estudio." } }
{ "translation": { "text": "Glossary:\n\"pregabalin\" -> \"pregabalina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: STATEMENT OF ACTIVE SUBSTANCE Each hard capsule contains 225 mg of pregabalin.\nSpanish: PRINCIPIO ACTIVO Cada cápsula dura contiene 225 mg de pregabalina.", "en_prompt": "<|im_start|>user\nGlossary:\n\"pregabalin\" -> \"pregabalina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: STATEMENT OF ACTIVE SUBSTANCE Each hard capsule contains 225 mg of pregabalin.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "pregabalin|||pregabalina", "en": "STATEMENT OF ACTIVE SUBSTANCE Each hard capsule contains 225 mg of pregabalin.", "es": "PRINCIPIO ACTIVO Cada cápsula dura contiene 225 mg de pregabalina." } }
{ "translation": { "text": "Glossaries:\n\"ulcer\" -> \"úlcera\"\n\"lesion\" -> \"lesión\"\n\"eye\" -> \"ojo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The lesion or ulcer in your eye will worsen and could lead to infections or impaired vision.\nSpanish: Si interrumpe el tratamiento con OXERVATE La lesión o la úlcera del ojo empeorarán y podrían causar infecciones o alteraciones de la vista.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"ulcer\" -> \"úlcera\"\n\"lesion\" -> \"lesión\"\n\"eye\" -> \"ojo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The lesion or ulcer in your eye will worsen and could lead to infections or impaired vision.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "ulcer|||úlcera\tlesion|||lesión\teye|||ojo", "en": "The lesion or ulcer in your eye will worsen and could lead to infections or impaired vision.", "es": "Si interrumpe el tratamiento con OXERVATE La lesión o la úlcera del ojo empeorarán y podrían causar infecciones o alteraciones de la vista." } }
{ "translation": { "text": "Glossary:\n\"monotherapy\" -> \"monoterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: *Please refer to the dabrafenib SmPC, Posology and method of administration, for dosing instructions for treatment with dabrafenib monotherapy.\nSpanish: *Por favor, para instrucciones de dosis en monoterapia con dabrafenib, consultar la sección “Posología y forma de administración” de la Ficha Técnica de dabrafenib.", "en_prompt": "<|im_start|>user\nGlossary:\n\"monotherapy\" -> \"monoterapia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: *Please refer to the dabrafenib SmPC, Posology and method of administration, for dosing instructions for treatment with dabrafenib monotherapy.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "monotherapy|||monoterapia", "en": "*Please refer to the dabrafenib SmPC, Posology and method of administration, for dosing instructions for treatment with dabrafenib monotherapy.", "es": "*Por favor, para instrucciones de dosis en monoterapia con dabrafenib, consultar la sección “Posología y forma de administración” de la Ficha Técnica de dabrafenib." } }
{ "translation": { "text": "Glossaries:\n\"creatinine\" -> \"creatinina\"\n\"pioglitazone\" -> \"pioglitazona\"\n\"albumin\" -> \"albúmina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In one year clinical trials, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline.\nSpanish: En ensayos clínicos de un año, la pioglitazona produjo de forma consistente una reducción significativa en el cociente de albúmina/creatinina en comparación con los valores iniciales.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"creatinine\" -> \"creatinina\"\n\"pioglitazone\" -> \"pioglitazona\"\n\"albumin\" -> \"albúmina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In one year clinical trials, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "creatinine|||creatinina\tpioglitazone|||pioglitazona\talbumin|||albúmina", "en": "In one year clinical trials, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline.", "es": "En ensayos clínicos de un año, la pioglitazona produjo de forma consistente una reducción significativa en el cociente de albúmina/creatinina en comparación con los valores iniciales." } }
{ "translation": { "text": "Glossary:\n\"tumour\" -> \"tumor\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: - To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour.\nSpanish: - Reducir la cantidad de calcio en la sangre en pacientes adultos en que es demasiado alto debido a la presencia de un tumor.", "en_prompt": "<|im_start|>user\nGlossary:\n\"tumour\" -> \"tumor\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: - To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "tumour|||tumor", "en": "- To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour.", "es": "- Reducir la cantidad de calcio en la sangre en pacientes adultos en que es demasiado alto debido a la presencia de un tumor." } }
{ "translation": { "text": "Glossaries:\n\"ritonavir\" -> \"ritonavir\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Even if you feel better, do not stop taking Darunavir Krka or ritonavir without talking to your doctor.\nSpanish: Aunque se encuentre mejor, no deje de tomar Darunavir Krka o ritonavir sin consultarlo con su médico.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"ritonavir\" -> \"ritonavir\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Even if you feel better, do not stop taking Darunavir Krka or ritonavir without talking to your doctor.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "ritonavir|||ritonavir\tdoctor|||médico", "en": "Even if you feel better, do not stop taking Darunavir Krka or ritonavir without talking to your doctor.", "es": "Aunque se encuentre mejor, no deje de tomar Darunavir Krka o ritonavir sin consultarlo con su médico." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"double\" -> \"doble\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A double dose should not be taken to make up for a missed dose.\nSpanish: No se debe tomar una dosis doble para compensar una dosis olvidada.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"double\" -> \"doble\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A double dose should not be taken to make up for a missed dose.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tdouble|||doble", "en": "A double dose should not be taken to make up for a missed dose.", "es": "No se debe tomar una dosis doble para compensar una dosis olvidada." } }
{ "translation": { "text": "Glossaries:\n\"susceptibility\" -> \"susceptibilidad\"\n\"nelfinavir\" -> \"nelfinavir\"\n\"nevirapine\" -> \"nevirapina\"\n\"lamivudine\" -> \"lamivudina\"\n\"in vitro\" -> \"in vitro\"\n\"zidovudine\" -> \"zidovudina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Clinical isolates (n=5) with decreased susceptibility to zidovudine, lamivudine, or nevirapine remain fully susceptible to nelfinavir in vitro.\nSpanish: Aislados clínicos (n=5) con susceptibilidad reducida a zidovudina, lamivudina, o nevirapina mantienen su susceptibilidad total a nelfinavir in vitro.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"susceptibility\" -> \"susceptibilidad\"\n\"nelfinavir\" -> \"nelfinavir\"\n\"nevirapine\" -> \"nevirapina\"\n\"lamivudine\" -> \"lamivudina\"\n\"in vitro\" -> \"in vitro\"\n\"zidovudine\" -> \"zidovudina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Clinical isolates (n=5) with decreased susceptibility to zidovudine, lamivudine, or nevirapine remain fully susceptible to nelfinavir in vitro.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "susceptibility|||susceptibilidad\tnelfinavir|||nelfinavir\tnevirapine|||nevirapina\tlamivudine|||lamivudina\tin vitro|||in vitro\tzidovudine|||zidovudina", "en": "Clinical isolates (n=5) with decreased susceptibility to zidovudine, lamivudine, or nevirapine remain fully susceptible to nelfinavir in vitro.", "es": "Aislados clínicos (n=5) con susceptibilidad reducida a zidovudina, lamivudina, o nevirapina mantienen su susceptibilidad total a nelfinavir in vitro." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: At the recommended dose, this is the desired effect.\nSpanish: A la dosis recomendada, este es el efecto deseado.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: At the recommended dose, this is the desired effect.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "At the recommended dose, this is the desired effect.", "es": "A la dosis recomendada, este es el efecto deseado." } }
{ "translation": { "text": "Glossary:\n\"retention\" -> \"retención\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Pleural and pericardial effusions as well as complications of fluid retention occurred in <1% of patients receiving Tasigna.\nSpanish: En <1% de los pacientes en tratamiento con Tasigna apareció derrame pleural y pericárdico, así como complicaciones derivadas de la retención de líquidos.", "en_prompt": "<|im_start|>user\nGlossary:\n\"retention\" -> \"retención\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Pleural and pericardial effusions as well as complications of fluid retention occurred in <1% of patients receiving Tasigna.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "retention|||retención", "en": "Pleural and pericardial effusions as well as complications of fluid retention occurred in <1% of patients receiving Tasigna.", "es": "En <1% de los pacientes en tratamiento con Tasigna apareció derrame pleural y pericárdico, así como complicaciones derivadas de la retención de líquidos." } }
{ "translation": { "text": "Glossary:\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It is therefore recommended not to store the infusion solution in a refrigerator.\nSpanish: Por ello, no se recomienda conservar la solución para perfusión en la nevera.", "en_prompt": "<|im_start|>user\nGlossary:\n\"infusion\" -> \"perfusión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It is therefore recommended not to store the infusion solution in a refrigerator.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfusión", "en": "It is therefore recommended not to store the infusion solution in a refrigerator.", "es": "Por ello, no se recomienda conservar la solución para perfusión en la nevera." } }
{ "translation": { "text": "Glossaries:\n\"intolerance\" -> \"intolerancia\"\n\"fatal\" -> \"fatal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Avermectins may not be well tolerated in all non-target species (cases of intolerance with fatal outcome are reported in dogs especially Collies, Old English Sheepdogs and related breeds or crosses, and also in turtles/tortoises).\nSpanish: Las avermectinas pueden no ser bien toleradas en todas las especies no de destino (se han notificado casos de intolerancia con resultado fatal en perros especialmente Collies, Bobtails y razas relacionadas o cruces, y también en tortugas.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"intolerance\" -> \"intolerancia\"\n\"fatal\" -> \"fatal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Avermectins may not be well tolerated in all non-target species (cases of intolerance with fatal outcome are reported in dogs especially Collies, Old English Sheepdogs and related breeds or crosses, and also in turtles/tortoises).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "intolerance|||intolerancia\tfatal|||fatal", "en": "Avermectins may not be well tolerated in all non-target species (cases of intolerance with fatal outcome are reported in dogs especially Collies, Old English Sheepdogs and related breeds or crosses, and also in turtles/tortoises).", "es": "Las avermectinas pueden no ser bien toleradas en todas las especies no de destino (se han notificado casos de intolerancia con resultado fatal en perros especialmente Collies, Bobtails y razas relacionadas o cruces, y también en tortugas." } }
{ "translation": { "text": "Glossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Tell your doctor if you\nSpanish: Informe a su médico si:", "en_prompt": "<|im_start|>user\nGlossary:\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Tell your doctor if you\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico", "en": "Tell your doctor if you", "es": "Informe a su médico si:" } }
{ "translation": { "text": "Glossaries:\n\"doctor\" -> \"médico\"\n\"hepatitis\" -> \"hepatitis\"\n\"vaccine\" -> \"vacuna\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • you need to be fully protected against hepatitis A and B infection within the next 6 monthsyour doctor may recommend a different vaccine\nSpanish: • necesita estar completamente protegido frente a la infección de hepatitis A y B en los próximos 6 meses (puede que su médico le recomiende una vacuna diferente)", "en_prompt": "<|im_start|>user\nGlossaries:\n\"doctor\" -> \"médico\"\n\"hepatitis\" -> \"hepatitis\"\n\"vaccine\" -> \"vacuna\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • you need to be fully protected against hepatitis A and B infection within the next 6 monthsyour doctor may recommend a different vaccine\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||médico\thepatitis|||hepatitis\tvaccine|||vacuna\tinfection|||infección", "en": "• you need to be fully protected against hepatitis A and B infection within the next 6 monthsyour doctor may recommend a different vaccine", "es": "• necesita estar completamente protegido frente a la infección de hepatitis A y B en los próximos 6 meses (puede que su médico le recomiende una vacuna diferente)" } }
{ "translation": { "text": "Glossaries:\n\"bilirubin\" -> \"bilirrubina\"\n\"clinical study\" -> \"estudio clínico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: * In a clinical study in Asian patients from China and South-Korea, increased blood ‘bilirubin'\nSpanish: * En un estudio clínico en pacientes Asiáticos de China y Corea del Sur, se notificaron aumentos de los niveles de “bilirrubina” en sangre en más de 1 de cada 10 personas (muy frecuente).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"bilirubin\" -> \"bilirrubina\"\n\"clinical study\" -> \"estudio clínico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: * In a clinical study in Asian patients from China and South-Korea, increased blood ‘bilirubin'\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "bilirubin|||bilirrubina\tclinical study|||estudio clínico", "en": "* In a clinical study in Asian patients from China and South-Korea, increased blood ‘bilirubin'", "es": "* En un estudio clínico en pacientes Asiáticos de China y Corea del Sur, se notificaron aumentos de los niveles de “bilirrubina” en sangre en más de 1 de cada 10 personas (muy frecuente)." } }
{ "translation": { "text": "Glossary:\n\"MAH\" -> \"TAC\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The MAH is of the opinion that the current EU SmPC accurately reflects the current literature and provides appropriate guidance to EU practitioners.\nSpanish: El TAC opina que la ficha técnica de la UE en vigor refleja con exactitud la bibliografía actual y ofrece pautas adecuadas para los profesionales de la UE.", "en_prompt": "<|im_start|>user\nGlossary:\n\"MAH\" -> \"TAC\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The MAH is of the opinion that the current EU SmPC accurately reflects the current literature and provides appropriate guidance to EU practitioners.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "MAH|||TAC", "en": "The MAH is of the opinion that the current EU SmPC accurately reflects the current literature and provides appropriate guidance to EU practitioners.", "es": "El TAC opina que la ficha técnica de la UE en vigor refleja con exactitud la bibliografía actual y ofrece pautas adecuadas para los profesionales de la UE." } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"medicinal product\" -> \"medicamento\"\n\"condition\" -> \"condición\"\n\"indication\" -> \"indicación\"\n\"information\" -> \"información\"\n\"reference medicinal product\" -> \"medicamento de referencia\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: <The European Medicines Agency has deferred the obligation to submit the results of studies with <{(Invented) Nname}> [or for generics: <the reference medicinal product containing {name of the active substance(s)}>] in one or more subsets of the paediatric population in {condition, as per Ppaediatric Iinvestigation Pplan (PIP) decision, for the granted indication} (see section 4.2 for information on paediatric use).>\nSpanish: <La Agencia Europea de Medicamentos ha concedido al titular un aplazamiento para presentar los resultados de los ensayos realizados con <{Denominación (de fantasía)}> [o para medicamentos genéricos: <el medicamento de referencia que contiene el {nombre del principio(s) activo(s)}>] en uno o más grupos de la población pediátrica en {condición establecida en la decisión sobre el Plan de Investigación Pediátrico (PIP), para la indicación autorizada) (ver sección 4.2 para consultar la información sobre el uso en la población pediátrica).>", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"medicinal product\" -> \"medicamento\"\n\"condition\" -> \"condición\"\n\"indication\" -> \"indicación\"\n\"information\" -> \"información\"\n\"reference medicinal product\" -> \"medicamento de referencia\"\n\"population\" -> \"población\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: <The European Medicines Agency has deferred the obligation to submit the results of studies with <{(Invented) Nname}> [or for generics: <the reference medicinal product containing {name of the active substance(s)}>] in one or more subsets of the paediatric population in {condition, as per Ppaediatric Iinvestigation Pplan (PIP) decision, for the granted indication} (see section 4.2 for information on paediatric use).>\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\tmedicinal product|||medicamento\tcondition|||condición\tindication|||indicación\tinformation|||información\treference medicinal product|||medicamento de referencia\tpopulation|||población", "en": "<The European Medicines Agency has deferred the obligation to submit the results of studies with <{(Invented) Nname}> [or for generics: <the reference medicinal product containing {name of the active substance(s)}>] in one or more subsets of the paediatric population in {condition, as per Ppaediatric Iinvestigation Pplan (PIP) decision, for the granted indication} (see section 4.2 for information on paediatric use).>", "es": "<La Agencia Europea de Medicamentos ha concedido al titular un aplazamiento para presentar los resultados de los ensayos realizados con <{Denominación (de fantasía)}> [o para medicamentos genéricos: <el medicamento de referencia que contiene el {nombre del principio(s) activo(s)}>] en uno o más grupos de la población pediátrica en {condición establecida en la decisión sobre el Plan de Investigación Pediátrico (PIP), para la indicación autorizada) (ver sección 4.2 para consultar la información sobre el uso en la población pediátrica).>" } }
{ "translation": { "text": "Glossaries:\n\"liver\" -> \"hígado\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In subjects with liver transplant, no cirrhosis and GT1 infection, patients were dosed with Viekirax and dasabuvir for 12-24 weeks, with and without RBV.\nSpanish: A los pacientescon trasplante de hígado, sin cirrosis y con infección por GT1, se les administró Viekirax y dasabuvir durante 12-24 semanas, con y sin RBV.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"liver\" -> \"hígado\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In subjects with liver transplant, no cirrhosis and GT1 infection, patients were dosed with Viekirax and dasabuvir for 12-24 weeks, with and without RBV.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "liver|||hígado\tinfection|||infección", "en": "In subjects with liver transplant, no cirrhosis and GT1 infection, patients were dosed with Viekirax and dasabuvir for 12-24 weeks, with and without RBV.", "es": "A los pacientescon trasplante de hígado, sin cirrosis y con infección por GT1, se les administró Viekirax y dasabuvir durante 12-24 semanas, con y sin RBV." } }
{ "translation": { "text": "Glossaries:\n\"placebo\" -> \"placebo\"\n\"arthritis\" -> \"artritis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Adalimumab, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA studies I and II.\nSpanish: El adalimumab, 40 mg administrados en semanas alternas, se ha estudiado en pacientes con artritis psoriásica activa moderada o grave en dos ensayos controlados con placebo (ensayos de la artritis psoriásica I y II).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"placebo\" -> \"placebo\"\n\"arthritis\" -> \"artritis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Adalimumab, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA studies I and II.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo\tarthritis|||artritis", "en": "Adalimumab, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA studies I and II.", "es": "El adalimumab, 40 mg administrados en semanas alternas, se ha estudiado en pacientes con artritis psoriásica activa moderada o grave en dos ensayos controlados con placebo (ensayos de la artritis psoriásica I y II)." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs.\nSpanish: Su médico puede recomendarle una dosis mayor o menor dependiendo de sus necesidades individuales de tratamiento.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"dose\" -> \"dosis\"\n\"doctor\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tdose|||dosis\tdoctor|||médico", "en": "A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs.", "es": "Su médico puede recomendarle una dosis mayor o menor dependiendo de sus necesidades individuales de tratamiento." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: You should not be given this medicine when breast-feeding, as small amounts of OlanzapineApotex can pass into breast milk\nSpanish: No debe tomar este medicamento cuando esté dando el pecho ya que pequeñas cantidades de Olanzapina Apotex pueden pasar a la leche materna.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicamento\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: You should not be given this medicine when breast-feeding, as small amounts of OlanzapineApotex can pass into breast milk\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicamento", "en": "You should not be given this medicine when breast-feeding, as small amounts of OlanzapineApotex can pass into breast milk", "es": "No debe tomar este medicamento cuando esté dando el pecho ya que pequeñas cantidades de Olanzapina Apotex pueden pasar a la leche materna." } }
{ "translation": { "text": "Glossaries:\n\"contamination\" -> \"contaminación\"\n\"reconstitution\" -> \"reconstitución\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: From a microbiological point of view, unless the method of reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.\nSpanish: Desde un punto de vista microbiológico, el medicamento se debe utilizar inmediatamente, a menos que el método de reconstitución y dilución excluya el riesgo de contaminación microbiológica.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"contamination\" -> \"contaminación\"\n\"reconstitution\" -> \"reconstitución\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: From a microbiological point of view, unless the method of reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "contamination|||contaminación\treconstitution|||reconstitución", "en": "From a microbiological point of view, unless the method of reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.", "es": "Desde un punto de vista microbiológico, el medicamento se debe utilizar inmediatamente, a menos que el método de reconstitución y dilución excluya el riesgo de contaminación microbiológica." } }
{ "translation": { "text": "Glossaries:\n\"product\" -> \"producto\"\n\"bioequivalence\" -> \"bioequivalencia\"\n\"absence\" -> \"ausencia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Therefore, given the serious doubts regarding the reliability and the correctness of the data from the critical pivotal bioequivalence study B050309, submitted in support of the marketing authorisation, and in the absence of a reliable bioequivalence study specifically designed to establish the bioequivalence of Leflunomide Apotex to its EU reference product, the CHMP was unable to conclude on the bioequivalence of Leflunomide Apotex.\nSpanish: Por tanto, a la vista de las graves dudas sobre la fiabilidad y la corrección de los datos del importante estudio fundamental de bioequivalencia B050309, presentado para apoyar la autorización de comercialización, y en ausencia de un estudio de bioequivalencia fiable diseñado específicamente para establecer la bioequivalencia de Leflunomide Apotex con su producto de referencia en la UE, el CHMP no pudo llegar a una conclusión sobre la bioequivalencia de Leflunomide Apotex.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"product\" -> \"producto\"\n\"bioequivalence\" -> \"bioequivalencia\"\n\"absence\" -> \"ausencia\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Therefore, given the serious doubts regarding the reliability and the correctness of the data from the critical pivotal bioequivalence study B050309, submitted in support of the marketing authorisation, and in the absence of a reliable bioequivalence study specifically designed to establish the bioequivalence of Leflunomide Apotex to its EU reference product, the CHMP was unable to conclude on the bioequivalence of Leflunomide Apotex.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "product|||producto\tbioequivalence|||bioequivalencia\tabsence|||ausencia", "en": "Therefore, given the serious doubts regarding the reliability and the correctness of the data from the critical pivotal bioequivalence study B050309, submitted in support of the marketing authorisation, and in the absence of a reliable bioequivalence study specifically designed to establish the bioequivalence of Leflunomide Apotex to its EU reference product, the CHMP was unable to conclude on the bioequivalence of Leflunomide Apotex.", "es": "Por tanto, a la vista de las graves dudas sobre la fiabilidad y la corrección de los datos del importante estudio fundamental de bioequivalencia B050309, presentado para apoyar la autorización de comercialización, y en ausencia de un estudio de bioequivalencia fiable diseñado específicamente para establecer la bioequivalencia de Leflunomide Apotex con su producto de referencia en la UE, el CHMP no pudo llegar a una conclusión sobre la bioequivalencia de Leflunomide Apotex." } }
{ "translation": { "text": "Glossary:\n\"S\" -> \"S\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Medimpex France S.A. Rigevidon\nSpanish: Medimpex France S.A. Rigevidon 0,03 mg de etinilestradiol", "en_prompt": "<|im_start|>user\nGlossary:\n\"S\" -> \"S\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Medimpex France S.A. Rigevidon\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "S|||S", "en": "Medimpex France S.A. Rigevidon", "es": "Medimpex France S.A. Rigevidon 0,03 mg de etinilestradiol" } }
{ "translation": { "text": "Glossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: ORENCIA 125 mg solution for injection in pre-filled syringe with needle guard Abatacept\nSpanish: ORENCIA 125 mg solución inyectable en jeringa precargada con protector de aguja Abatacept", "en_prompt": "<|im_start|>user\nGlossary:\n\"syringe\" -> \"jeringa\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: ORENCIA 125 mg solution for injection in pre-filled syringe with needle guard Abatacept\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "syringe|||jeringa", "en": "ORENCIA 125 mg solution for injection in pre-filled syringe with needle guard Abatacept", "es": "ORENCIA 125 mg solución inyectable en jeringa precargada con protector de aguja Abatacept" } }
{ "translation": { "text": "Glossary:\n\"dyspnoea\" -> \"disnea\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hypertension, Hypotension Respiratory, thoracic and mediastinal disorders Wheezing, dyspnoea\nSpanish: Trastornos vasculares Rubefacción Hipertensión, hipotensión Trastornos respiratorios, torácicos y mediastínicos Sibilancia, disnea Hipoxia, broncoespasmos, tos", "en_prompt": "<|im_start|>user\nGlossary:\n\"dyspnoea\" -> \"disnea\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hypertension, Hypotension Respiratory, thoracic and mediastinal disorders Wheezing, dyspnoea\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dyspnoea|||disnea", "en": "Hypertension, Hypotension Respiratory, thoracic and mediastinal disorders Wheezing, dyspnoea", "es": "Trastornos vasculares Rubefacción Hipertensión, hipotensión Trastornos respiratorios, torácicos y mediastínicos Sibilancia, disnea Hipoxia, broncoespasmos, tos" } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"medicinal product\" -> \"medicamento\"\n\"anaesthesia\" -> \"anestesia\"\n\"metformin\" -> \"metformina\"\n\"elective surgery\" -> \"cirugía programada\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: As this medicinal product contains metformin, the treatment must be discontinued 48 hours before elective surgery with general, spinal or peridural anaesthesia.\nSpanish: Como este medicamento contiene metformina, el tratamiento se debe suspender 48 horas antes de una cirugía programada con anestesia general, espinal o epidural.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"medicinal product\" -> \"medicamento\"\n\"anaesthesia\" -> \"anestesia\"\n\"metformin\" -> \"metformina\"\n\"elective surgery\" -> \"cirugía programada\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: As this medicinal product contains metformin, the treatment must be discontinued 48 hours before elective surgery with general, spinal or peridural anaesthesia.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tmedicinal product|||medicamento\tanaesthesia|||anestesia\tmetformin|||metformina\telective surgery|||cirugía programada", "en": "As this medicinal product contains metformin, the treatment must be discontinued 48 hours before elective surgery with general, spinal or peridural anaesthesia.", "es": "Como este medicamento contiene metformina, el tratamiento se debe suspender 48 horas antes de una cirugía programada con anestesia general, espinal o epidural." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The recommended dose is one tablet taken once a day with food, normally for 12 or 24 weeks.\nSpanish: La dosis recomendada es de un comprimido tomado una vez al día con alimentos, normalmente durante 12 o 24 semanas.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"dosis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The recommended dose is one tablet taken once a day with food, normally for 12 or 24 weeks.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis", "en": "The recommended dose is one tablet taken once a day with food, normally for 12 or 24 weeks.", "es": "La dosis recomendada es de un comprimido tomado una vez al día con alimentos, normalmente durante 12 o 24 semanas." } }
{ "translation": { "text": "Glossary:\n\"factor\" -> \"factor\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: NAME OF THE MEDICINAL PRODUCT Vihuma 250 International Units powder and solvent for solution for injection simoctocog alfa (recombinant human coagulation factor VIII)\nSpanish: Vihuma 250 Unidades Internacionalespolvo y disolvente para solución inyectable simoctocog alfa (factor VIII de coagulación humano recombinante)", "en_prompt": "<|im_start|>user\nGlossary:\n\"factor\" -> \"factor\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: NAME OF THE MEDICINAL PRODUCT Vihuma 250 International Units powder and solvent for solution for injection simoctocog alfa (recombinant human coagulation factor VIII)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "factor|||factor", "en": "NAME OF THE MEDICINAL PRODUCT Vihuma 250 International Units powder and solvent for solution for injection simoctocog alfa (recombinant human coagulation factor VIII)", "es": "Vihuma 250 Unidades Internacionalespolvo y disolvente para solución inyectable simoctocog alfa (factor VIII de coagulación humano recombinante)" } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"exposure\" -> \"exposición\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Limited pharmacokinetic data obtained in adolescent patients with RLS (13-17 years, n=24) following treatment with multiple doses of 0.5 to 3mg/24h showed that systemic exposure to rotigotine was similar to that observed in adults.\nSpanish: Los escasos datos farmacocinéticos obtenidos en pacientes adolescentes con SPI (13-17 años, n=24) después del tratamiento con dosis múltiples de 0.5 a 3mg/24h mostraron que la exposición sistémica a rotigotina fue similar a la observada en adultos.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"exposure\" -> \"exposición\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Limited pharmacokinetic data obtained in adolescent patients with RLS (13-17 years, n=24) following treatment with multiple doses of 0.5 to 3mg/24h showed that systemic exposure to rotigotine was similar to that observed in adults.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\texposure|||exposición", "en": "Limited pharmacokinetic data obtained in adolescent patients with RLS (13-17 years, n=24) following treatment with multiple doses of 0.5 to 3mg/24h showed that systemic exposure to rotigotine was similar to that observed in adults.", "es": "Los escasos datos farmacocinéticos obtenidos en pacientes adolescentes con SPI (13-17 años, n=24) después del tratamiento con dosis múltiples de 0.5 a 3mg/24h mostraron que la exposición sistémica a rotigotina fue similar a la observada en adultos." } }
{ "translation": { "text": "Glossaries:\n\"efficacy\" -> \"eficacia\"\n\"analysis\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The efficacy results from the joint analysis of the NSABP B-31 and NCCTG N9831 trials at the time of the definitive analysis of DFS* are summarised in Table 7.\nSpanish: Los resultados de eficacia del análisis conjunto de los ensayos NSABP B-31 y NCCTG N9831 en el momento del análisis definitivo de SLE* están resumidos en la tabla 7.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"efficacy\" -> \"eficacia\"\n\"analysis\" -> \"análisis\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The efficacy results from the joint analysis of the NSABP B-31 and NCCTG N9831 trials at the time of the definitive analysis of DFS* are summarised in Table 7.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "efficacy|||eficacia\tanalysis|||análisis", "en": "The efficacy results from the joint analysis of the NSABP B-31 and NCCTG N9831 trials at the time of the definitive analysis of DFS* are summarised in Table 7.", "es": "Los resultados de eficacia del análisis conjunto de los ensayos NSABP B-31 y NCCTG N9831 en el momento del análisis definitivo de SLE* están resumidos en la tabla 7." } }
{ "translation": { "text": "Glossary:\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Mild to moderate renal impairment (eGFR <90 - ≥30 ml/min/1.73m2) doses should be reduced by 30% (see Table 2).\nSpanish: Para los pacientes con insuficiencia renal leve a moderada (eGFR<90 - ≥30 ml/min/1,73m2) las dosis se deben reducir un 30% (ver Tabla 2).", "en_prompt": "<|im_start|>user\nGlossary:\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Mild to moderate renal impairment (eGFR <90 - ≥30 ml/min/1.73m2) doses should be reduced by 30% (see Table 2).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "renal|||renal", "en": "Mild to moderate renal impairment (eGFR <90 - ≥30 ml/min/1.73m2) doses should be reduced by 30% (see Table 2).", "es": "Para los pacientes con insuficiencia renal leve a moderada (eGFR<90 - ≥30 ml/min/1,73m2) las dosis se deben reducir un 30% (ver Tabla 2)." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"dosis\"\n\"diclofenac\" -> \"diclofenaco\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The available information on the dose effect of diclofenac is limited.\nSpanish: La información disponible sobre el efecto de la dosis de diclofenaco es limitada.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"dosis\"\n\"diclofenac\" -> \"diclofenaco\"\n\"information\" -> \"información\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The available information on the dose effect of diclofenac is limited.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||dosis\tdiclofenac|||diclofenaco\tinformation|||información", "en": "The available information on the dose effect of diclofenac is limited.", "es": "La información disponible sobre el efecto de la dosis de diclofenaco es limitada." } }
{ "translation": { "text": "Glossaries:\n\"immune system\" -> \"sistema inmunitario\"\n\"cure\" -> \"cura\"\n\"system\" -> \"sistema\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It does not cure HIV infection or AIDS but, when used in combination with other antivirals, it holds off the damage to the immune system and the development of infections and diseases associated with AIDS.\nSpanish: No cura la infección por el VIH ni el SIDA, pero cuando se usa en combinación con otros antivíricos sí puede frenar el deterioro del sistema inmunitario y la aparición de infecciones y enfermedades asociadas al SIDA.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"immune system\" -> \"sistema inmunitario\"\n\"cure\" -> \"cura\"\n\"system\" -> \"sistema\"\n\"infection\" -> \"infección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It does not cure HIV infection or AIDS but, when used in combination with other antivirals, it holds off the damage to the immune system and the development of infections and diseases associated with AIDS.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "immune system|||sistema inmunitario\tcure|||cura\tsystem|||sistema\tinfection|||infección", "en": "It does not cure HIV infection or AIDS but, when used in combination with other antivirals, it holds off the damage to the immune system and the development of infections and diseases associated with AIDS.", "es": "No cura la infección por el VIH ni el SIDA, pero cuando se usa en combinación con otros antivíricos sí puede frenar el deterioro del sistema inmunitario y la aparición de infecciones y enfermedades asociadas al SIDA." } }
{ "translation": { "text": "Glossaries:\n\"syringe\" -> \"jeringa\"\n\"active substance\" -> \"principio activo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Arixtra contains the active substance fondaparinux sodium (1.5, 2.5, 5, 7.5 or 10 mg per syringe).\nSpanish: Arixtra contiene el principio activo fondaparinux sódico (1,5 mg, 2,5 mg, 5 mg, 7,5 mg o 10 mg por jeringa).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"syringe\" -> \"jeringa\"\n\"active substance\" -> \"principio activo\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Arixtra contains the active substance fondaparinux sodium (1.5, 2.5, 5, 7.5 or 10 mg per syringe).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "syringe|||jeringa\tactive substance|||principio activo", "en": "Arixtra contains the active substance fondaparinux sodium (1.5, 2.5, 5, 7.5 or 10 mg per syringe).", "es": "Arixtra contiene el principio activo fondaparinux sódico (1,5 mg, 2,5 mg, 5 mg, 7,5 mg o 10 mg por jeringa)." } }
{ "translation": { "text": "Glossary:\n\"release\" -> \"liberación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Name and address of the manufacturer(s) responsible for batch release\nSpanish: Nombre y dirección del (de los) fabricante(s) responsable(s) de la liberación de los lotes S.C. Zentiva S.A.", "en_prompt": "<|im_start|>user\nGlossary:\n\"release\" -> \"liberación\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Name and address of the manufacturer(s) responsible for batch release\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "release|||liberación", "en": "Name and address of the manufacturer(s) responsible for batch release", "es": "Nombre y dirección del (de los) fabricante(s) responsable(s) de la liberación de los lotes S.C. Zentiva S.A." } }
{ "translation": { "text": "Glossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: To prevent painful injections and minimise leakage from the injection site Fertavid should be slowly administered intramuscularly or subcutaneously.\nSpanish: Con el fin de evitar que las inyecciones sean dolorosas y minimizar las pérdidas en el lugar de la inyección, Fertavid debe administrarse lentamente por vía intramuscular o subcutánea.", "en_prompt": "<|im_start|>user\nGlossary:\n\"injection\" -> \"inyección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: To prevent painful injections and minimise leakage from the injection site Fertavid should be slowly administered intramuscularly or subcutaneously.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "injection|||inyección", "en": "To prevent painful injections and minimise leakage from the injection site Fertavid should be slowly administered intramuscularly or subcutaneously.", "es": "Con el fin de evitar que las inyecciones sean dolorosas y minimizar las pérdidas en el lugar de la inyección, Fertavid debe administrarse lentamente por vía intramuscular o subcutánea." } }
{ "translation": { "text": "Glossaries:\n\"section\" -> \"sección\"\n\"trastuzumab\" -> \"trastuzumab\"\n\"platelet count\" -> \"recuento de plaquetas\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the event of decreased platelet count to Grade 3 or greater (< 50,000/mm3), do not administer trastuzumab emtansine until platelet counts recover to Grade 1 (≥ 75,000/mm3) (see section 4.2).\nSpanish: En caso de que se observen disminuciones del recuento de plaquetas de Grado 3 o mayor (< 50.000/mm3), no se administrará trastuzumab emtansina hasta que el recuento de plaquetas se restablezca a Grado 1 (≥ 75.000/mm3) (ver sección 4.2).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"section\" -> \"sección\"\n\"trastuzumab\" -> \"trastuzumab\"\n\"platelet count\" -> \"recuento de plaquetas\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In the event of decreased platelet count to Grade 3 or greater (< 50,000/mm3), do not administer trastuzumab emtansine until platelet counts recover to Grade 1 (≥ 75,000/mm3) (see section 4.2).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección\ttrastuzumab|||trastuzumab\tplatelet count|||recuento de plaquetas", "en": "In the event of decreased platelet count to Grade 3 or greater (< 50,000/mm3), do not administer trastuzumab emtansine until platelet counts recover to Grade 1 (≥ 75,000/mm3) (see section 4.2).", "es": "En caso de que se observen disminuciones del recuento de plaquetas de Grado 3 o mayor (< 50.000/mm3), no se administrará trastuzumab emtansina hasta que el recuento de plaquetas se restablezca a Grado 1 (≥ 75.000/mm3) (ver sección 4.2)." } }
{ "translation": { "text": "Glossary:\n\"suspension\" -> \"suspensión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The suspension for injection is for single use only.\nSpanish: La suspensión inyectable es para un solo uso.", "en_prompt": "<|im_start|>user\nGlossary:\n\"suspension\" -> \"suspensión\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: The suspension for injection is for single use only.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "suspension|||suspensión", "en": "The suspension for injection is for single use only.", "es": "La suspensión inyectable es para un solo uso." } }
{ "translation": { "text": "Glossary:\n\"reconstitution\" -> \"reconstitución\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Use andexanet alfa within eight hours after reconstitution when stored at room temperature.\nSpanish: Utilice andexanet alfa en las ocho horas posteriores a la reconstitución si la mantiene a temperatura ambiente.", "en_prompt": "<|im_start|>user\nGlossary:\n\"reconstitution\" -> \"reconstitución\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Use andexanet alfa within eight hours after reconstitution when stored at room temperature.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "reconstitution|||reconstitución", "en": "Use andexanet alfa within eight hours after reconstitution when stored at room temperature.", "es": "Utilice andexanet alfa en las ocho horas posteriores a la reconstitución si la mantiene a temperatura ambiente." } }
{ "translation": { "text": "Glossary:\n\"range\" -> \"rango\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Age (years): median (range) Race:\nSpanish: Edad (años): mediana (rango) Raza:", "en_prompt": "<|im_start|>user\nGlossary:\n\"range\" -> \"rango\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Age (years): median (range) Race:\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "range|||rango", "en": "Age (years): median (range) Race:", "es": "Edad (años): mediana (rango) Raza:" } }
{ "translation": { "text": "Glossaries:\n\"cross-reactivity\" -> \"reactividad cruzada\"\n\"toxicity\" -> \"toxicidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent TNF and to the development of neutralizing antibodies in rodents.\nSpanish: No se llevaron a cabo ni estudios de carcinogénesis ni de evaluación estándar de la fertilidad y de la toxicidad postnatal con adalimumab, debido a la falta de modelos apropiados para estudiar un anticuerpo con reactividad cruzada limitada al TNF del roedor y al desarrollo de anticuerpos neutralizantes en roedores.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"cross-reactivity\" -> \"reactividad cruzada\"\n\"toxicity\" -> \"toxicidad\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent TNF and to the development of neutralizing antibodies in rodents.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "cross-reactivity|||reactividad cruzada\ttoxicity|||toxicidad", "en": "Neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent TNF and to the development of neutralizing antibodies in rodents.", "es": "No se llevaron a cabo ni estudios de carcinogénesis ni de evaluación estándar de la fertilidad y de la toxicidad postnatal con adalimumab, debido a la falta de modelos apropiados para estudiar un anticuerpo con reactividad cruzada limitada al TNF del roedor y al desarrollo de anticuerpos neutralizantes en roedores." } }
{ "translation": { "text": "Glossary:\n\"staff\" -> \"personal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • male and female staff who are trying to conceive and female staff who are pregnant should be excluded from working with the substance;\nSpanish: • el personal de sexo masculino y femenino que está intentando tener descendencia, y las mujeres embarazadas no deben trabajar en la manipulación de esta substancia;", "en_prompt": "<|im_start|>user\nGlossary:\n\"staff\" -> \"personal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: • male and female staff who are trying to conceive and female staff who are pregnant should be excluded from working with the substance;\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "staff|||personal", "en": "• male and female staff who are trying to conceive and female staff who are pregnant should be excluded from working with the substance;", "es": "• el personal de sexo masculino y femenino que está intentando tener descendencia, y las mujeres embarazadas no deben trabajar en la manipulación de esta substancia;" } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratamiento\"\n\"enoxaparin sodium\" -> \"enoxaparina sódica\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In treatment of DVT with or without PE, patients receiving enoxaparin sodium were treated with either a 100 IU/kg (1 mg/kg) SC\nSpanish: En el tratamiento de la TVP con o sin EP, los pacientes que recibían enoxaparina sódica fueron tratados con una dosis de 100 UI/kg (1 mg/kg) SC cada 12 horas o con una dosis de 150 UI/kg (1,5 mg/kg) SC una vez al día.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratamiento\"\n\"enoxaparin sodium\" -> \"enoxaparina sódica\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: In treatment of DVT with or without PE, patients receiving enoxaparin sodium were treated with either a 100 IU/kg (1 mg/kg) SC\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratamiento\tenoxaparin sodium|||enoxaparina sódica", "en": "In treatment of DVT with or without PE, patients receiving enoxaparin sodium were treated with either a 100 IU/kg (1 mg/kg) SC", "es": "En el tratamiento de la TVP con o sin EP, los pacientes que recibían enoxaparina sódica fueron tratados con una dosis de 100 UI/kg (1 mg/kg) SC cada 12 horas o con una dosis de 150 UI/kg (1,5 mg/kg) SC una vez al día." } }
{ "translation": { "text": "Glossary:\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hepatic and renal impairment\nSpanish: Disfunción hepática y renal", "en_prompt": "<|im_start|>user\nGlossary:\n\"renal\" -> \"renal\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Hepatic and renal impairment\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "renal|||renal", "en": "Hepatic and renal impairment", "es": "Disfunción hepática y renal" } }
{ "translation": { "text": "Glossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It is recommended that therapeutic infectious agents not be given concurrently with Remicade (see section 4.4).\nSpanish: No se recomienda la administración simultánea de agentes infecciosos terapéuticos y Remicade (ver sección 4.4).", "en_prompt": "<|im_start|>user\nGlossary:\n\"section\" -> \"sección\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: It is recommended that therapeutic infectious agents not be given concurrently with Remicade (see section 4.4).\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "section|||sección", "en": "It is recommended that therapeutic infectious agents not be given concurrently with Remicade (see section 4.4).", "es": "No se recomienda la administración simultánea de agentes infecciosos terapéuticos y Remicade (ver sección 4.4)." } }
{ "translation": { "text": "Glossary:\n\"insulin\" -> \"insulina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Within-subject variability of the time action profile of Levemir and NPH insulin Pharmacodynamic Endpoint\nSpanish: Variabilidad intraindividual del perfil de acción de Levemir e insulina NPH", "en_prompt": "<|im_start|>user\nGlossary:\n\"insulin\" -> \"insulina\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Within-subject variability of the time action profile of Levemir and NPH insulin Pharmacodynamic Endpoint\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "insulin|||insulina", "en": "Within-subject variability of the time action profile of Levemir and NPH insulin Pharmacodynamic Endpoint", "es": "Variabilidad intraindividual del perfil de acción de Levemir e insulina NPH" } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"enfermedad\"\n\"treatment\" -> \"tratamiento\"\n\"indication\" -> \"indicación\"\n\"physician\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For CAPS, TRAPS, HIDS/MKD, FMF and Still's disease, the treatment should be initiated and supervised by a specialist physician experienced in the diagnosis and treatment of the relevant indication.\nSpanish: Para CAPS, TRAPS, HIDS/MKD, FMF y enfermedad de Still, el tratamiento debe ser iniciado y supervisado por un médico especialista con experiencia en el diagnóstico y tratamiento de la indicación.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"enfermedad\"\n\"treatment\" -> \"tratamiento\"\n\"indication\" -> \"indicación\"\n\"physician\" -> \"médico\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: For CAPS, TRAPS, HIDS/MKD, FMF and Still's disease, the treatment should be initiated and supervised by a specialist physician experienced in the diagnosis and treatment of the relevant indication.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||enfermedad\ttreatment|||tratamiento\tindication|||indicación\tphysician|||médico", "en": "For CAPS, TRAPS, HIDS/MKD, FMF and Still's disease, the treatment should be initiated and supervised by a specialist physician experienced in the diagnosis and treatment of the relevant indication.", "es": "Para CAPS, TRAPS, HIDS/MKD, FMF y enfermedad de Still, el tratamiento debe ser iniciado y supervisado por un médico especialista con experiencia en el diagnóstico y tratamiento de la indicación." } }
{ "translation": { "text": "Glossaries:\n\"efficacy\" -> \"eficacia\"\n\"Scale\" -> \"Escala\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Secondary efficacy parameters included OFF Time, UPDRS II and III (Unified Parkinson's Disease Rating Scale - sections II and III), and CGI-C (Clinical Global Impression of Change)\nSpanish: Las variables secundarias de eficacia incluyeron el periodo OFF, UPDRS II y III (Escala Unificada de Evaluación de la Enfermedad de Parkinson, parte II y III) y la impresión clínica global del cambio (ICG-C).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"efficacy\" -> \"eficacia\"\n\"Scale\" -> \"Escala\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Secondary efficacy parameters included OFF Time, UPDRS II and III (Unified Parkinson's Disease Rating Scale - sections II and III), and CGI-C (Clinical Global Impression of Change)\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "efficacy|||eficacia\tScale|||Escala", "en": "Secondary efficacy parameters included OFF Time, UPDRS II and III (Unified Parkinson's Disease Rating Scale - sections II and III), and CGI-C (Clinical Global Impression of Change)", "es": "Las variables secundarias de eficacia incluyeron el periodo OFF, UPDRS II y III (Escala Unificada de Evaluación de la Enfermedad de Parkinson, parte II y III) y la impresión clínica global del cambio (ICG-C)." } }
{ "translation": { "text": "Glossary:\n\"dexamethasone\" -> \"dexametasona\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Cataract has been reported with a higher frequency in patients receiving lenalidomide in combination with dexamethasone particularly when used for a prolonged time.\nSpanish: Se han notificado casos de cataratas con más frecuencia en los pacientes que reciben lenalidomida en combinación con dexametasona, especialmente cuando se administran durante un periodo de tiempo prolongado.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dexamethasone\" -> \"dexametasona\"\nTranslate the source text from English to Spanish following the provided translation glossaries.\nEnglish: Cataract has been reported with a higher frequency in patients receiving lenalidomide in combination with dexamethasone particularly when used for a prolonged time.\nSpanish:<|im_end|>\n<|im_start|>assistant\n", "terms": "dexamethasone|||dexametasona", "en": "Cataract has been reported with a higher frequency in patients receiving lenalidomide in combination with dexamethasone particularly when used for a prolonged time.", "es": "Se han notificado casos de cataratas con más frecuencia en los pacientes que reciben lenalidomida en combinación con dexametasona, especialmente cuando se administran durante un periodo de tiempo prolongado." } }
